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Quotation
“When one idea is drawn from another, we say that there has been an association. Some
are even of the opinion that the whole human mental process derives from this
succession of stimuli, sometimes unconscious, sometimes only pretending to be
unconscious, which achieves original combinations, new relationships of thoughts
interlinked by the species and together forming what might be called a commerce, an
industry of ideas, because man, apart from all the other things he is, has been, or will be,
performs an industrial and commercial function, first as producer, then as retailer, and
finally as consumer, but even this order can be shuffled and rearranged. I am speaking
only of ideas and nothing else. So, then, we can consider ideas as corporate entities,
independent or in partnership, perhaps publicly held, but never with limited liability,
never anonymous, for a name is something we all possess.”
José Saramago, Year of the Death of Ricardo Reis, 1984
___
“Quando uma ideia puxou outra, dizemos que houve associação delas, não falta mesmo
quem seja de opinião que todo o processo mental humano decorre dessa sucessiva
estimulação, muitas vezes inconsciente, outras nem tanto, outras compulsiva, outras
agindo em fingimento de que o é para poder ser adjunção diferente, inversa quando
calha, enfim, relações que são muitas, mas entre si ligadas pela espécie que juntas
constituem e parte do que latamente se denominará comércio e indústria dos
pensamentos, por isso o homem, entre o mais que seja, tenha sido ou venha a ser, é lugar
industrial e comercial, produtor primeiro, retalhista depois, consumidor finalmente, e
também baralhada e reordenada esta ordem, de ideias falo, de aí não, então lhe
chamaríamos, com propriedade, ideias associadas, com ou sem companhia, ou em
comandita, acaso sociedade cooperativa, nunca de responsabilidade limitada, jamais
anónima, porque, nome, todos o temos.”
José Saramago, O Ano da morte de Ricardo Reis, 1984
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Abstract
Cervical cancer is the second most common cancer in women worldwide. For decades,
most developed countries have applied organized cytology screening programs using
the Papanicolau (PAP) test to identify abnormal cases. Despite a high specificity of 9598%, Pap test sensitivity is reported to vary greatly from 74 to 96% with constant
testing needed to achieve the highest values. Semi-automated cytology screening
platforms, immunocytochemistry panels and other methodologies such as human
papilloma virus (HPV) testing has been developed to help reduce false negative rates.
More recently, HPV testing, thus far used for triage of abnormal cytology cases and test
of cure, have been recommended for primary screening. However HPV testing only
informs on the presence of the virus not adding on the abnormal transformation of the
cells. Its suitability for screening of younger women (<30 years) whom present the
highest rates of transient viral infection is also questionable. The potential of Raman
spectroscopy has also been acknowledged with its ability of detecting spectral changes
in malignant and pre-malignant cells extensively reported. In this project the potential of
Raman spectroscopy for cytological diagnosis of samples from a cervical cancer
screening population was assessed. Routinely used ThinPrep® glass slides were used as
spectroscopy substrates in order to minimize costs and simplify sample processing.
Raman spectra were recorded from single cell nuclei and subjected to multivariate
statistical analysis. Different approaches were tested to minimize the glass contribution
to the sample spectra and a non-negative least squares method was found to provide the
best results. Normal and abnormal ThinPrep® samples were discriminated based on
their biochemical fingerprint using Principal Component Analysis (PCA). Principal
Component Analysis – Linear Discriminant Analysis (PCA-LDA) was further
employed to build classification models using both Cervical Intraepithelial Neoplasia
vii

(CIN) and Squamous Intraepithelial Lesion (SIL) terminology. Results showed that
Raman spectroscopy can be successfully applied to the study of routine cervical
cytology samples from a cervical screening programme and normal and abnormal
samples could be discriminated with high sensitivity and specificity rates (>95%) when
tested with leave one patient out cross validation. In addition, the results suggested that
HPV infection and previous disease history might be inferred from negative samples
and might influence the performance of classifiers. In summary this study has shown
Raman spectroscopy has potential as a screening tool for Thinprep® cervical cytology
samples.
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CHAPTER 1

INTRODUCTION: THE CERVIX, CANCER AND
DIAGNOSIS CHALLENGES

1

1.1 The Cervix
1.1.1 Embryology

The cervix like the uterine fundus and upper vagina, develops from the embryonic
paramesonephric ducts (Sahdev 2010).
The process begins at the fifth week of gestation, when the Wolffian mesonephric and
the Müllerian paramesonephric ducts are formed from the intermediate mesoderm. In
the absence of testosterone and Müllerian inhibitory substance, the mesonephric ducts
regress and the paramesonephric ducts continue to develop the female reproductive
structures; this is completed by the fifth month of pregnancy when the vagina and a
variable portion of the ectocervix become covered by squamous epithelium (Sahdev
2010).

1.1.2 Anatomy & Histology

Macroscopically, the cervix is the lower extension of the uterus, presenting a fusiform
shape of 2,5 to 3 cm in diameter and 3 to 5 cm in length. It can be divided into two
parts, the interior portio vaginallis or ectocervix, which protrudes into the vagina and the
supravaginal part or endocervix (Sahdev 2010).
The endocervical canal measures 6 to 8 mm wide and contains ridges perpendicular to
the long axis of the canal, the plicae palmateae (Mescher 2013). It communicates with
the uterine cavity through the internal os and, its opening at the portio vaginalis is
known as the external os (Mescher 2013).
Histologically, three different areas can be found in a normal human cervix as shown in
Figure 1.1. The endocervix, the closest part to the uterus, is lined by a mucin-producing
simple columnar epithelium. The ectocervix, the part next to the vagina, is lined with a
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stratified squamous epithelium. And, the area where the endocervix joins the ectocervix
which is known as the squamo-columnar junction, also called the transformation zone
because it is the site where the simple columnar epithelium undergoes transition to
stratified squamous epithelium (Mescher 2013; Sahdev 2010).

Figure 1.1 Schematic representation of the female genital tract and of the ecto and endocervical epithelia
adapted from (A.D.A.M. 2016) and (Mescher 2013).

The stratified squamous epithelium of the ectocervix consists of layers of basal,
parabasal, intermediate and superficial cells, as shown in Figure 1.2.
The basal cells are the smallest, measuring about 10 μm diameter; they are immature
cells with a round to elliptical shape and large spherical nucleus. Derived from the basal
layers, the parabasal cells are similar in shape but somewhat larger, about 10 μm to 15
μm in diameter (Koss et al. 2006).
Intermediate cells, in comparison, are larger, measuring from 15 to 40 μm in diameter,
and present a more elongated shape and a smaller nucleus (Koss et al. 2006).
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Measuring from 40 μm to 60 μm in diameter, the superficial cells are the largest; they
are mature cells with small, dense, pyknotic 1 nuclei. During the maturation process,
cells migrate from the basal layer to the surface (superficial layer), accumulate glycogen
in the cytoplasm, and acquire a flattened shape. The epithelial layer of cells is composed
of 15-20 cells with a thickness of 200-400 μm (Koss et al. 2006).

Figure 1.2 Schematic representation of the stratified squamous epithelium of the ectocervix with
representation of the different cell types present; adapted from (Frazer 2004).

1.1.3 Function

The cervix has several important functions, most of them related with the female
reproductive cycle.
As it connects the body of the uterus to the vagina, it allows the menstrual flow of blood
and debris, to come from the uterus into the vagina and out of the body. Similarly, it
also directs sperm into the uterus during intercourse (Almeida et al. 2010).

1

Pyknosis –condensation of DNA causing shrinking of the nucleus.
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Moreover, cervical secretions change cyclically, and play a significant role in
fertilization and early pregnancy. At the end of ovulation, the mucous secretions are
maximal, watery, and facilitate movement of the sperm through the uterus. In the luteal
phase, high progesterone levels cause the mucous secretions to become viscous and
hinder the passage of both sperm and microorganisms into the body of the uterus.
During pregnancy, cervical glands proliferate and secrete abundant, highly viscous
mucus which forms a plug in the endocervical canal to help keep the foetus inside the
womb (Mescher 2013).
Similarly, the cervical epithelium is also affected by the cyclical changes arising from
the menstrual cycle. In the proliferative phase of the cycle, between day 5 and 13,
oestrogen levels reach their peak leading to the complete maturation of the squamous
epithelium which therefore presents a high proportion of superficial cells compared to
intermediate and basal cells. Inversely, in the secretory phase, between day 14 and 28, it
is progesterone that reaches its peak preventing the complete maturation of the
epithelium that now presents more intermediate and immature cells. Once a woman
stops ovulating, usually between the ages of 48 and 55 years of age, she is considered to
be menopausal.

At this stage, levels of both oestrogen and progesterone drop

dramatically and there is a gradual arrest of the squamous epithelial maturation,
resulting in the gradual loss of superficial and intermediate cells with the squamous
epithelium composed entirely of parabasal cells and classed as atrophic (Koss et al.
2006; Jordan et al. 2006).
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1.2 Cancer
1.2.1 What is cancer?

The proliferation, differentiation and survival of individual cells in multicellular
organisms, as in the human body, are carefully regulated to meet the needs of the
organism as a whole (Cooper et al. 2013).
Cells from different parts of the body that look, function and ultimately are different, are
in intrinsic collaboration resting, growing, dividing, differentiating or dying as needed
for human body function (Alberts et al. 2014).
Of the more than 1014 human cells, billions of them experience mutations 2 every day;
normally, the now abnormal cells would try to reverse these mutations, activating a
correction mechanism and undergoing apoptosis 3 when they fail. However when the
mutation gives the cell a selective advantage that allows it to grow, survive and divide
in a more vigorous and unregulated manner, this becomes a founder of growing mutant
clones (Alberts et al. 2014).
As a result, a tumor also known as neoplasm – from the Greek new growth – can
develop from a single altered cell that begins to grow and proliferate abnormally
(Cooper et al. 2013). A tumor can be either benign, if it remains confined to its site of
origin, or malignant, if its cells have acquired the ability to invade surrounding tissue
and spread (metastasise) throughout the body via circulatory or lymphatic systems
(Cooper et al. 2013; Kumar et al. 2012). Only the malignant type is referred to as
cancer.

2

Mutation – permanent alteration of the nucleotide sequence of the genome of an
organism, virus, or extrachromosomal DNA or other genetic elements.
3
Apoptosis – Mechanism of programmed cell death.
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1.2.2 Carcinogenesis

Carcinogenesis, oncogenesis, or tumorigenesis, is the dynamic process by which normal
cells are transformed into cancer cells. It is characterized by a succession of changes at
the genetic and cellular level that ultimately reprogramme a cell to undergo uncontrolled
cell division, thus forming a malignant neoplasm (Kumar et al. 2012).
Three distinct phases can be identified in this multistage process as illustrated in Figure
1.3. First there is Initiation when the cells are exposed to a carcinogen 4 which makes
them more susceptible to Deoxyribose nucleic acid (DNA 5) damage and possible
malignant transformation. Then, there is Promotion when the mutant cells are induced
by various chemicals and growth factors to undergo an unregulated accelerated growth.
And finally, a Progression when these cells acquire a malignant phenotypic that
promotes

autonomous

growth

tendencies,

increased

chromosomal

instability,

invasiveness and metastatic competence (Almeida et al. 2010; Porth 2014).

Figure 1.3 Schematic of the carcinogenesis process: Initiation, Promotion and Progression (Almeida et al.
2010).
4

Carcinogen – Any substance or agent an agent that induces changes to a cell
population which can cause cancer.
5
DNA - Deoxyribonucleic acid is a nucleic acid containing the genetic instructions used
in the development and functioning of all known living organisms with exception of
RNA virus.
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1.3 Cervical cancer
1.3.1 Statistics: Worldwide, Europe and Ireland

Cervical cancer is the fourth most common cancer in women worldwide, and the
seventh overall, with an estimated 528,000 new cases in 2012 alone. The majority of
cases arise in less developed regions where almost nine out of ten cervical cancer deaths
occur (IARC 2012b).
In 2012 there were an estimated 266,000 deaths from cervical cancer worldwide which
accounts for 7.5% of all female cancer deaths (IARC 2012b).
Across Europe, the overall incidence and mortality cases for 2012 were estimated at
58348 and 24397 respectively as shown by EUCAN data (Ferlay et al. 2013; IARC
2012a).
Amongst the 28 member states of the European Union (EU) approximately 34,000 new
cases and 13,000 deaths occur annually, and despite the significant progress made in
reducing the burden of the disease, mortality rates are still high in many member states,
particularly those that joined the EU after 2003 (Ferlay et al. 2013; IARC 2012a; von
Karsa et al. 2015).
In Ireland, the incidence rates of cervical cancer have been shown to rise from 1994 to
2008. On average, 1300 women were diagnosed with cervical intraepithelial neoplasia
(CIN) 3, 210 with invasive cervical cancer and 75 women died each year (O’Brien et al.
2013). According to GLOBOCAN 2012 data and taking into account the demographic
effect, cervical cancer incidence in Ireland is predicted at 357 for 2012 and 372 for
2015, whilst mortality is predicted at 101 for 2012 and 106 for 2015, as shown in Table
1.1 which also contains European and United Kingdom (UK) projections.
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Table 1.1 2015 Cervical cancer incidence and mortality forecasts for Europe, Ireland and the United Kingdom.
Values obtained from GLOBOCAN 2012 (IARC) on 28th August 2015 and computed using age-specific rates
and corresponding populations for 10 age-groups. Population forecasts were extracted from the United
Nations, World Population prospects, the 2012 revision (IARC 2012b).

2012

Incidence
Mortality

2015

Europe

Ireland

United
Kingdom

Europe

Ireland

United
Kingdom

67355

357

2659

68431

372

2675

28003

101

979

28863

106

1008

1.3.2 Histological Types

According to the World Health Organization, tumors of the cervix are as summarized in
Table 1.2 (IARC 2015).
Table 1.2 Tumors of the Cervix adapted from IARC screening group (IARC 2015) .

Epithelial tumours
Squamous tumours and precursors
Squamous cell carcinoma, not otherwise specified
Keratinizing
Non-keratinizing
Verrucous
Warty
Papillary
Lymphoepithelioma-like
Squamotransitional
Early invasive (microinvasive) squamous cell
carcima
Squamous intraepithelial neoplasia
Cervical intraepithelial neoplasia (CIN 3)
Squamous cell carcinoma in situ
Benign squamous cell lesions
Condyloma acuminatum
Squamous papilloma
Fibroepithelial polyp
Glandular tumours and precursors
Adenocarcinoma
Mucinous adenocarcinoma
Endocervical
Intestinal
Signet-ring cell
Minimal deviation
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Villoglandular
Endometrioid adenocarcinoma
Clear cell adenocarcinoma
Serous adenocarcinoma
Mesonephric adenocarcinoma
Early invasive adenocarcinoma
Adenocarcinoma in situ
Glandular dysplasia
Benign glandular lesions
Müllerian papilloma
Endocervical polyp
Other epithelial tumours
Adenosquamous carcinoma
Glassy cell carcinoma variant
Adenoid cystic carcinoma
Adenoid basal carcinoma
Neuroendocrine tumours
Carcinoid
Atypical carcinoid
Small cell carcinoma
Large cell neuroendocrine carcinoma
Undifferentiated carcinoma
Mesenchymal tumours and tumour-like
conditions
Leiomyosarcoma
Endometrioid stromal sarcoma, low grade
Undifferentiated endocervical sarcoma
Sarcoma botryoides
Alveolar soft part sarcoma
Angiosarcoma
Malignant peripheral nerve sheath tumour
Leiomyoma
Genital Rhabdomyoma
Postoperative spindle cell nodule
Mixed epithelial and mesenchymal tumours
Carcinosarcoma (malignant müllerian mixed
tumour)
Adenosarcoma
Wilms tumour
Adenofibroma
Adenomyoma
Melanocytic tumours
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Malignant melanoma
Blue naevus
Miscellaneous tumours
Tumours of germ cell type
Yolk sac tumour
Dermoid cyst
Mature cystic teratoma
Lymphoid and haematopoetic
Malignant lymphoma (specify type)
Leukaemia (specify type)

Between 85% and 95% of cervical cancers are squamous cell carcinomas (SCC).
Developing almost exclusively at the squamo-columnar junction, most of them involve
the ectocervix and may be visible on direct speculum examination as exophytic 6,
especially in younger women, when the junction lies outside the external os (Sahdev
2010).
Adenocarcinomas arise from the glandular epithelium and the endocervical glands of
the endocervical canal, and comprise 5% of all cervical tumors. Because of their deep
endocervical origin, adenocarcinomas are usually detected at a later stage than SCC, and
often present large infiltrative lesions that lead to poor prognosis (Sahdev 2010).
Malignant lymphomas of the female genital tract are rare and often a diagnostic
challenge. In advanced disease status it is almost impossible to determine whether they
are primary, originated from the genital tract and then spread to lymph nodes, or
secondary if they originated from the lymphatic system; in either case, diffuse large Bcell and follicular are the prevailing type among lymphomas (Sahdev 2010).

6

Exophytic – growing outward; in oncology, proliferating externally or on the surface

epithelium of an organ in which the growth originated.
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Even rarer than lymphomas, sarcomas of the cervix such as Malignant Mixed Müllerian
tumors (MMMTs) and leiomyosarcomas, mainly occur in postmenopausal women,
between the age of 50 and 70 years. Nevertheless, primary leiomyosarcomas of the
cervix have only been reported as case reports, with the majority originating from the
corpus uteri and involving the cervix (Sahdev 2010).
Finally, neuroendocrine tumors represent less than 1% of cervical malignancies. This
type of tumor is extremely aggressive, and often diagnosed in an advanced stage thus
holding poor prognosis; small cell carcinomas and carcinoids are the two most frequent
subtypes diagnosed (Sahdev 2010).

1.3.3 Aetiology – Human Papillomavirus (HPV)

The association between HPV and cervical cancer is one of the strongest statistical
relations ever identified in cancer epidemiological studies. Both biological and
epidemiological retrospective and prospective studies have demonstrated an
unequivocal association between HPV infection and higher risk of malignancy, from the
early lesion states to invasive carcinoma (Franco et al. 2003; Boulet et al. 2007).
Human papillomaviruses are sexually transmitted small circular double-stranded DNA
viruses from the Papovaviridae family. Their genome, as represented in Figure 1.4,
consists of 8000 base-pair (bp) long circular DNA molecules wrapped into a protein
shell composed of L1 and L2 proteins; it has the capacity for coding these two late
expression proteins as well as six other early proteins (E1 to E7) necessary for the
replication of viral DNA and its assembly within infected cells. There is also an
upstream regulatory region (URR) that, although not coding for any proteins, contains
cis-elements required for regulation, expression and packaging the genome into the
virus (Muñoz et al. 2006).
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Figure 1.4 Schematic presentation of the HPV genome, showing the arrangement of the early E or nonstructural genes, the capsid genes (L1 and L2) and the URR (Cooper et al. 2013).

From more than 200 different HPV types identified, about 40 are known to infect the
genital tract. These mucosal types are classified as “low-risk” or “high-risk” (HR-)
based on their prevalence ratio in cervical cancer and its precursor lesions (Boulet et al.
2007; Woodman et al. 2007).
Low-risk HPV types, such as 6 and 11, are believed to induce benign lesions with
minimum risk of malignant progression, whereas HR types have a higher oncogenic
potential. Approximately, 99% of cervical cancers contain HR-HPV DNA, with
HPV16, 18, 31, 33 and 45 being the most prevalent worldwide in that order (Boulet et
al. 2007).
The HPV life cycle is perfectly adapted to its natural tissue host, the epithelium; being
strongly linked to epithelial differentiation (Muñoz et al. 2006; Pyeon et al. 2009).
In the cervix, HPV is thought to access the basal cells through micro-abrasions in the
epithelium and infect the dividing basal cells during wound healing (Pyeon et al. 2009).
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Following entry, the early genes (E1 – E7) are expressed and the viral DNA replicates
from the episomes 7, afterwards in the upper layers of the epithelium the genome is
replicated further and the late genes (L1 and L2) are expressed; they then encapsulate
the viral genome from progeny virions in the nucleus and the newly shed virus can
initiate a new infection (Woodman et al. 2007; Doorbar et al. 2015).
Expressed in the lower epithelial layers, E6 and E7 are the critical proteins for HPV
replication as their function inactivates the products of two important tumor suppressor
genes – p53 and pRb, respectively. While E6 acts as repressor of p53 and therefore of
apoptosis, mediating survival of severely damaged cells; E7 is a promoter of pRb and
therefore of cell growth and replication. Referred to as oncoproteins as they induce
proliferation, immortalization and malignant transformation of the infected cells; their
joint function is complementary and synergistic inducing an even more marked
malignant transformation (Boulet et al. 2007).
Whereas the low-risk HPV genomes are preferentially maintained in episomes, highrisk HPV types have a greater tendency for integration with the host DNA. This
integration, represented in Figure 1.5, usually occurs by the E2 region downstream of
the E6 and E7 genes which leads to an increase in their expression due to the loss of the
regulatory control of E2. Moreover, integrated-derived transcripts are more stable than
those originating from episomes, which represent a growth advantage (Doorbar 2005;
Woodman et al. 2007).

7

Episome - A segment of DNA that can exist and replicate either autonomously in the
cytoplasm or as part of a chromosome.
14

Figure 1.5 Representation of the integration of HPV DNA into the host cell DNA (Woodman et al. 2007).

1.3.4 Grading

Dysplasia, characterised by increased mitotic activity 8 of the cells and decreased
glycogen levels in cytoplasmic regions, usually develops in the transformation zone.
Dysplasia is a pre-cancer condition in which dysplastic cells have increased nuclear size
and resemble undifferentiated basal cells, but unlike normal basal cells, these abnormal
cells exhibit large nuclei, chromatin 9 clumping, scant cytoplasm and irregular nuclear
borders. Low grade and moderate cervical dysplasia can spontaneously regress without
leading to cervical cancer, however some may progress to severe dysplasia, and finally
invasive cancer (Koss et al. 2006; Cibas et al. 2009; Moscicki et al. 2010a).
The three-tier cervical intraepithelial neoplasia (CIN) nomenclature is directly linked to
the severity of dysplastic changes in the cervix epithelium and is widely used for
histology reporting of cervical tissue; whereas the two-tier squamous intraepithelial
lesion (SIL) nomenclature corresponds to the cytological diagnosis defined by the
Bethesda system (Apgar et al. 2003). The Bethesda system was introduced in 1988 in
an attempt to standardise the cytology reporting. Its revision in 2001 created the
nomenclature currently recommended for reporting cervical cytology (Appendix 2).
Despite this, some laboratories still report cytology using CIN nomenclature.

8

Mitotic activity – Mitosis, the process in cell division by which the nucleus divides.
9
Chromatin – The complex of DNA and protein that makes up chromosomes.
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CIN 1 [low to mild dysplasia] and changes associated with HPV are classed as low
grade squamous intraepithelial lesions (LSIL), whereas high grade squamous
intraepithelial lesions (HSIL) correspond to CIN 2 [moderate dysplasia] and CIN 3
[severe dysplasia] as shown in Figure 1.6.

Figure 1.6 Representation of the progression from normal cervical epithelium to invasive carcinoma adapted
from (Lowy et al. 2006). SIL (red) and CIN (blue) reporting systems are indicated as well as the grade of
dysplasia associated with each classification.

In 2012, the American College of Pathology in an international consensus conference,
called the Lower Anogenital Squamous Terminology (LAST) Project, made
recommendations on the use of SIL as a uniform, two-tiered terminology to describe the
histology of human papillomavirus-associated squamous disease across all anogenital
tract tissues. SIL is recommended to be used in the reporting of cervical biopsies with
p16 (discussed in more detail in section 1.6.1.1 of this chapter) tissue immunostaining
also recommended to better classify lesions that would earlier have been diagnosed
morphologically as CIN 2 (Waxman et al. 2012).
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1.3.5 Symptoms

Cervical cancer is typically the last stage of a somewhat slow carcinogenesis process.
Precancerous changes occur gradually; usually taking several years until full
transformation from normal epithelium to dysplasia and subsequently to invasive SCC
is completed.
Although, initial abnormal changes in the cervix are asymptomatic, the development of
cervical dysplasia may cause various symptoms such as vaginal bleeding outside
menstruation periods or after intercourse and/or atypical vaginal discharges. In late
stages, SCC can spread into the pelvic tissues causing pain (Arends et al. 1998; Franco
et al. 2003).

1.3.6 Risk factors

While HPV is recognised as the main aetiological agent, it is not the only factor for
cervical cancer. Potential co-factors to persistent HPV infection reported for cervical
cancer are as follows:
•

Sexual behaviours and other sexually transmitted infections (STI). Women
with a promiscuous and unsafe sexual behaviour, or those whose partner is, are
at increased risk of contracting STI such as HPV, the principal aetiology factor
in cervical cancer. There has been a renewed interest in the possible role of other
STIs, especially Herpes simplex virus (HSV) and Chlamydia trachomatis as
potential HPV cofactors (American Society of Clinical Oncology 2012).
Although some studies suggest that women who have genital herpes have a
higher risk of developing cervical cancer, a recent longitudinal meta-analysis
reported the evidence supporting a harmful effect of HSV infection on cervical
cancer was inadequate and recommended further studies are needed to fully
clarify any association (Cao et al. 2014). Similarly, more evidence is still needed
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to elucidate the possible role of Chlamydia trachomatis in cervical
carcinogenesis but recent studies have reported higher prevalence of HPV
multiple infections in women affected with chronic Chlamydia trachomatis
infection, further suggesting Chlamydia infection may promote a favourable
microenvironment for HPV infection through disruption of both apoptotic and
cellular pathways (Seraceni et al. 2014; Vriend et al. 2015).
•

Immunosuppression. When immunosuppressed, the human body does not
monitor and respond to internal, such as mutations, and external, such as HPV
infections, challenges efficiently. Therefore, by allowing these aggressions and,
their subsequent abnormal and malignant induced changes to proceed, the
immunosuppressed state is one of the risk factors for cervical cancer. This state
can be caused by immune suppression from corticosteroid medications, organ
transplantations, treatments for other types of cancer, or from human
immunodeficiency virus (HIV), the virus that causes acquired immune
deficiency syndrome (AIDS) (Palefsky 2007; Dugué et al. 2013; Chen et al.
2015) .

•

Oral contraceptive use. The plausibility of this association rests on the
possibility that hormones affect HPV infected cells; it has been shown that oral
contraceptive use increases the risk of cervical cancer (Gierisch et al. 2013; La
Vecchia et al. 2014; Roura et al. 2016) and that steroid stimulation may trigger
viral oncogene-related events leading to the integration of the virus into the
host’s genome (Moodley et al. 2003). However, further research is needed to
understand how oral contraceptive use and the development of cervical cancer
are associated.
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•

Reproductive history. High parity has consistently been found to increase the
risk of cervical cancer. A recent study found the number of full-term
pregnancies was positively associated with increased risk of CIN3/cervical
cancer with a p-value of 0.03 (Roura et al. 2016). Independently of the sexual
behaviour, multiple pregnancies may induce a cumulative traumatic or
immunosuppressive element on the cervix, facilitating HPV infection. Moreover,
pregnancy hormonal alterations could affect HPV genome elements that respond
to progesterone (Castellsagué et al. 2003; Jensen et al. 2013).

•

Smoking habits. Several studies suggest that women who smoke are about
twice as likely to develop cervical cancer as women who do not smoke
(Castellsagué et al. 2003; Louie et al. 2011). It has also been reported that
smoking increases the risk of high-grade cervical lesions in women with
persistent high-risk HPV infection (Jensen et al. 2012). However, the
mechanism by which smoking affects cervical carcinogenesis is not clear
(Fonseca-Moutinho 2011).

•

Race and Ethnicity. Even though the genetic/biological principles demand
further clarification, recent epidemiological research showed HPV associated
cervical cancer to be more common amongst Black and Hispanic women despite
an overall decrease in the incidence of disease (Viens et al. 2016). Similarly, a
study of the population of Singapore reported it was still unclear why Chinese
women remain at higher risk of cervical cancer, as compared to Malay and
Indian women (Lam et al. 2015). However, a microRNA genotype study showed
miR-146a (rs2910164) polymorphism to be correlated with ethnicity and tumor
dimension, with the odds ratio of cervical cancer for Uygur women 3.332 times
that found for Han women (Ma et al. 2015).
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•

Diet. There is biological plausibility for a protective effect of diet in
carcinogenesis. Epidemiological studies have been relatively consistent
indicating protective effects for consumption of fruits and vegetables, betacarotene and, vitamins A, C and E; Carotenoids, tocopherols and ascorbic acid,
to mention a few, are shown to be potent antioxidants as they are able to reduce
intracellular reactive radicals, thus potentially preventing DNA damage and
oxidative stress (Franco et al. 2003; Gutierrez-Salmean et al. 2015).

•

Microbiome. The role of microbiome in disease has been the subject of much
research in recent years. Studies concerning cervical cancer found vaginal
microbiota to be significantly associated with HPV infection (Brotman et al.
2014); HPV positivity was also associated with greater microbiome diversity
(Gao et al. 2013; Lee et al. 2013) and higher vaginal pH (Clarke et al. 2012) due
to a decrease in Lactobacilli species (Clarke et al. 2012; Lee et al. 2013).

•

Frequency of screening & Low socioeconomic status. Medical surveillance
which comprises an appropriate screening frequency is crucial to detect cervical
abnormalities at the early stages and thus prevent cervical cancer. Women from
lower socioeconomic status are less likely to be aware of these risk factors and
attend regular medical appointments so this might be one of the reasons that
drive later diagnosis and consequent poor prognosis for cervical cancer for this
group (Ibfelt et al. 2013; Tadesse 2015).
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1.4 Current diagnostic methods and technologies for cervical cancer
1.4.1 Papanicolau (Pap) test

Also called the Pap smear, cervical smear or smear test, the Pap test is a screening
method invented independently by George Papanicolaou and Aurel Babeş. Introduced
in the United States of America in the mid 1940s, only in the 1970s did it become a
routine screening test for cervical cancer (Koss et al. 2006; Safaeian et al. 2007). .
The Pap test consists of cytological screening, under a light microscope, of a cervical
smear according to standard guidelines with the Bethesda system the most widely used.
The smear is collected by scraping the cervix with a cervical brush and it should ideally
obtain representative material of the transformation zone where the stratified squamous
epithelium of the ectocervix turns into the columnar mucus-secreting epithelium of the
endocervix as this is the most common onset site of cervical cancers (Koss et al. 2006),
as shown in Figure 1.7.

Figure 1.7 Representation of the cervical smear collection, with indication of the transformation zone location
(The Johns Hopkins University 2012).

The cells are then transferred onto a slide by one of the two following methods:
1. Conventional method – where, immediately after collection, the cells are
spread along the slide and fixed with a spray fixative as illustrated in Figure 1.8
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by the clinician or the trained nurse who carried out the collection (Safaeian et
al. 2007).

Figure 1.8 Schematic representation of the conventional method adapted from (Rovers Medical Devices B.V.
2006).

2. Liquid Based Cytology (LBC) – introduced in the late 1990s was quickly
adopted because it allowed the laboratories to prepare the slides rather than
having them sent from the collection sites with various degrees of fixation and
preparation. Moreover, LBC methodologies provide a clearing of the samples
from obscuring elements such as blood or mucus, which is one of the reasons
cited to justify its lower unsatisfactory rates compared with conventional
cytology (Fontaine et al. 2012). The two main platforms or LBC methods are:
a. ThinPrep® method (Hologic) where the cells, instead of being spread
on the slide after collection, are transferred into a vial with PreservCyt®
solution 10 and subsequently processed in an automated system that
prepares the slides through 3 steps: first the cells are dispersed (to get rid
of debris that may obscure them), then collected by a thin filter and
finally transferred onto a slide by imprinting the filter on the slide
(Hologic 2010), as shown in Figure 1.9.

10

PreservCyt® solution – methanol based preservative/fixative solution.
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Figure 1.9 Schematic representation of the ThinPrep® method (West Coast Pathology Laboratories 2011).

b. SurePath® method (Becton Dickson), uses a broom-like device or
combination brush/spatula with detachable heads for the collection of
the smear; the detachable head is then dropped into the BD SurePath™
vial

11

assuring that 100% of the collected sample is sent for processing

(Figure 1.10). The BD PrepStain™ Slide Processor allows processing
the samples in a standardized way and also enhancing the concentration
of cells needed for diagnostic testing (Becton Dickson 2016).

Figure 1.10 Schematic representation of the SurePath® method (Becton Dickson 2016).

Until 1996, when the ThinPrep® method was introduced, the conventional method was
the most widely used. However, over recent years, the new LBC methods were shown
to be more efficient by a 65% increase in the detection of low grade and severe lesions
while simultaneously reducing the false negative rate by 39%, this led to LBC being
widely implemented and used routinely (Koss et al. 2006).

11

BD SurePath™ vial – preservative/fixative solution.
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Research comparing ThinPrep® and SurePath® methods are still ongoing to find if
there is any significant difference between the specificity and/or sensitivity of the two
methods. Although ThinPrep® appears to be the most accepted in many developed
countries, literature shows that SurePath® allows lower unsatisfactory rates of available
cells for diagnosis (Fontaine et al. 2012).
Once on a slide, the cells are stained and evaluated by a highly trained technician or a
pathologist according to the Bethesda system nomenclature (Appendix 2).
The Pap test has the advantages of being minimally invasive, inexpensive and a widely
accepted technique. And, although it has a high specificity of 95-98%, sensitivity rates
vary from 74 to 96% due to sampling ( incorrect or inadequate collection), technical
(inaccuracy of technical procedure) and/or inter-observer (subjectivity of screening
system) errors therefore frequent intra and inter-laboratory testing is necessary to obtain
the highest specificity values reported (Nanda et al. 2000b; Koss et al. 2006).
Moreover, an abnormal Pap smear is normally followed by colposcopy, biopsy and
histological confirmation of the diagnosis. Regardless of its slowness, the major
concerns of this process are the subjectivity of the grading characteristics and the fact
that pre-malignancy or early malignancy stages could be missed due to their low
morphological perceptibility (Nanda et al. 2000a; Bengtsson et al. 2014).
1.4.1.1 Papanicolaou (Pap) stain
The Papanicolaou (Pap) stain is a multichromatic staining technique developed by
George Papanicolaou and it is the “gold standard” stain for gynaecological cytology.
Its most common form involves the application of three different stain solutions. A
nuclear stain, haematoxylin, is used to stain cell nuclei; then orange G (OG)-6 (where -6
denotes the used concentration of phosphotungstic acid) is used to stain keratin; and
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finally, eosin azure (EA)-50 (where -50 denotes the proportion of 3 different dyes in
solution) is employed to counterstain the cytoplasm (Gil 2013).
On a well prepared specimen, the cell nuclei are dark blue to black. Superficial cells are
orange to pink, and intermediate and parabasal cells are turquoise green to blue. Some
intermediate cells called navicular cells stain a yellowish colour due to a high keratin
and glycogen content. Figure 1.11 shows a bright-field microscopic image of a negative
ThinPrep® cervical smear at low magnification.

Figure 1.11 Bright-field image of a Pap stained negative ThinPrep® cervical smear showing superficial cells
with orange stained cytoplasm and intermediate cells with blue stained cytoplasm.

1.4.1.2 Semi-automated screening systems
Semi-automated screening systems consist of a highly automated microscope coupled to
a computer that works on image interpretation. The “semi” nomination is due to the fact
that none of the currently available systems provides fully automated screening without
human intervention at some stage. In fact, in the majority of cases, the final decision
still lies with cytology screener, not overcoming the subjectivity problem found in
manual screening.
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The procedure starts with the scanning of the slide and the identification of cells deemed
useful for analysis by their separation from the surrounding “background” (such as
inflammatory cells, cellular debris or overlapping cell clusters). Subsequently, image
segmentation algorithms perform a separation of the nuclei from the cytoplasm of the
cells allowing the calculation of morphometric parameters such as nuclear size, nucleus
to cytoplasm ratio or even definition of the texture of the observed object (Birdsong
1996; Desai 2009; Kitchener et al. 2011).
From all the systems available, there are only two FDA 12 approved automated
machines, the FocalPoint™ GS Imaging system by BD Diagnostics and the ThinPrep™
Imaging system by Hologic, both represented in Figure 1.12.
The FocalPoint™ GS Imaging system (Figure 1.12 A) initially called TriPath
AutoPap® system, is able to process up to 144,000 SurePath™ slides annually, while
the ThinPrep™ Imaging system (Figure 1.12 B) formerly known as Cytyc ThinPrep™
Imaging system can process 100,000 ThinPrep™ slides, if allowed to run continuously
(Desai 2009; Kitchener et al. 2011).
The FocalPoint™ can sort and rank the slides using the FocalPoint™ Slide Profiler
(Figure 1.12 A (a)) without requiring a first stage of human intervention as needed for
the ThinPrep™ Imaging system. Moreover, it is also able to process conventional smear
slides (Desai 2009; Kitchener et al. 2011).
Both systems are expected to double the productivity of cervical cancer screening
(Desai 2009); and, despite reports that semi-automated screening systems increase
sensitivity and specificity of Pap smear testing when compared to the manual screening

12

Food and Drug Administration agency of the government of the United States of
America; responsible for protecting and promoting public health through products and
medical procedures regulation.
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method, a recent publically funded trial by the National Institute of Health Research
(UK), found that automated reading was 8% less sensitive than manual, 6.3% in
absolute terms. Furthermore, this allied with an uncertainty over cost-effectiveness, led
to no recommendation being made on the implementation of semi-automated systems in
screening programmes (Desai 2009; Kitchener et al. 2011).

Figure 1.12 Automated slide screening systems. A - The FocalPoint™ GS Imaging system, (a) - FocalPoint™
Slide Profiler, (b) - Guided Screener Workstation, (c) – a screenshot of the screening window (IARC 2012a). B
– The ThinPrep™ Imaging system, (a) - Image Processor, (b) - Review Scope, (c) – an example of the field of
view with the guiding marker showing stained cervical cells (Franco et al. 2003).

1.4.2 HPV Testing

HPV testing has recently been added to the range of clinical options for cervical cancer
screening. The latest published inventory reported that there are a total of 193 distinct
HPV tests commercially available and in excess of 120 variations (Poljak et al. 2016)
which could be grouped into eight categories as follows:
I.
II.

hr-HPV DNA screening tests
hr-HPV DNA screening tests with concurrent or reflex partial
genotyping for the main hr-HPV types

III.

HPV DNA full genotyping tests
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IV.
V.
VI.
VII.
VIII.

HPV DNA type- or group-specific genotyping tests
HR-HPV E6/E7 mRNA tests
In situ hybridization DNA-based HPV tests
In situ hybridization mRNA-based HPV tests
HPV DNA tests targeting miscellaneous HPV types

However only 57% of these had at least one publication in peer-review literature and
only 35.7% have their analytical/clinical performance documented (Poljak et al. 2016).
For the sake of clarity, only the more widely used HPV tests are explained in more
detail in the following subsections. Although, substantial research suggests that HPV
testing could be cost-effective and an accurate primary screening method especially in
women over 30 and it has indeed been recommended in some countries including in the
UK; much debate is still ongoing within the scientific and clinical communities about
whether cytology could be replaced by HPV DNA testing as a primary screening tool
(Dudding et al. 2015). Highly sensitive and specific screening algorithms are still
needed to identify all women at risk of developing cervical cancer and its precursor
lesions, further research is still required (Brown et al. 2012a; Poljak et al. 2016).
1.4.2.1 DNA-based HPV assays
HPV DNA-based assays can further be divided into target-amplification methods like
polymerase chain reaction (PCR) with consensus or type specific primers and HPV
mRNA amplification; and, signal amplification methods such as liquid phase and in situ
hybridization (Chan et al. 2012).
The Hybrid Capture 2® (HC2®) test developed by Qiagen and approved by FDA in
2003; was initially the most widely used. It is capable of detecting 13 different HPV
types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) through the use of full
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genomic probes complementary to HPV DNA, specific antibodies, signal amplification
and chemiluminescent detection (Brink et al. 2006; Brown et al. 2012a).
Hologic laboratories introduced to the market the Cervista® HPV HR test, also
approved in 2003, capable of detecting the same 13 types as HC2®, and then the
Cervista® HPV 16/18, approved in 2009, for specific detection of HPV types 16 and
18. Both tests consist of applying an isothermal enzymatic DNA amplification process
followed by fluorescent read out (Brink et al. 2006; Brown et al. 2012a).
The cobas® HPV Test developed by Roche is an automated test which is able to
identify HPV DNA from 14 high-risk types. The test specifically identifies types HPV
16 and HPV 18 while concurrently detecting the rest of the HR types (31, 33, 35, 39,
45, 51, 52, 56, 58, 59, 66 and 68) (U.S. Food and Drug Administration 2013). Cobas®
is FDA approved since 2011 and in 2014 it became the first test to receive FDA
approval for primary screening of cervical cancer.
1.4.2.2 E6/E7 mRNA-based HPV assays
As discussed in section 1.3.3, E6 and E7 are oncoproteins involved in cervical
carcinogenesis.

The principle behind mRNA-based assays is that the detection of

mRNA encoded by E6 and E7 may provide a better predictive value for malignant or
high-grade lesions as it would establish not only if the virus is present but also if its
proteins are being expressed.
The PreTect HPV-Proofer (Norchip) and the NucliSENS Easy Q (BioMerieux) are
based on the same technology but marketed under different brand names in different
countries. Both systems detect E6/E7 mRNA from five HR-HPV types (16, 18, 31,33
and 45) (Chan et al. 2012).
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Providing a broader coverage, the APTIMA HPV Assay (Gen-Probe), FDA approved
since 2012, targets mRNA from 14 HR-HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 66, and 68) (Chan et al. 2012).

1.4.3 Colposcopy

Colposcopy (Figure 1.13) is a medical procedure developed in 1925 by the German
physician Hans Hinselmann. Usually suggested as follow up for an abnormal Pap test, it
is based on the visual examination of the cervical and vaginal tissues using a
magnifying colposcope – a binocular magnification of x4-12 that provides a threedimensional view of the cervix and the adjacent vagina (Leeson 2005).

Figure 1.13 Colposcopic examination scheme (National Screening Unit 2016).

The abnormal areas can be identified followed by the application of 3-5% acetic acid or
Lugol’s iodine (Schiller’s test) on the cervix. The acetic acid causes the precipitation of
nuclear and cytoplasmic proteins and, at the same time, induces cellular swelling that
confers an opalescent/white appearance to dysplastic tissue while the Lugol’s iodine
stains mature glycogen-containing tissue allowing the identification of unstained
epithelium as columnar, immature or dysplastic (Leeson 2005).
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Although the “whitening” level of the epithelium is assessed according to standard
guidelines through a scale of 0, ½+, 1+ to 2+, its grading is subjective and, if any
abnormality is suspected, colposcopy directed punch biopsies may be taken or, in more
severe cases, a loop excision performed (Leeson 2005). Given its critical significance
as primary onset site of cervical cancers, a careful visualization of the transformation
zone is also mandatory (Abdel-Hady et al. 2006).
Colposcopy can be considered a sensitive technique, about 92%, for identifying
abnormal cervical changes; however, its specificity is reported to be approximately
67%, requiring further diagnostic confirmation, usually through biopsy/histology
(Cantor et al. 2008; Barut et al. 2015)
1.4.3.1 Dynamic Spectral Imaging (DSI)
Developed by Dr Balas (Balas et al. 1999), Dynamic Spectral Imaging represented in
Figure 1.14, has been showing promising results through quantitative measurements and
mapping of dynamic light-scattering characteristics of the cervical epithelium (Soutter
et al. 2009; Louwers et al. 2011).
The DSI system DySIS™ (Figure 1.14 A), is an imaging platform technology by
DySISmedical® which aims to improve cervical cancer diagnosis (DySISmedical Ltd.
2001). It was granted FDA approval and it is currently the only system recommended
by NICE 13 as a clinical and cost-effective option to aid standard colposcopy (National
Institute for Health Care and Excelence (NICE) 2015).
By enabling the detection and mapping of functional and structural alterations occurring
in abnormal epithelial cells during the progression of the disease, DySIS™ aims to

13

National Institute for Health and Care Excellence is a non-departmental public body,
part of the Department of Health in the United Kingdom, which makes
recommendations to the National Health Service (NHS).
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improve the in vivo examination of the cervix (Balas et al. 2008). It applies an image
processing algorithm that measures the acetowhitening level, which can be highly
correlated with the altered structure and functionality of the abnormal epithelium
(Soutter et al. 2009).
Parameters characterising the acetowhitening process are used to create a dynamic map
(Figure 1.14 B) which is overlaid onto the colour image of the tissue and is used for
grading of the lesion, diagnosis and/or screening (DySISmedical Ltd. 2001; Soutter et
al. 2009).

Figure 1.14 The DSI. A - The DySIS™ instrumentation, B – example of application of the DySIS™ to map the
acetowhitening level (DySISmedical Ltd. 2001).

Nevertheless, a recent study reported the DySISTM colposcopy system to be inferior to
conventional colposcopy in detecting high-grade lesions and therefore was not
recommended to replace conventional colposcopy with random biopsies (Roensbo et al.
2015).
1.4.3.2 LUMA™ Cervical imaging system
As an adjuvant to colposcopy, the LUMA™ Cervical Imaging System (Figure 1.15)
received market approval from the FDA in 2006. This system allows the examination of
the cervix based on the results of three combined optical measurements: fluorescence
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excitation (337nm), white light backscattering (360-720nm) and video imaging
(Kendrick et al. 2007).
The cervix is scanned for 12 seconds while a 337nm ultraviolet nitrogen laser induces
fluorescence, then two xenon flash lamps provide broadband white light in order obtain
reflectance measurements and finally, a video system record the image. The measured
spectra are afterwards analyzed by a multivariate classification algorithm which
determines whether or not the tissue contains neoplastic changes and displays the results
in 30 seconds (Kendrick et al. 2007).
A colour overlay superimposed on the video image of the cervix indicates the areas with
the highest degree of abnormality (Figure 1.15 B) thus guiding a more accurate
colposcopic biopsy; which have shown to improve detection of more high-grade
precancerous abnormalities (26%-33%) compared to colposcopy alone (Kendrick et al.
2007).

Figure 1.15 The LUMA™ Cervical Imaging System. A - LUMA™ console (Scranton Gillette Communications.
2014), B – Image of the cervix utilising LUMA™ Cervical Imaging System to identifying high grade dysplasia
(in blue), adapted from (Poliakoff 2012).
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1.4.4 Histopathology

Derived from the Greek words: “histos”, “pathos” and “logos”, meaning respectively
tissue, disease-suffering, and study, histopathology is the evaluation of pathology at a
tissue level (Orchard et al. 2012). It is the study of pathological processes in tissues by
microscopic examination of stained tissue sections obtained from biopsy and/or surgical
procedure (Quirk et al. 1999).
The histopathological process begins with specimen collection, in other words, with the
acquisition of tissue from the body. Two main methods can be used to tissue collection:
biopsy or surgical removal. While surgical removal is typically performed to extract an
already diagnosed tumour or malignant lesion, which, in many cases can reach the
whole organ; biopsy is a less invasive procedure where only a small, representative
sample of tissue is removed with preservation of the histological architecture. There are
different types of biopsies according to the target tissue that consequently require
different techniques and equipment (Bancroft et al. 2008).
1.4.4.1 Cervical Biopsy
Cervical biopsy is performed for diagnosis of cervical cancer and its precursor lesions;
normally guided by colposcopy or a similar real-time imaging technique such as DSI.
The most common types of cervical biopsy are punch biopsy to conform diagnosis prior
to ablative therapy and, LLETZ (large loop excision of the transformation zone of the
cervix), LEEP (loop electrosurgical excision procedure) and cone biopsy to excise
abnormal tissue.
Punch biopsy (Figure 1.16 a) uses a punch instrument for cutting and removing a disk
of tissue from the cervical area appearing to be abnormal (white after swabbing with
acetic acid) during the colposcopy examination. Cone biopsy (Figure 1.16 b) also
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known as conisation, is the surgical procedure in which a cone-shaped piece of tissue
from the cervix and cervical canal is removed (Cook 2006).

Figure 1.16 Biopsy of the cervix a) punch biopsy, b) cone biopsy adapted from (Penn Medicine 2008).

1.4.4.2 Fixation, Processing & Embedding
After collection, the tissue is fixed in order to prevent degradation and preserve all its
characteristics, ensuring it to be as similar to in vivo as possible; this normally occurs by
submersion of the sample in a fixative solution for an optimal period of time. 10%
formaldehyde is the most common fixative solution used in routine histopathology
(Cook 2006; Orchard et al. 2012).
After fixation, the specimen is then processed through several chemical solutions which
prepare the tissues for embedding in a mounting medium – normally paraffin wax – that
provides physical support for tissue sectioning (Orchard et al. 2012).
1.4.4.3 Sectioning & Staining
Tissue sectioning is performed on a microtome which allows micron (μm) thickness of
sample to be cut. The section thickness relies on internal optimization and may differ
according to different tissue types and their molecular constitutions; typically between 2
and 7 μm for cervical samples. The section is then transferred onto a microscope slide to
be stained (Orchard et al. 2012).
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Different stains can be used to distinguish between different tissues and cellular
components yet the primary and the most commonly used in histopathology is the
Haematoxylin & Eosin (H&E) stain (Orchard et al. 2012).
1.4.4.4 H&E stain
H&E is based on the principle that the cell’s cytoplasm and nucleus have different
acidic and basic properties; the cytoplasm and connective fibres stain with eosin and the
nucleus stains with haematoxylin, allowing good nuclear detail (Bancroft et al. 2008).
Haematoxylin is extracted from the heartwood of the logwood Haematoxylon
campechianum tree and because it stains poorly itself, it is firstly oxidised to its
haematein form which is then combined with a mordant, usually a metal salt, staining
the tissue sections a deep blue to a black colour (Bancroft et al. 2008).
The most common haematoxylins used are the aluminium ones that stain the nuclei red
which is then converted into blue to black by washing the tissue in a weak alkaline
solution, usually tap water. Harris’s haematoxylin is an example of this type of
haematoxylin and it is also the most widely used, both regressively (over-stained and
then differentiated) or progressively (for 1 to 3 minutes stopping the reaction when the
desired intensity colour is achieved) (Carson 1990; Bancroft et al. 2008).
After nuclear staining there is a counterstain of the cytoplasm and connective tissue
with eosin because this is the most suitable stain to contrast with haematoxylin in order
to demonstrate the general histological architecture of the tissue (Bancroft et al. 2008).
Among all the eosins commercially available, the most widely used is eosin Y, a 0.5%
or 1% solution in distilled water which gives varying shades and intensities of pink,
orange and red to its staining components. After staining, dehydration is performed

36

through a series of alcohol concentrations, the section is then cleared in Xylene and a
glass coverslip applied using a resin mounting media. (Bancroft et al. 2008).
1.4.4.5 Diagnosis: Staging & Grading
After staining and mounting, the histological slide is ready for examination under a light
microscope by a trained pathologist. The diagnosis is formulated and a
histopathological report enclosing any abnormal or important findings is available to
clinicians and patients to consult (Cook 2006).
The information generated by the histopathology procedure can be divided into
diagnostic, staging and grading categories; and regardless which disease is diagnosed, a
correct staging and grading is essential for an efficient treatment approach. In case of a
cancer diagnosis, an accurate staging and grading is even more crucial as it will
determine the disease prognosis and therapeutic decisions (Cross et al. 2011).
Based on histopathological characteristics of the tissue, grading assesses the degree of
malignancy or aggressiveness of the abnormal cells by comparing various parameters
such as cellular anaplasia, differentiation and mitotic activity with counterparts in
normal cells and tissue (Yarbro et al. 2010). In general terms, a lower grade indicates a
slower-growing cancer and a higher grade refers to a faster-growing cancer (NHS
2012). The histological grades of cervical cancer are summarized in Table 1.3.
Table 1.3 Cervical cancer grades adapted from (Sobin et al. 2009).

Cancer
grades

Microscopic Characteristics

Grade X

Grade cannot be assessed

Grade I

Well differentiated

Cancer cells resemble normal cells and are not growing
rapidly.

Grade II

Moderately
differentiated

Cancer cells have features between grades I and III - they do
not look like normal cells and are growing somewhat faster
than normal cells.

Grade III

Poorly or
undifferentiated

Cancer cells that look more abnormal and grow or spread
more aggressively.
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Staging on the other hand, is probably the most important characteristic for treatment
selection and evaluation, and is used to assess the extent of the disease. It also
constitutes the most reliable information for prognosis as it describes the size of a
tumor and how much it has spread from where it originally started (Yarbro et al. 2010;
Sobin et al. 2009). Table 1.4 details the staging guidelines in use for cervical cancer
created by the International Federation of Gynecology and Obstetrics (FIGO) in 1995
(Sobin et al. 2009).
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Table 1.4 FIGO Staging for Cervical Cancer adapted from (Sobin et al. 2009).

Stage 0
Carcinoma in situ.
Stage I A1

Stage I A

Stage I

Invasive cancer identified only
microscopically. Invasion is limited to
measured stromal invasion with a maximum
depth of 5 mm and no wider than 7 mm.

Carcinoma is strictly confined to the cervix.

Measured invasion of the
stroma no greater than 3 mm in
depth and no wider than 7 mm
diameter.
Stage I A2
Measured invasion of stroma
greater than 3 mm but no
greater than 5 mm in depth and
no wider than 7 mm in
diameter.
Stage I B1

Stage I B
Clinical lesions confined to the cervix or
preclinical lesions greater than Stage IA. All
gross lesions even with superficial invasion
are Stage IB cancers.

Clinical lesions no greater than
4 cm in size.
Stage I B2
Clinical lesions greater than 4
cm in size.

Stage II

Stage II A

Carcinoma that extends beyond the cervix, but does not extend into
the pelvic wall. The carcinoma involves the vagina, but not as far as

No obvious parametrial involvement. Involvement of up to the upper twothirds of the vagina.
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the lower third.

Stage III
Carcinoma that has extended into the pelvic sidewall. On rectal
examination, there is no cancer-free space between the tumor and the
pelvic sidewall. The tumor involves the lower third of the vagina. All
cases with hydronephrosis or a non-functioning kidney are Stage III
cancers.

Stage II B
Obvious parametrial involvement, but not into the pelvic sidewall.
Stage III A
No extension into the pelvic sidewall but involvement of the lower third of the
vagina.
Stage III B
Extension into the pelvic sidewall or hydronephrosis or non-functioning
kidney.
Stage IV A

Stage IV
Carcinoma that has extended beyond the true pelvis or has clinically
involved the mucosa of the bladder and/or rectum.

Spread of the tumor into adjacent pelvic organs.
Stage IV B
Spread to distant organs.
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1.5 Guidelines for cervical cancer screening programmes
Despite the implementation of organised cervical cancer screening programmes
throughout much of the developed world, there is no international strategy and different
countries have different recommendations as to which screening methodology(ies) to
use, the target population and referral intervals. There can also be wide-ranging
guidelines within different parts of the same country as different trials are run in order
to evaluate new procedures to improve performance and cost-effectiveness. Here, for
the sake of clarity, the Republic of Ireland guidelines are presented along with those of
the UK and United States of America (USA).

1.5.1 Republic of Ireland

CervicalCheck is the national cervical screening programme currently in place in the
Republic of Ireland. Managed by the National Screening Service (NSS) and funded by
the Department of Health through the Health Service Executive (HSE); the programme
stated on September 1st 2008 and it provides free cervical screening through the means
of cervical smear tests, to women aged 25 to 60 resident in the Republic of Ireland.
Smear tests are provided every three years to women aged 25 to 44 and following two
consecutive ‘no abnormality detected’ results, women aged 45 to 60 are screened every
five years (The National Cancer Screening Service 2009). Figure 1.7 shows a flowchart
of the screening process offered by CervicalCheck until 2015.
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Figure 1.17 CervicalCheck Screening Process adapted from (The National Cancer Screening Service 2009). The
actions taken by different partners are indicated by different colours with the programme office in black,
smear-taker in green, cytology laboratory in red, colposcopy clinic in blue and histology laboratory in purple.
ASC-US: atypical squamous cells of undetermined significance; ASC-H: atypical squamous cells of
undetermined significance, cannot exclude high grade; AGUS: atypical glandular cells of undetermined
significance; AGC: atypical glandular cells AGH: atypical glandular cells, favour neoplastic process.

Since April 2015 HR-HPV testing is used as a triage test when atypical cells of
undetermined significance (ASCUS) or LSIL cells are detected on cytology specimens.
The HR-HPV test result is used to determine the recall recommendation; if HPV
negative, screening resumes as appropriate every 3 or 5 years; if HR-HPV positive, the
women are referred to colposcopy. A cytological result of HSIL, atypical squamous
cells, cannot exclude HSIL (ASC-H), atypical glandular cells (AGC), atypical glandular
cells of undetermined significance (AGUS), or atypical glandular cells, favour
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neoplastic process (AGH) are also referred to colposcopy without HR-HPV testing
(CervicalCheck 2015a).

1.5.2 UK - England and Northern Ireland

A similar screening programme based on cytological evaluation of cervical smears with
HR-HPV triage is also provided by National Health Service (NHS) England. The NHS
cervical screening programme is available free of charge to women aged 25 to 64
resident in England. Women aged 25 to 49 receive screening invitations every 3 years
and women aged 50 to 64 every 5 years (Public Health England 2015). Following the
review of the pilot sites data, the UK National Screening Committee recommended in
January 2016 that HPV primary screening should be adopted by this screening
programme (NHS Cervical Screening Programme 2016). Information regarding the new
screening guidelines and implementation has not yet been released.
In Northern Ireland, the cervical screening programme also offers cervical smears every
3 or 5 years to women aged 25 to 49 years and 50 to 64, respectively. As in
CervicalCheck, HPV triage is also used to further evaluate LSIL and ASCUS cytology
results, with all other abnormal results being referred to colposcopy (HSC Public Health
Agency 2013).

1.5.3 USA

In the United States of America, a National Breast and Cervical Cancer Early Detection
Program (NBCCEDP) is available to low-income, uninsured, and underserved women.
In 2012 the American Cancer Society, the American Society for Colposcopy and
Cervical Pathology and the American Society for Clinical Pathology issued joint
guidelines to which screening method should be used in a particular population (Saslow
et al. 2012). A summary of these guidelines is presented in Table 1.5.
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Table 1.5 Summary of the cervical screening recommendations made by the American Cancer Society, the
American Society for Colposcopy and Cervical Pathology and the American Society for Clinical Pathology,
adapted from (Saslow et al. 2012).

POPULATION

RECOMMENDED SCREENING METHOD

Aged < 21 years

No screening

Aged 21-29 years

Cytology alone every 3 years

Aged 30-65 years

HPV and cytology co-testing every 5 years (preferred)
Cytology alone every 3 years (acceptable)

Aged > 65 years

No screening following adequate negative prior screening

After hysterectomy

No screening

HPV vaccinated

Follow age-specific recommendations (same as unvaccinated women)

1.6 Biomarkers
As defined by the National Cancer Institute, a biomarker, also called a molecular
marker or a signature molecule, is “a biological molecule found in blood, other body
fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or
disease” such as cancer that can also “be used to see how well the body responds to a
treatment for a disease or condition” (National Cancer Institute 2016).
There are a variety of biomarkers, from proteins (e.g. enzyme or receptor), nucleic acids
(e.g. microRNA or other non-coding RNA), antibodies, and peptides, to mention but a
few categories. Biomarkers can also refer to a collection of alterations, such as gene
expression, proteomic or metabolomic signatures (Henry et al. 2012).
Biomarkers are used in clinical and biomedical research to gain further knowledge of
the underlying disease. A 2011 review reported that from the more than 1000 DNA and
proteomic biomarkers discovered less than 100 have been validated for routine clinical
practice (Poste 2011).
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Biomarkers for the study of cancer remains one of the most interesting fields of
biomedical research thus is in continuous innovation. The potential uses for cancer
biomarkers are as follows:
•

Estimate risk of developing the disease;

•

Screening;

•

Differential diagnosis;

•

Prognostic determination;

•

Predict response to therapy;

•

Monitoring for disease recurrence;

•

Monitoring for response or progression in metastatic disease (Henry et al.
2012).

1.6.1 Biomarkers in cervical cancer

The limitations of current diagnostic strategies have accelerated the use of alternative
and more objective methods as adjuncts to histopathology, aiming to overcome
diagnosis difficulties (Martin et al. 2011).
In cervical disease, the use of biomarkers in both cytology and histopathology has
demonstrated the ability to reduce issues with false-positive and false-negative results,
leading to an improvement in the positive predictive value of cervical screening results
(Brown et al. 2012b).

The enormous advances in gene profiling and biomarker

discovery technologies in recent years have led to the description of several molecular
biomarkers for CIN and cervical cancer. Mostly involved in HPV-induced molecular
alterations, some of these markers have already been tested and validated to identify
dysplastic cells in cervical smear specimens, and therefore have potential to enhance
and improve current screening performance and, in some cases, have therapeutic
potential as well (Martin et al. 2011).
45

Although, the most extensively used and investigated are Ki-67 and p16, others like
topoisomerase IIa (TOP2A), Survivin, MYBL2 and some of the minichromosome
maintenance (MCM) markers also show promising results. Table 1.6 compiles the most
promising biomarkers in the field with reference to their potential

clinical value

(diagnostic or prognosis) as well as their reported sampling (histology and/or cytology
samples) and the type of assay tested.
Table 1.6 Most promising biomarkers for cervical cancer detection together with their clinical value and
reported sample and assay type.

Biomarker

Clinical value

Sampling

p16

Differential diagnosis of
CIN 2+

Histology &
cytology

p16/Ki67

Differential diagnosis of
CIN 2+

Cytology

MYBL2

Diagnosis of CIN

Histology

MCM 2/ TOP2A

Diagnosis of HSIL

Cytology

Cytoactiv HPV
L1 Capsid
Protein

Prognosis of LSIL

Histology and
Cytology

Survivin

Prognosis

Histology

p63/p73

Diagnosis of HSIL+

Cytology

PIK3CA

LSIL diagnosis

Cytology

Celldetect®

Diagnosis of CIN

Histology and
Cytology

Assay Type

Immunohistochemistry/I
mmunocytochemistry

Specialist stain

1.6.1.1 p16INK4a (CDKN2A) and Ki-67

p16INK4a is a cell-cycle regulator whose expression is tightly regulated in normal cells
and is perhaps the most widely investigated biomarker for cervical cancer and its
precursor lesions.
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It is the product of the CDKN2A tumor suppressor gene; a cyclin-dependent kinase
inhibitor protein involved in cell cycle regulation through the retinoblastoma complex
(Murphy et al. 2005; Martin et al. 2011).
In the absence of HPV, p16INK4a inhibits the cyclin-dependent kinases CDK4 and 6,
which phosphorylate the retinoblastoma (Rb) protein. The binding of phosphorylated
Rb (pRb) to the transcription factor E2F, blocks E2F and down-regulates the
progression of the cell cycle through the G 1 -S transition checkpoint. However, in a
transforming HPV infection, the viral oncoprotein E7 binds and inactivates pRb,
thereby releasing E2F which promotes cell-cycle progression. Meanwhile, E2F is no
longer controlled through action of CDK4 and 6 and p16INK4a, now with no effect on
cell-cycle activation, accumulates in the cell nucleus and cytoplasm over time. The
overexpression of p16INK4a at cellular levels can be detected by immunocytochemistry
(ICC) and serves as a surrogate biomarker for persistent HPV infection (Martin et al.
2011; Pinto et al. 2012; Brown et al. 2012b).
It is widely accepted that p16INK4a is a sensitive and specific marker of dysplastic cells
of the cervix and several studies have tested the application of p16INK4a in cytology
samples and, the majority have demonstrated the effectiveness for improving the
cytological detection of HSIL (Pinto et al. 2012).
Many antibodies have been tested in research studies in order to detect p16; however the
E6H4 clone appears to be the most commonly used.
Ki-67 is a nuclear protein expressed during all the phases of the cell cycle (G1, S, G2
and M), except G0 - resting cells. While its function remains unclear, its expression
appears to be an absolute requirement for progression through the cell division cycle;
for that reason Ki-67 has been used as a cellular proliferation marker to help the
diagnosis and prognosis of many pathologies (Martin et al. 2011; Brown et al. 2012b).
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Although extensively used as an aid for CIN grading, it is not thought to be involved
specifically in cervical cancer carcinogenesis or progression (Martin et al. 2011). Many
studies have however reported that dual ICC of ki-67 and p16 using the CIN Tec PLUS
kit (Roche) is useful to diagnose CIN2+ in cytology samples as it combines superior
sensitivity and non-inferior specificity over Pap cytology alone (Ikenberg et al. 2013).
More recently, it has been suggested this dual ICC could be especially useful in the
triage of abnormal cytology in younger women where HPV testing has limitations.
CINtec PLUS showed similar performance to

the Cobas 4800 HPV test in the

prediction of HSIL among women with cytology diagnosed LSIL (Possati-Resende et
al. 2015).
1.6.1.2 MYBL2

MYBL2 or B-MYB is a member of the MYB proto-oncogene family which encodes the
DNA-binding proteins involved mainly in cell proliferation and cellular differentiation
(Ansieau 1997).
Its transcription levels have been shown to be tightly regulated during the cell cycle by
an E2F dependent mechanism, being of higher level only in late G1 and S phase which
suggest that MYBL2 is involved in activating G1/S phase progression genes (Bessa et
al. 2001; Martin et al. 2011).
MYBL2 also appears to play a role in prevention of apoptosis and HPV16 affects its
expression levels (Sala 2005; Lam et al. 1994).
Different groups have shown MYBL2 to be over expressed in malignancies such as
breast and colorectal cancer (Sheffer et al. 2009; Williams et al. 2009). The overexpression of MYBL2 in cervical CIN and invasive cancer was not identified in normal
cervical epithelial cells (Astbury et al. 2011; Martin et al. 2014). This is in agreement
with previous microarray data that showed MYBL2 expression was absent from normal
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cervix while present in CIN and cervical cancer, suggesting a potential role for the
biomarker in histological diagnosis of CIN (Chen et al. 2003; Astbury et al. 2011).
1.6.1.3 TOP2A & MCM2 – BD ProEx C

MCM 2 functions during DNA replication loading the pre-replication complex onto
DNA and unwinding DNA through helicase activity in order to permit DNA synthesis,
while TOP2A is responsible for the enzymatic unlinking of DNA strands during
replication. Consequently, these two proteins play an important role in the regulation of
DNA replication during S-phase and are over-expressed whenever cell cycle induction
is aberrant (Pinto et al. 2012).
BD ProEx C is a protein-based biomarker reagent developed by BD Diagnosis
(Burlington, NC, USA) that contains antibodies to both MCM 2 and TOP2A (Brown et
al. 2012b). In the normal cervical epithelium, BD ProEx C staining is limited to the
basal proliferating layer, but strongly present throughout a whole dysplastic epithelium.
This is mostly due to the increased transcription of S-phase genes (aberrant S-phase
induction) resulting from the action of HPV E7 oncoprotein (Brown et al. 2012b; Pinto
et al. 2012). Created in 2006, this combined biomarker test was aimed to identify HSIL
in cytological samples (Kelly et al. 2006).
1.6.1.4 Cytoactiv HPV L1 Capsid Protein (L1)

L1 is the name of the major capsid protein of the HPV family and is also the name of an
antibody against a protein of the HPV16 capsid that is only expressed in early
productive phase of the viral infection and therefore is progressively lost during cervical
carcinogenesis (Hilfrich et al. 2008). This loss of L1 expression is believed to result
from the integration of viral DNA into the human genome, which may occur by the
disruption of the L1 gene or loss of its expression by segregating the viral promoter; or
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an abnormality in the transcription pathways or in control of L1 protein translation
(Sherman et al. 2006; McMurray et al. 2001).
L1 stains predominantly the nucleus, although cytoplasmic staining can also be
observed. And, as L1 capsid protein is one of the main targets for T cell-mediated
immune response, cells with a lack of L1 synthesis may escape immune recognition,
therefore allowing disease progression. Its inverse pattern of distribution along the
evolutionary spectrum of SIL when compared to most of the other biomarkers discussed
is in support of the notion that a progressive disease is more frequent in L1-negative SIL
(Pinto et al. 2012; Griesser et al. 2009; Hilfrich et al. 2008; Rauber et al. 2008; Griesser
et al. 2004).
Griesser et al. reported that L1-negative cases tend to progress to HSIL, while L1positive cases do not. Since then, other groups have proposed the combination of L1
and p16IKN4a biomarkers for a prognostic prediction of LSIL in LBC samples (Griesser
et al. 2004; Hilfrich et al. 2008; Sherman et al. 2005; Ngureanu et al. 2010).
1.6.1.5 Survivin

The recently discovered member of the inhibitor of apoptosis proteins family, Survivin,
is thought to have a role in cell death and division (Martin et al. 2011).
Over expression of survivin is thought to be related with the degradation of p53 tumorsuppressor proteins through interaction with HPV E6 oncoproteins and has been
reported in a wide range of cancers including cervical cancer. It is associated with
resistance to treatment (chemoradiation followed by radical surgery) and increased risk
of recurrence and poor survival (Altieri 2003; Santin et al. 2005; Borbély et al. 2006;
Zannoni et al. 2014).
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The expression of survivin protein and mRNA increases in cervical pre-cancer with the
severity of the dysplasia and it is also associated with high-risk HPV infection (Kim et
al. 2002; Branca et al. 2005).
1.6.1.6 p63/p73

p63 and p73 are homologues of the p53 gene; multiple isoforms of proteins of both
genes exist. Cheung et al conducted a study where antibodies anti-p63 4A4 (against
isoforms TAp3 and ΔNp63 of p63) and Tap73 (against isoform TAp73α of p73) were
tested in LBC samples. Using a scoring system, the authors concluded that
immunoreactivity for Tap73 and p63 4A4, together with morphological assessment,
could detect HSIL and cervical cancer. Moreover, p63 4A4 immunoreactivity in women
with ASC-US and a high Tap73 index in women with LSIL correlated with a higher rate
of progression to HSIL or above (Cheung et al. 2010).
However, it is important to highlight that, similar to p16INK4a, p63 also stains the normal
immature squamous cells present in atrophic samples and thus morphological
evaluation is needed to minimize false positive results. These and other isoforms of p63
and p73 should be further investigated (Cheung et al. 2010; Pinto et al. 2012).
1.6.1.7 PIK3CA

PIK3CA, composed of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit, is
an important component of the lipid signalling pathway. Its subsequent activation of the
downstream serine/threonine protein kinase has been reported to be related to ovarian
cancer, squamous cell carcinoma of the head and neck, and uterine cervix
carcinogenesis (Pinto et al. 2012; Redon et al. 2001).
Goto et al. tested PIK3CA as a carcinogenic-related marker for cervical cancer in LBC.
They concluded that Ki-67 and PIK3CA might be useful as adjuvant tools to HPV-DNA
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testing; Ki-67 could relate to the growing potential of the cell whilst PIK3CA would act
as a carcinogenesis-related marker for early disease (Goto et al. 2006).
More recently, several studies have shown PIK3CA mutations to be frequent in cervical
cancer (both adenocarcinoma and SSC) however the response to molecularly targeted
therapies in different cervical cancer histology warrants investigation in clinical trials
(Tornesello et al. 2014; Arjumand et al. 2016).
1.6.1.8 CellDetect®

CellDetect® (Zetiq Technologies Ltd, Israel) is a staining technique for cancer
diagnosis. It has been shown to consistently differentiate cancer from normal and
reactive tissues in histological and cytological preparations as well as cell lines
(Idelevich et al. 2009; Sagiv et al. 2009).
The stain targets the cytoplasm where non-neoplastic cells stain green/blue while
neoplastic cells stain red/magenta. With these staining characteristics being presented
even in small foci of neoplasia, CellDetect® allows a clear distinction of neoplasia from
the surrounding tissue which can sometimes be difficult to achieve with common H&E
(He et al. 2014).
CellDetect® has been applied to cervical cancer research in both

histology and

cytology specimens with the latest report showing a 95.36% sensitivity and 87.31%
specificity for detection of

CIN+ and SCC on cytology specimens indicating a

promising colorimetric biomarker tool for disease diagnosis (He et al. 2014).
1.6.1.9 DNA Methylation

DNA methylation is a covalent chemical modification in which a methyl group is added
to the DNA, usually to the fifth carbon ring, therefore modifying the function of the
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genes. It is simultaneously the most common and significant epigenetic modification in
the mammalian genome (Mersakova et al. 2015).
The methylation of specific biomarkers has recently been suggested as a promising tool
for cervical cancer diagnosis. It has been observed in other cancers such as breast
(Zubor et al. 2008) and endometrial (Fiolka et al. 2013). Whilst cell adhesion molecule
1 (CADM1), cadherin 1 (CDH1), death-associated protein kinase 1 (DAPK1),
erythrocyte membrane protein band 4.1-like 3 (EPB41L3) family with sequence
similarity 19, chemokine (CC motif)-like, member A4 (FAM19A4) myelin and
lymphocyte protein (MAL), paired box 1 (PAX1), protease domain domain-containing
14 (PRDM14), and telomerase reverse transcriptase (TERT) are among the most
common methylating genes for samples with SSC and adenocarcinoma; in CIN, the
methylation frequency was higher for the CADM1 gene, followed by CDH1, DAPK1,
and TERT (Wentzensen et al. 2009). The most reliable panel seems to include genes
from CADM1 and MAL with several groups testing its performance for cancer and CIN
detection (Mersakova et al. 2015). Finally, alteration in the DNA methylation of deathassociated protein kinase 1 (DAPK1), retinoic acid receptor beta (RARB), Wntinhibitory factor-1 (WIF1), and slit guidance ligand 2 (SLIT2) were reported to increase
specificity of cervical cancer detection when compared to HPV testing (Siegel et al.
2015).
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1.7 Optical Spectroscopy
As described in section 1.4 of this chapter, the current methods for diagnosis of cervical
cancer hold several limitations. The cytological evaluation of Pap smears, for example,
is subjective; HPV testing cannot inform on cellular abnormality; and colposcopy is too
invasive to be used as a primary or co-screening method.
Furthermore, the majority of biomarkers available are more extensively reported and
optimized for histology specimens. Nevertheless, even when successfully applied to
cytology specimens, only a limited amount of proteins (usually two) can be detect in the
same sample before the stain becomes indistinguishable at microscopic evaluation.
Optical spectroscopy methods such as vibrational spectroscopy (Raman and Infrared
spectroscopy) probe the intramolecular vibrations and rotations of a sample when
irradiated with light (Baker et al. 2016). The vibrations are dependent on the
biochemical composition of the analysed sample and are therefore highly specific.
Recent studies have shown both Raman and Infrared spectroscopy to be promising new
biomedical tools for the diagnosis of cancer (Kong et al. 2015; Hughes et al. 2016).
Infrared measurements display higher signal-to-noise (S/N) ratios and can be carried out
over an entire cell in a few seconds, whereas Raman acquisition could take up to 100
times longer, being usually used to sample a small part of the cell instead. Nevertheless,
Raman spectroscopy has the advantages of allowing higher spatial resolution, as little as
1 µm in diameter, and requiring minimal sample preparation; with biological specimens
it also has the advantage of lower interference with water and not requiring expensive
reflective substrates (Diem et al. 2008; Butler et al. 2016). Raman spectroscopy was
therefore preferred for this study.
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1.7.1 Raman Spectroscopy
1.7.1.1 Theory

The theory of Raman scattering or the Raman effect postulates that a small fraction of
the radiation scattered by certain molecules differs from that of the incident beam, and
that the shifts in the wavelength depend upon the chemical structure of the molecules
responsible for scattering (Skoog et al. 1997).
When interacting with a molecule, the incident photon may be absorbed or scattered.
Elastic scattering, also called Rayleigh or Mie scattering occurs when the scattered
photon is of the same energy as the incident photon. Raman spectroscopy is however
based on inelastic scattering phenomena when the energy of the scattered photon is of
lower (Stokes scattering) or higher (anti-Stokes scattering) energy than that of the
incident photon (Skoog et al. 1997; Ball 2001). A simplified diagram illustrating these
concepts is presented in Figure 1.18.

Figure 1.18 Energy level diagram for Rayleigh, Stokes and anti-Stokes scattering (Ostrowska 2011).

In order for Stokes scattering to occur a molecule needs to be excited to a virtual energy
level that comprises a distortion of an electron cloud so when it then returns to the first
excited vibrational state, a photon with a lower energy (longer wavelength) is emitted.
The energy difference between the incident and emitted photon excite the molecule to a
higher vibrational state (Skoog et al. 1997; Gauglitz et al. 2003; Ball 2001).
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In anti-Stokes scattering the molecule is in a higher vibrational energy level so when
subsequently excited to a virtual energy level, relaxes, and returns to the ground
vibrational state. In this case, the energy difference between emitted and excited photon
is converted to radiant energy and a vibrational quantum has been annihilated (Skoog et
al. 1997; Gauglitz et al. 2003; Ball 2001).
For a molecular vibration to be Raman active, a change in net molecular polarizability
must occur. The polarizability (α) represents the ability of an applied electric field, E, to
induce a dipole moment, μ 0 , in an atom or molecule; a process represented
mathematically by the equations below (Ball 2001):

µo = α E
Equation 1.1 Dipole moment.

At the molecule’s nuclear geometry equilibrium the polarizability has a value, α 0 . In
case of displacement, ∆r, away from the molecule’s equilibrium geometry, the
instantaneous polarization α is given by:

 ∂α 
α=
α o +   ∆r
 ∂r 
Equation 1.2 Instantaneous polarization at equilibrium displacement where

 ∂α 
 ∂r 

represents the change in

polarizability as a function of displacement.

If the molecule is vibrating in a sinusoidal fashion, ∆r can be written as a sinusoidal
function in terms of the frequency of the vibration, ν s , and the time, t:
∆𝑟 = 𝑟𝑚𝑎𝑥 𝑐𝑜𝑠(2𝜋𝑣𝑡)
Equation 1.3 Equilibrium displacement when the molecule vibrates in a sinusoidal fashion where r max is the
maximum vibrational amplitude.

Light of a particular frequency, ν o , has an associated electric field, E, which also has
sinusoidal behaviour:
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E = Emax cos ( 2π v0t )
Equation 1.4 Electric field where E max is the maximum electric field frequency.

Equations 1.1 to 1.4 can thus be written into equation 1.5 so that the first term
represents the scattered phenomenon of a photon with the same intensity as the incident
photon – Rayleigh scattering. The second term represents the Raman scattering of
frequency v 0 +v s (anti-Stokes scattering) when the frequency of the scattered photon
increases by molecular motion, v s ; and v 0 -v s (Stokes scattering) when the frequency
decreases.

 dα 
=
µ0 α 0 Emax cos(2πυ0t ) + Emax rmax   cos(2πυs t ) cos(2πυ0t ) ⇔
 dr 
=
⇔ µo α o Emax cos ( 2π vot ) +

Emax rmax  ∂α 
cos ( 2π t ( vo + vs ) ) + cos ( 2π t ( vo − vs ) )
2  ∂r 

Equation 1.5 Scattered light component frequencies by oscillating polarization in which v 0 is the frequency of
incident light and v s is the frequency of the scattered molecular motion.

1.7.1.2 Raman Spectrometer and Raman spectra

Raman spectra are acquired by irradiating a sample with a powerful laser source
(usually monochromatic visible, near-infrared or ultraviolet (UV) radiation) and
measuring the scattered radiation with a suitable spectrometer (Skoog et al. 1997; Ball
2001). Figure 1.19 shows the process involved in collection of Raman spectra and the
main components of a Raman spectrometer.
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Figure 1.19 Schematic showing the process involved in Raman spectra collection. When the sample is
illuminated by an incident monochromatic light, the majority of the scattered light is of the same wavelength elastically scattered (green arrow). A notch filter is therefore used to block the elastically scattered light which
would otherwise overwhelm the weak signal of the Raman or inelastically scattered light (orange arrow). The
Raman scattered light may be dispersed according to wavelength through a grating and detected by a CCD
(charge-coupled device) detector. A Raman spectrum is finally shown upon software analysis.

Knowing the frequency of the incident light and measuring the frequency of the Raman
scattered light, it is possible to calculate the vibrational energy difference. This energy
is known as the Raman shift and is usually expressed in wavenumbers (cm-1) in a plot
known as the Raman spectrum. Raman spectral features can be used as identification
markers of particular substances as complex molecules have several specific vibrational
energy modes allowing the Raman spectrum of each substance to be highly specific and
distinctive (Sasic 2007). Figure 1.20 shows an example of a Raman spectrum recorded
from a cervical cancer cell line, CaSki. The full spectral range is shown from 400-3500
cm-1, including the fingerprint region, 400-1800 cm-1, which provides information on
proteins, lipids and nucleic acids, and the high wavenumber region, 2800 – 3500 cm-1,
which provides information on lipids and proteins.
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Figure 1.20 Raman spectrum of cervical cancer CaSki cell line. The variation of Raman shift wavelength is
expressed in wavenumbers (cm-1) and can be observed along the X-axis whilst the intensity is represented
along the Y-axis. The fingerprint and the high wavenumber (HW) regions of the spectrum are indicated by the
arrows.
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1.8

Overall aims of the present study

Despite the great success that the implementation of cytology based screening
programmes had in decreasing disease mortality, the current LBC methods present great
variability in the sensitivity rates reported (74 to 96%) with repetitive testing and crosschecking needed to achieve the highest standard results (Kitchener et al. 2011).
Furthermore, HPV testing, which is currently recommended as a co-test and even as a
primary screening method in some countries (NHS Cervical Screening Programme
2016), does not provide information with regards to cellular abnormality. Raman
spectroscopy can theoretically offer a non-subjective, label-free biochemical fingerprint
of the analysed samples with minimal sample preparation; and this present study aims to
investigate the applicability of Raman spectroscopy to the diagnosis of cervical cancer
and pre-cancer using LBC (ThinPrep®) samples from a screening population.
Overall this thesis comprises a total of 9 chapters. Chapter 1 is an introduction to
cervical cancer and the current screening methodologies as well as the theory of Raman
spectroscopy. Chapter 2 is a literature review of the application of Raman spectroscopy
to the study of cervical cancer which has previously been published in a peer-reviewed
journal. Chapter 3 describes all materials and methods used in this study as well as the
sample databases used; the study’s results are presented in chapter 4 to 8, according to
the specific aims addressed:
•

To establish the potential of Raman spectroscopy for liquid based
cervical cytology samples to distinguish normal and CIN cytology;
further investigating the best way to correct/minimize the substrate
(glass) contribution to the sample spectra and the PCA-LDA
classification algorithms (chapter 4).
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•

To assess the influence of age, HPV profile, menstruation cycle and
previous disease history on the sample spectral profiles, probing if they
can be inferred from PCA-LDA classification algorithms (chapter 5).

•

To evaluate the performance of PCA-LDA algorithms for both CIN and
SIL reporting systems (chapter 6).

•

To further test the PCA-LDA classification models on an independent
sample test set (chapter 7).

•

To determine the p16 and Ki-67 biomarker profiles of the samples by
immunocytochemistry (chapter 8)

Finally, a general discussion and future research directions are presented in chapter 9.
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CHAPTER 2

CURRENT ADVANCES IN THE APPLICATION

OF RAMAN SPECTROSCOPY FOR MOLECULAR DIAGNOSIS
OF CERVICAL CANCER
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This chapter was adapted from a peer-reviewed literature review article by Inês Raquel
Martins Ramos, Alison Malkin, and Fiona Mary Lyng, entitled “Current Advances in
the Application of Raman Spectroscopy for Molecular Diagnosis of Cervical Cancer” in
BioMed Research International, vol. 2015, Article ID 561242, 9 pages, 2015.
doi:10.1155/2015/561242.
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2.1 Raman spectroscopy for biomedical applications
Raman spectroscopy has been applied in numerous scientific fields, from chemistry and
biochemistry to arts and archaeology, as a powerful spectroscopic technique which
allows a spectral fingerprint capable of identifying and studying the structure and
function of molecules, cells, tissues or materials (Krafft 2004; Baraldi et al. 2008). Its
application to medical diagnostics has been of increasing interest in the past few
decades (Diem et al. 2008).
Raman spectroscopy has been reported for the detection of different types of
pathologies including cancer (Kendall et al. 2009; Matousek et al. 2015; Kong et al.
2015) .A number of studies concerning the investigation of cervical cancer with this
particular vibrational spectroscopic technique have demonstrated its usefulness in
understanding the disease progression at the molecular level.
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2.2 Raman spectroscopy in cervical cancer research

Raman spectroscopy has increasingly been reported in the cervical cancer literature
since the late 1990s when the first exploratory experiments started to be documented.
Table 2.1 compiles all the Raman spectroscopy studies concerning cervical cancer
reported in the literature so far. All studies are referred to in the following sections
which are grouped according to sample type. In vivo measurements relate to those
acquired directly from the cervix of patients, ex vivo refers to the measurements
acquired from the surface of biopsies and other surgical material extracted from the
patient’s cervix, and in vitro refers to spectra obtained from cell lines. Formalin fixed
paraffin preserved (FFPP) histological sections and cytology are referred to separately.
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Table 2.1 Raman spectroscopy studies concerning cervical cancer reported in the literature until November 2016 sorted by diagnosis (D), treatment response (R) and further
conditions analysed. Sampling numbers and data analysis methodology are also indicated as maximum representation and discrimination feature (MRDF), sparse multinomial logistic
regression (SMLR), principal component analysis (PCA), linear discriminant analysis (LDA), genetic algorithm-partial least squares-discriminant analysis (GA-PLS-DA), partial
least squares-discriminant analysis (PLS-DA), Fisher’s discriminant analysis (FDA), principal component analysis logistic regression (PCA-LR) and spectral analysis when no
multivariate statistical method was reported.
Raman
spectroscopy
Sampling

Sampling

[spectral

Year
type

Data Analysis

Authors (Research

numbers

Sort Category

Other considerations
methodology

group)
region; laser
used]
Mahadevan-Jansen et al.
Fingerprint

Not disclosed

1998

(Mahadevan-Jansen et al.

D

Spectral Analysis

-

D

Spectral analysis

-

D

MRDF and SMLR

Multiclass development

D

MRDF and SMLR

Hormonal variation influence

D

PCA-LDA

-

region; 789nm
1998a)
Utzinger et al. (Utzinger et
1000-1800cm25

2001

al. 2001) (Mahadevan1

; 789nm

Jansen group)

In vivo
Kanter et al. (Kanter et al.
Fingerprint

n=12
66

2009

2009a) (Mahadevan-Jansen
region; 785nm
group)
Kanter et al. (Kanter et al.
Fingerprint

31

2009

2009b) (Mahadevan-Jansen
region; 785nm
group)

46

2009

Mo et al. (Mo et al. 2009)

HW (2800-

66

(Huang group)

3700cm-1)
region; 785nm

Kanter et al. (Kanter et al.
Fingerprint
102

2009

2009c) (Mahadevan-Jansen

D

MRDF and SMLR

D

SMLR

-

region; 785nm
group)
Vargis et al. (Vargis et al.
Fingerprint
172

2011

2011a) (Mahadevan-Jansen

Normal variability and

region; 785nm

previous disease

group)
Duraipandian et al.
Fingerprint
29

2011

(Duraipandian et al. 2011)

Additional genetic algorithm
D

GA-PLS-DA

region; 785nm

techniques

(Huang group)
Vargis et al. (Vargis et al.
Fingerprint
75

2011

2011b) (Mahadevan-Jansen

Investigation of normal
D

MRDF and SMLR

region; 785nm

patient variability

group)
Fingerprint &

44

Duraipandian et al.

HW (2800-

(Duraipandian et al. 2012)

3700cm-1)

2012

D

PLS-DA

-

-

PLS-DA

Vagifem treatment

D

PCA-LDA

-

region; 785nm

26

26

2013

2016

Duraipandian et al.

HW (2800-

(Duraipandian et al. 2013)

3700 cm-1)

(Huang group)

region; 785nm

Shaikh et al. ((Shaikh et al.

Fingerprint;

67

2016) (Krishna group)

785 nm

Mahadevan-Jansen et al.
Fingerprint
20

1998

(Mahadevan-Jansen et al.

D

FDA and PCA

-

D

PCA

-

R

PCA

-

D

MRDF and SMLR

region; 789nm
1998b)

150

Krishna et al. (Krishna et al.

Fingerprint

2006a)

region; 785nm

2006

Vidyasagar et al.
Fingerprint
66

2008

(Vidyasagar et al. 2008)
region; 785nm
(Krishna group)

Ex vivo

Keller et al. (Keller et al.
Fingerprint

n=8

102

2008

2008) (Mahadevan-Jansen

Investigation of temporal and

region; 785nm

spatial effects

group)
Fingerprint
Martinho et al. (Martinho et
63

region;

2008

D

PCA-LR

Cervicitis influence

D

Spectral analysis

-

R

PCA-LDA

Chemo-radiotherapy

D

PCA-LDA

-

al. 2008)
1064nm

14

42

Kamemoto et al.

Fingerprint

(Kamemoto et al. 2010)

region ;785nm

Rubina et al. (Rubina et al.

Fingerprint

2013b) (Krishna group)

region; 785nm

2010

2013

Daniel, et al. (Daniel et al.
61

Fingerprint

2016
2016a)

region ;

68

Polarized,
784.14 nm
Fingerprint
Daniel, et al. (Daniel et al.
Not disclosed

region ;

2016
2016a)

-

PCA-KMA

-

D

Spectral analysis

-

D

PCA

-

D

PCA

HPV influence

-

Spectral analysis

Polarized,
784.14 nm

-

-

1999

Yazdi et al. (Yazdi et al.

600-2500cm-1;

1999) (Richards-Kortum

Resonance,

group)

257nm

Jess et al. (Jess et al. 2007)

Fingerprint

(Herrington group)

region; 785nm

Ostrowska et al. (Ostroswka

Fingerprint

et al. 2010) (Lyng group)

region; 532nm

Kim et al. (Kim et al. 2010)

Fingerprint

2007

In vitro
n=5
-

-

2010

2010
(Goodacre group)

HPV16 influence (E6

region; 830nm

protein)

Vargis et al. (Vargis et al.
Fingerprint

In vitro & Cytology

50

2012

2012) (Mahadevan-Jansen

-

SMLR

HPV detection

-

PCA-LDA

-

region; 785nm
group)

Cytology

94

2013

Rubina et al. (Rubina et al.

Fingerprint

69

2013a) (Krishna group)

n=3

region; 785nm

Bonnier et al.
63

2014

(Bonnier et al.
2014) (Lyng

Fingerprint ;

Protocol for evaluation of
-

PCA

532nm

ThinPrep samples

group)

18

FFPP
n=3
60

20

Krishna et al. (Krishna et al.

Fingerprint

2006b)

region; 785nm

Lyng et al. (Lyng et al.

Fingerprint;

2007)

514.5nm

Rashid et al.(Rashid et al.

Fingerprint;

2006

2007

2014

Cervical Fluids

2015

9

plasma

110

42

D

PCA-LDA

-

PCA ; K-means cluster
analysis

Fingerprint;
-

HPV detection

D

HPV and dysplasia detection

SERS, 785nm

Kim et al. (Kim et al. 2016)

Fingerprint;

(Choi group)

SERS, 785nm

Feng et al. (Feng et al.

350-1750cm-1;

2013) (Huang group)

SERS, 785nm

González-Solís et al.

Fingerprint

(González-Solís et al. 2013)

region; 830nm

2013

n=2

-

785nm

2016

Blood
serum

Choi et al. ((Choi et al.
2015)

n=2

PCA

D
2014) (Lyng group)

9

D

2013

70

D

PCA-LDA

-

D

PCA

-

2.2.1 In vivo - spectra recorded from the patient

Mahadevan-Jansen et al. in 1998 were the first to report the Raman spectrum of cervical
tissues and acknowledged the potential of Near Infrared (NIR) Raman spectroscopy to
detect cervical pre-cancers amongst other pathologies. They developed a compact fibreoptic probe which they used to record ex vivo and in vivo spectra (Mahadevan-Jansen et
al. 1998b; Mahadevan-Jansen et al. 1998a).
The overall ex vivo conclusions stated that in the Raman spectrum of squamous
intraepithelial lesions, peaks attributed to collagen (1656, 1070 cm-1) consistently
decreased in intensity while peaks assigned to phospholipids, DNA and glucose 1phosphate (1454, 1330, 978 cm-1) increased in intensity. Although the authors
acknowledged these findings to be consistent with tumour progression, as the number of
cells in the epithelium increases with lesion development, further evidence was
recommended in order to quantitatively relate the differences in the tissue NIR Raman
spectra to tumour biochemical changes. Furthermore, the application of multivariate
methods to data analysis allows the differentiation of precancers from all other tissues
with a sensitivity and specificity of 82% and 92% (Mahadevan-Jansen et al. 1998a).
Their exploratory in vivo results appear to be in line with those observed ex vivo
showing similar Raman spectra obtained in the fingerprint region (Mahadevan-Jansen et
al. 1998b). The main differences reported were a band at 936 cm-1 only observed in
vivo, a peak at 978cm-1 that was not consistently observed ex vivo and the amide band at
1252 cm-1 that was more prominent in vivo. The need to increase patient numbers was
pointed out along with possible solutions towards in vivo technology improvement
(Mahadevan-Jansen et al. 1998a).
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With advances in fiber-optic technology by 2001, Utzinger et al. designed a more
comprehensive study to assess the viability of Raman spectroscopy not only to detect
but also classify cervical precancer lesions (Utzinger et al. 2001). A small clinical trial
was undertaken using histopathology biopsies as the gold standard classification and it
was concluded that useful Raman spectra could be acquired from in vivo sampling. The
results showed agreement with their group’s ex vivo experiments (Mahadevan-Jansen et
al. 1998b) with a consistent increase in Raman intensity of phospholipids and DNA
assignments, ~1330, 1454 and 1650 cm-1 respectively, as the lesions progressed to highgrade dysplasia (Utzinger et al. 2001). Despite these encouraging results the authors
noted the heterogeneity of the tissue and thus the possible contribution of normal
epithelial cells to the spectral data; they also suggested that further technological
advances were once again needed to test the viability of large scale clinical trials
(Utzinger et al. 2001).
The influence of normal patient variability, hormonal variation and proximity to disease
contributing to the accuracy of cervical cancer diagnosis by Raman spectroscopy has
also been explored by the same group.
Characterizing the hormonal changes, particularly menstrual cycle and menopausal state
and introducing them into the in vivo diagnosis algorithm, Kanter et al. improved the
accuracy of Raman spectroscopy to 94% (Kanter et al. 2009a) reaching 97 % for lowgrade dysplasia detection (Kanter et al. 2009b). With the main mean normal and lowgrade dysplasia Raman spectral differences observed within the 1230-1300 cm-1 range,
the analysis of postmenopausal, perimenopausal, premenopausal normal cervix before
and after ovulation showed subtle but consistent differences at 1250 cm-1 and 13001320 cm-1, assigned to collagen and other cellular features like lipids, Amide III and
nucleotides (Kanter et al. 2009b).
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Similarly, previous disease history and the proximity to malignant lesions were also
shown to influence Raman spectral profiles. ‘True’ normal and ‘previous disease’
normal spectra do not appear to differ greatly, the principal qualitative differences were
found in the 1200-1400cm-1 range with assignments to proteins and collagen type I
being higher in ‘true’ normal spectra whilst the DNA and glycogen assignments (~1330
cm-1) were higher in ‘previous disease’ normal Raman spectra (Vargis et al. 2011a). The
1200-1400 cm-1 range was also found to comprise the most significant differences
between Raman spectra of ‘true’ normal, ‘adjacent to disease’ normal, low-grade
dysplasia and high-grade dysplasia. Collagen assignment was yet again higher in both
‘true’ and ‘adjacent to disease’ normal whereas DNA was higher in low and high-grade
dysplasia (Vargis et al. 2011a).
In an attempt to further establish the greatest sources of intra-class variation among
normal Raman spectra, Vargis et al. addressed race & ethnicity, body mass index
(BMI), parity and socioeconomic status in their in vivo study. Their results concluded
that BMI and parity were the only significant sources of separation within normal
spectra. The influence on dysplasia and disease remains to be assessed as they were not
investigated (Vargis et al. 2011b).
Daniel et al. compared polarized and conventional Raman spectroscopy and reported
additional information about the orientation of tyrosine, collagen and DNA molecules in
cervical tissue. DNA/RNA assignments at 785, 1084, 1174, 1375 and 1578 cm−1 were
found to be enhanced in cancer samples whereas collagen (817, 937, 1247, 1265, 1340
and 1656 cm−1), glycogen (850 and 1022 cm−1) and lipids (968, 1032, 1057, 1087, 1264,
1372 and 1445 cm−1) were characteristic of normal tissue samples. In addition, crossvalidated LDA of polarised Raman spectra was found to yield better accuracy, with
96.7% of cases being correctly classified as either normal or cancer against 80.3%
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accuracy using conventional Raman spectroscopy. The authors concluded polarized
Raman spectroscopy therefore offers a better diagnostic potential than conventional
Raman spectroscopy for the detection of cervical cancer and it warrants further
investigation (Daniel et al. 2016a).
Conventional Raman spectroscopy was also compared against diffuse reflectance
spectroscopy (DRS) in a study by Rubina et al. Based on the elastic scattering process,
DRS is able to detect changes in tissue morphology, vasculature, and chromophores; it
has previously been reported to detect cervical cancer in real-time and non-invasive
matter (Mirabal et al. 2002; Marín et al. 2005). In this in vivo study, the cervix of 26
patients (20 cancer and 6 negative controls) was accessed with both Raman
spectroscopy and DRS; PCA-LDA with LOPOCV was used to classify between cancer
and normal sites. The overall accuracy (>91%) for the model generated by Raman
spectral data was superior to that of DRS (>85%) and, although recommended for
centralized facilities, the authors point out that the lower cost and easier handling of
DRS might be more suited for cervical cancer screening in rural communities (Shaikh et
al. 2016).

2.2.2 Ex vivo – spectra recorded from excised patient tissue

Krishna et al. reported Raman spectral differences between normal and malignant
biopsy samples. Amide I, III and structural proteins such as collagen seemed to be
characteristic of normal tissue whilst the presence of DNA, lipids and non-collagenous
proteins dominated the abnormal spectral features (Krishna et al. 2006a).
A Raman microspectroscopy study provided deeper insights by showing Raman
spectroscopy could detect changes to adjacent regions of dysplasia or HPV infection
that cannot be detected histologically. The average Raman spectra profiles from the
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stroma below tissue presenting HPV associated histological changes show visible
differences for DNA (1316 and 1334 cm-1) and glycogen (1048, 1083, 1256, 1333 cm-1)
assignments. Whilst increased DNA levels and decreased levels of glycogen in the
epithelium has been extensively described before as dysplasia progresses, Keller et al.
argued that nothing was ever reported concerning alterations of the histologically
normal stroma below diseased epithelium. Further differences at 1260 and 1304 cm-1
Amide III band are proposed to be related to the angiogenesis process or the disease has
extended without histologically visible effects (Keller et al. 2008). Either way, further
study of this phenomenon is warranted as disease classification depends on stromal
invasion.
Martinho et al. investigated the role of cervicitis in Raman spectroscopy diagnosis of
low-grade dysplasia. Despite an overall 93% sensitivity and a specificity of 85%, the
results showed that the main spectral changes observed at 857, 925, ~1247, 1370 and
1525 cm-1 vibrational bands made the cervicitis group fall mid-way between the normal
and low-grade dysplasia groups and were intrinsically identified as dysplasia. Data
showed that a severe inflammatory condition such as cervicitis makes the identification
and correct diagnosis of early malignancy stages such as low-grade dysplasia difficult
and must therefore be taken into account when developing the data analysis algorithms
(Martinho et al. 2008).
Finally a NIR micro-Raman spectroscopy study by Kamemoto et al. showed that
Raman spectra from collagen bands at the low frequency 775-975 cm-1 region
distinguish normal from cervical cancer cells, and is concordant with the analysis of CH stretching in high wavenumber (HW) region (2800-3700 cm-1) (Kamemoto et al.
2010).
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2.2.3 FFPP sections – spectra recorded from histological sections

Raman spectroscopy studies have been undertaken on histological FFPP sections in
parallel, further confirming Raman spectroscopy as a powerful informative tool in
cervical cancer research. Archival FFPP material is extremely valuable as it allows
retrospective studies to be undertaken after diagnosis and outcome is known.
Krishna et al. studied formalin fixed cervical tissues by both Raman and FTIR
spectroscopy, reporting the discrimination of malignant tissues through both techniques.
In Raman spectra, differences in protein, lipids and nucleic acid peaks were observed
along with stronger Amide III assignments suggestive of disordered, helical secondary
structure of protein components in malignant conditions (Krishna et al., 2006).
Further confirmation of the potential of Raman spectroscopy as a solid powerful
diagnosis tool for cervical cancer was reported by Lyng et al. when their work
demonstrated the viability of using formalin fixed paraffin preserved samples and
investigated the underlying biochemical changes associated with cervical cancer (Lyng
et al. 2007). Results showed glycogen bands at 482, 849 and 938 cm-1 are absent from
carcinoma spectra which similar to previous reports show prominent nucleic acid bands
(724, 779, 829, 852, 1002, 1098, 1240 and 1578 cm-1). An increase intensity of Amide I
was also reported for carcinoma spectra (Lyng et al. 2007).

In 2014 our group further

reported a Raman microscpectoscopy study on FFPP cervical biopsies. Results showed
Raman spectroscopy could distinguish tissues classified as negative for intraepithelial
lesion and malignancy (NILM) from LSIL and HSIL tissues. Furthermore, K-means
cluster analysis (KMCA) allowed the differentiation of NILM cervical tissue into three
clear epithelial layers, stroma, basal/para-basal and superficial, dominated by collagen,
DNA and glycogen assignments respectively. For LSIL and HSIL samples, KMCA
clustered the superficial layer together with the basal layer suggesting a loss of
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differentiation in these groups. Furthermore, PCA showed that this feature could also be
observed in normal areas of LSIL and HSIL samples where morphological changes
were not yet apparent (Rashid et al. 2014).
More recently, another study comprising the Raman micro-spectroscopy mapping and
k-mean clustering analysis of normal cervix, including endocervical and ectocervical
regions, neoplastic cervix and cervical carcinoma was also published by Daniel et al.
NNLS was further used to extract chemometric information of the molecular
components present in each tissue type. DNA, histone and cholesterol content were
found to be increased in cancer as opposed to actin, beta-carotene, protein and collagen
content which all decreased. Glycogen content in neoplasia was found to be lower than
in normal tissue but increased slightly on progression to carcinoma (Daniel et al.
2016b).

2.2.4 In vitro – spectra recorded from cell lines

Yazdi et al. described the use of UV resonance Raman spectroscopy at 257nm to
distinguish between normal and malignant breast [MCF-10A, MCF-7 McGuire and
MDA-MB435] and cervical [CrEc-Ec 4665 (primary culture from normal cervix
epithelium), SiHa and HeLa] cultured cells. They reported an increase in DNA/protein
ratio and a change in purine scattering in malignant cells that could allow the
application of resonance Raman spectroscopy in cytology screening by monitoring
DNA and RNA differences between normal and abnormal cells (Yazdi et al. 1999).
Despite being the main aetiology factor in cervical cancer, HPV was only brought under
Raman spectroscopy investigation towards the end of the last decade with a cell culture
study by Jess et al. Raman microspectroscopy was applied to discriminate PHK
(primary human keratinocytes), PHK E7 and CaSki cells, where PHK E7 cells express
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the E7 gene of HPV16 and CaSki expresses HPV16. The mean Raman spectra showed
variations at DNA and protein level, consistent with HPV gene expression and
malignancy in both live and fixed cells. Together with principal component analysis
(PCA) results, it proved Raman spectroscopy to be a valuable tool in identifying and
characterizing the different stages of HPV-associated malignancies which is compatible
with the current screening methods (Jess et al. 2007).
Ostrowska et al. applied both FTIR and Raman spectroscopy to the study of cervical
cancer cell lines. Their data suggest that HPV negative (C33a) and low HPV copy
number (SiHa with 1-2 copies) cell lines are biochemically very similar whilst
significantly different from mid (HeLa) and high (CaSki) HPV copy number cell lines.
The main variations were encountered at protein, nucleic acid and lipid levels, and
confirmed by both mean spectra and PCA analysis (Ostroswka et al. 2010). In the PCA,
a discrimination of cell lines suggestive of HPV integration dependence constituted a
major breakthrough compounding the potential of Raman spectroscopy to identify HPV
induced biochemical changes (Ostroswka et al. 2010).
Worthy of highlight is also a comparative study by Kim et al. of the distribution of
intracellular components in cells expressing HPV16 E6 oncoprotein. The key finding of
Raman mapping data suggests that E6 oncoprotein expression induces major phenotypic
changes in the cells which are also targeted by an HIV antiviral drug – Indinavir, further
acknowledging Raman spectroscopy as an powerful imaging technique (Kim et al.
2010).
Vargis et al. also reported Raman micro-spectroscopy to successfully detect HPV and
differentiate among specific virus strains, in a complementary cell line and in vitro
study with cellular pellets from cytology samples. Normal HPV negative cell line
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NHEK was used alongside three cervical carcinoma cell lines: HPV positive (HeLa and
SiHa) and HPV negative C33a. Once again, specificity values of 89-97% for cell lines
and 98.5% for cytology samples are extremely encouraging and confirm the enormous
potential of Raman spectroscopy to provide an accurate differential diagnosis (Vargis et
al. 2012).

2.2.5 Cytology – spectra recorded from exfoliated patient cells

Rubina et al. used Raman spectroscopy to distinguish between 49 cervical cancer and
45 negative control cytology samples. Cellular pellets were generated from ThinPrep®
material and subjected to Raman analysis. Amide I (1660 cm-1), ∂CH 2 (1450 cm-1) and
phenylalanine (1002 cm-1) are the main features dominating the control Raman spectra
whereas the spectra of cervical cancer samples was dominated by blood features such as
fibrin (1570 cm-1) and heme (1620 cm-1). The profile loadings of the PCA-LDA (linear
discriminant analysis) yield a classification efficiency of ~90% also suggestive of blood
as the major discriminative factor between the two groups. As bleeding is a common
occurrence in cervical infections, uterine cancer and menstrual cycle, 57 samples (28
controls and 29 cancers) were further treated with RBC (red blood cell) lysis buffer
prior to Raman acquisition. The absence of heme and fibrin bands confirms the effective
removal of blood from the samples and makes evident an increase in protein content (at
1006, 1450 and 1660 cm-1) and changes in their secondary structure due to positive
Amide III bands. In this case the PCA-LDA analysis yields a classification efficiency of
~80% which the authors suggest is comparable to the Pap test. Sample heterogeneity
and the fact that the distribution of the abnormal cells in the cervical cancer specimens
vary from 1-2% to 20-40% are suggested as the major causes of misclassification; the
authors suggest further studies on pure cancerous and pre-cancerous specimens as a
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means to build standard and validation models that could then be applied to blinded
specimens (Rubina et al. 2013a).
In 2014 a study by our group reported a protocol for the preparation of ThinPrep®
samples for analysis by Raman spectroscopy (Bonnier et al. 2014).

The protocol

suggested ThinPrep® samples should be submitted to a hydrogen peroxide (H 2 O 2 )
treatment to remove the presence of blood residue which would otherwise be detected
by Raman spectroscopy swamping the true signal of the cervical cells. Results showed
that after treatment, the blood features were removed from the data without altering
either the cell morphology or their spectral features. PCA of the spectral region between
1150 and 1800 cm-1 showed clear separation between spectra from normal and CIN 3
samples. This separation was dominated by assignments at 1381, 1426 and 1581 cm-1
related to the DNA/RNA content of the cells. This work demonstrated the improved
potential of Raman spectroscopy for the analysis of ThinPrep cervical cytology samples
based on improved protocols for sample preparation (Bonnier et al. 2014).

2.2.6 Cervical Fluids

In 2015, Choi et al. reported the use of surface-enhanced Raman spectroscopy (SERS)
to detect HPV infection in cervical fluids collected by centrifugation of saturated
cervical brush (SurePathTM) used for smear collection. Results show different Raman
spectral profiles between HPV positive (n=5) and HPV negative (n=4) patients. Raman
acquisition from the central zone of the cervical fluid drop further allowed different
HPV types (-11 & 35; 16; 18; 20 & 21; and 52) to be detected, with HPV16 and 18
showing similar band patterns after 1000 cm-1 and dissimilar pattern before this spectral
region (Choi et al. 2015). A more recent report by the same group described not only
the detection of HPV infection but also of cervical dysplasia through SERS analysis of
cervical fluids. Despite the limited number of samples (n=9), the results suggested it
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was feasible to detect both HPV infection and cervical dysplasia with different Raman
profiles based on HPV type. In healthy controls, the Raman spectra of cervical fluids
displayed stronger intensities for symmetric C-C stretching and phosphate assignments
at 877 and 963 cm-1 respectively; and for the C-H deformation modes at 1448 cm-1
(Kim et al. 2016).

2.2.7 Treatment response

In their dual Raman and FTIR study, already mentioned in the FFPP section, Krishna et
al. also presented data concerning Raman spectra after radiotherapy cycles, showing
small changes, especially in antioxidant levels.

Hence, at the same time whilst

validating the use of formalin fixed tissue for Raman spectroscopy analysis, it opens the
door to research aimed not only at cervical cancer diagnosis but also prognosis and
treatment response monitoring (Krishna et al., 2006).
A further study to detect the response of radiotherapy was attempted by Vidyasagar et
al. in an ex vivo pilot study (Vidyasagar et al. 2008). Tissues were collected after a
second fraction of radiotherapy, classified based on clinical evaluation into complete,
partial and no response, Raman spectra were then acquired and compared against the
malignant spectra through PCA. The authors concluded that PCA results provided a
clear separation between responding and non-responding samples as well as between
complete and partial radiotherapy response. Such results indicate the potential of Raman
spectroscopy in early radiotherapy response prediction (Vidyasagar et al. 2008).
In a more recent ex vivo study, Rubina et al. explored the feasibility of fibre-optic-based
Raman spectroscopy in predicting tumor response to concurrent chemoradiotherapy
(CCRT) through a PCA classification pattern which also showed encouraging results
despite needing a greater body of evidence (Rubina et al. 2013b).
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A study Duraipandian et al. confirmed Raman spectroscopy as a broad diagnosis and
treatment assessment tool not only for cervical cancer but also to help in other
conditions and possibly in the gynaecology clinic. HW Raman spectroscopy was used to
non-invasively, in vivo, assess the effect of Vagifem treatment in women (Duraipandian
et al. 2013). The conclusions indicated that a bimolecular Raman spectroscopy model
can not only successfully identify hormone/ menopausal related changes in cervical
epithelium, but also assess the effect of Vagifem treatment during colposcopic
inspections as the protein and lipid Raman signals increase after treatment and start to
resemble pre-menopausal values (Duraipandian et al. 2013).

2.2.8 Improving data analysis & recording

The refinement of subtleties on the overall sensitivity and specificity of Raman
spectroscopy for in vivo diagnosis of cervical cancer has also led researchers to address
better statistical analysis algorithms and methods.
A study by Kanter et al. explored binary and multiclass discrimination algorithms to
analyse Raman spectroscopy data: maximum representation and discrimination feature
(MRDF) and sparse multinomial logistic regression (SMLR). It concluded that although
both provide an improvement over the current method of diagnosis – colposcopy-guided
biopsy (with sensitivity of 87% and specificity of 72%), the use of a multiclass
algorithm improves the overall Raman spectroscopy sensitivity from 92% to 98% and
the specificity from 81% to 96% thus advocating that the key benefit of multiclass
algorithms for the prevention of misdiagnosis can overcome the downside of more
complex implementation (Kanter et al. 2009c).
Similarly, the use of genetic algorithm techniques to complement Raman spectroscopy
data was also proposed and explored by Duraipandian et al. through the application of
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genetic algorithm-partial least squares-discriminant analysis (GA-PLS-DA) with double
cross-validation (dCV). By employing a GA-PLS-DA algorithm which used significant
Raman bands selected from 925-935, 979-999, 1080-1090, 1240-1460, 1320-1340,
1400-1420 and 1625-1645 cm-1, a 72.5% specificity and 89.2% sensitivity for precancer detection was achieved and could therefore be further investigated as a feasible
alternative to current PCA methods (Duraipandian et al. 2011).
Still in the in vivo context, modifications in the recording process have also been
considered and reported in the literature.
HW Raman spectroscopy, 2800-3700 cm-1, was successfully described by Mo et al.
with 93.5% and 97.8% diagnostic sensitivity and specificity respectively (Mo et al.
2009). The results showed that the intensity of the Raman signal within the 2800-3035
cm-1 range, which comprises proteins and lipids, from dysplastic tissue, is significantly
lower than observed for normal tissue. An increase in the vibrational signal of water
from the dysplastic tissue was also observed and in line with that reported with FTIR
spectroscopy (Kondepati et al. 2008; Hornung et al. 1999). The authors further support
these observations with literature concerning the increase of aquaporins at the dysplastic
cell membrane and the fact that higher DNA levels or hydration of DNA due to the
unfolding step in cell division could also account for this observation (Mo et al. 2009).
Simultaneous fingerprint and HW Raman spectroscopy has also been described by
Duraipandian et al. who acknowledged their complementary potential and ability to
improve early disease detection. The results showed a significant intensity increase in
dysplastic tissue spectra at 1001, 1095, 1313 and 3400 cm-1 along with a decrease at
854, 937, 1445, 1654 and 2946 cm-1. The sensitivity and specificity values of 85% and
81.7% respectively for integrated fingerprint and HW Raman spectroscopy were shown
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to be higher than those of fingerprint or HW Raman spectroscopy alone (Duraipandian
et al. 2012).
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CHAPTER 3

MATERIALS AND METHODS

85

3.1

Samples

3.1.1 Sample reception and database construction
3.1.1.1 Modelling set database

A total of 98 negative, 43 CIN1, 23 CIN2 and 34 CIN3 cytology samples were received
from Altnagelvin Hospital, Northern Ireland. As per ethical approval (Appendix 1) the
samples received consisted of one unstained ThinPrep® slide per case, accompanied by
clinical information regarding the final cytological diagnosis, patient’s age, HPV test
result (as appropriate), previous disease history, date of last menstruation period (LMP)
(if available) and collection date.
Some of the samples received were considered unsuitable for Raman spectroscopy due
to insufficient cellularity and/or masking effects of debris which can be common when
the ThinPrep® slide is obtained from the end of the collection vial. From the 32 samples
considered unsuitable for Raman spectroscopy, 10 were negative, 8 CIN1, 2 CIN2 and
12 CIN3. Appendix 3 compiles all the samples considered in this study and respective
clinical information.
3.1.1.2 Independent test set database

A total of 39 negative, 20 CIN1, 9 CIN2 and 10 CIN3 cytology samples were received
from Altnagelvin Hospital, Northern Ireland. Like the modelling set samples, each test
set sample received consisted of one unstained ThinPrep® slide per case, accompanied
by clinical information regarding the final cytological diagnosis, patient’s age, HPV test
result, previous disease history, LMP and collection date. The test set samples were
subjected to the exact same protocols as the modelling set samples.
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Similar to the modelling set, some of the samples received were considered unsuitable
for Raman spectroscopy due to insufficient cellularity and/or masking effects of debris
as a result of the ThinPrep® slide being collected from the end of the collection vial.
From the 31 samples considered unsuitable for Raman spectroscopy, 12 were negative,
11 CIN1, 3 CIN2 and 5 CIN3. All the test set samples considered in this study as well
as their clinical information are as indicated in Appendix 4.

3.1.2 Hydrogen peroxide (H 2 O 2 ) Treatment

Following reception, as per in-house protocol (Bonnier et al. 2014), all samples were
treated with hydrogen peroxide (H 2 O 2 ) (Sigma-Aldrich, UK ) for 10 minutes at room
temperature to clear the samples from blood and debris. Samples were then air-dried in
a fume hood, at room temperature for a minimum of 24 hours prior to Raman
spectroscopy.
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3.2

Raman spectroscopy

Raman spectroscopy measurements presented in this study were performed on an
XploRA (Horiba Jobin Yvon) system represented as shown in Figure 3.1 operating with
a 532nm laser.

Figure 3.1 Xplora (Horiba Jobin Yvon) confocal microscope.

3.2.1 Calibration Procedures

Daily calibration of the system was carried out according to the in-house standard
operating procedure (SOP) developed by Lyng and Bonnier (Appendix 5). The system
was calibrated to the 520.7 cm-1 spectral line of silicon. Dark current, reference
spectrum of polystyrene (from a clean petri dish lid) and laser intensity were also
monitored.
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3.2.2 Measurements’ Settings

Raman measurements were performed using a HORIBA Jobin Yvon XploRATM system
(Villeneuve d’Ascq, France), described earlier in this section. To avoid any photo
damage to the sample, the power of the laser was set at 50% (~7.5mW). The confocal
hole was set at 100µm and the 1800 lines/mm grating was used, which gave a spectral
dispersion of ~3 cm-1 per pixel. The backscattered light was collected using an aircooled CCD detector (Andor, 1024 x 256 pixels) and the spectrometer was controlled
by Labspec V5.0 software.
Raman signals from each cell nucleus were integrated twice for 20 seconds in the
spectral range of 400-1800 cm-1. Manual focus (Z plane) was used to minimise substrate
contribution to the nuclear spectra which was acquired from the centre of each nuclei.
Spectra from a minimum of 10 cell nuclei were recorded per sample, depending on the
quality of each slide. The data is presented as the average of all 10 cellular spectra
recorded from each individual patient. Figure 3.2 shows a cervical ThinPrep® sample as
presented upon Raman microscopy.
For negative samples in the modelling set, cells were selected at random whereas for
CIN samples abnormal looking cells were chosen based on their morphology. All test
set samples were recorded in a similar fashion.

Figure 3.2 Negative ThinPrep® cervical cytology sample as presented upon Raman microscopy.
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3.3 Statistical Techniques
3.3.1 Pre-processing Procedures

Data analysis was performed in Matlab [Mathworks, CA, USA] according to protocols
developed in house (Bonnier et al. 2014; Bonnier et al. 2012). Pre-processing of the raw
Raman spectra included the application of a Savitsky-Golay filter (5th order, 13 points)
to smooth the spectra. The data set was also corrected for baseline and vector
normalized to facilitate comparison.

3.3.2 Glass correction methods

3.3.2.1 [1200-1800 cm-1] Spectral Range

In this model, the recorded spectral range of 400-1800 cm-1 was cut and only the
spectral range between 1200-1800 cm-1 was considered for data analysis; thus leaving
out of the data analysis the major regions where glass spectral features can be observed
around 550 and 1100 cm-1.
3.3.2.2 Iterative glass correction method

This in-house model (Bonnier et al. 2014) reduces the intensity of a given glass
spectrum by a factor of 10 which is then sequentially subtracted from the cellular
spectrum until the ratio between the phenylalanine peak (~1005 cm-1) and the main
glass peak (~1093 cm-1) is equal or less than 1.5. This ratio was established by Bonnier
(unpublished data 2011) by recording cervical cells on calcium fluoride slides.
3.3.2.3 Non-negative least squares (NNLS)

This in-house model (Ibrahim et al. 2016) considers the spectral data obtained as linear
functions resulting from the underlying cellular components and the glass substrate.
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It aims to reconstitute a vector x that explains the observed spectra as well as possible,
based on known observations. So, given the spectra obtained and a set of known
observations such as a matrix of (1) glass recorded from the 166 model set samples
considered in the study and (2) a selection of cellular components listed in Table 3.1; it
is possible to find a nonnegative vector that estimates the contribution of these known
observations to the spectra. The known observations are then multiplied by the
nonnegative vector before being subtracted from the initial spectral matrix, correcting
for the glass contribution.
Table 3.1 Cellular components used for the NNLS model.

Cellular component
DNA
RNA
Cholesterol
Collagen
Glutathione reductase
Glutathione oxidase
Acetic acid
Phosphatidylinositol
Myrestic acid
Steric acid
Phosphatidylserine
Phosphatidylethanolamine
Thymidine

3.3.3 Principal Component Analysis (PCA)

Principal component analysis (PCA) is a statistical method widely used in exploratory
analysis and model prediction. Developed in 1901 by Karl Pearson (Pearson 1901). It is
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an unsupervised data reduction technique that allows the user to identify variances
within the dataset that may be used to classify objects into certain groups.
PCA involves the calculation of the eigenvalue decomposition of a data matrix, usually
after mean centring the data for each attribute. The results of a PCA are usually
discussed in terms of component scores and loadings (Martens et al. 1989).
In Raman spectroscopy, PCA is used to reduce the matrix of spectral data in which
objects (individual spectra) are measurements of a large number of variables
(wavenumbers), whilst retaining most of the variation within the dataset. It works by (1)
subtracting the mean of the dataset to obtain the mean centred matrix, (2) calculating the
covariance matrix (linear relationships between the individual spectra) of the mean
centred matrix and (3) finding the eigenvectors and eigenvalues of the covariance
matrix (Gautam et al. 2015).
The eigenvector with the highest eigenvalue explains the most variance in the data set
and is called the first principal component (PC). The first PC therefore describes the
largest source of variance across all the spectra, the second PC the next largest source of
variance and so on, with all PCs describing mutually independent sources of variance in
decreasing proportions of spectral variance (Gautam et al. 2015; Bonnier et al. 2012).
Generally, the first three PCs represent the highest variance present in the data sets, up
to 99%, therefore allowing the best visualisation of the differentiation of the data set
clusters. However when recording Raman data from single cells, the noise present in
the spectra can increase the intragroup variability, thus reducing the specificity of the
PCA; in such cases, typically the first 10 PCs can be taken into account for specific
analysis (Bonnier et al. 2012; Varmuza et al. 2009).
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3.3.4 Principal component analysis – linear discriminant analysis (PCALDA)

Linear discriminant analysis (LDA) (Rao 1948) is a classification method that aims to
find linear functions in a dataset which can then be used to classify the data in two or
more classes. It produces a line or hyperplane that represents the maximum separation
of two or more classes in the dataset.
Whereas unsupervised PCA looks for projections to maximize overall variance,
supervised LDA looks for projections to maximize the variance ratio of inter to intraclass. LDA can be used in conjunction with PCA, in PCA-LDA, where it uses PCA
scores as latent variables and tries to find the linear hyperplane that discriminates
between the two or more populations of PCA scores (Gautam et al. 2015).

3.3.5 Leave one patient out cross validation (LOPOCV)

Cross validation of any spectral classification models is important firstly to avoid over
or under-fitting the model due to inappropriate selection of the components used, and
secondly to determine the prediction error of the model.
In leave one patient out cross validation (LOPOCV) one observation is excluded at a
time from the training set and the resulting model is evaluated on the left out
observation. The procedure is repeated for all observations in the data set and the
average performance across all interactions is considered the performance of the
classification model (Gautam et al. 2015).
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3.4

Immunocytochemistry (ICC)

3.4.1 CINTec® PLUS kit dual staining

The CINTec® PLUS kit (Ventana for Roche, Ireland) is an immunocytochemistry
(ICC) assay for the simultaneous detection of p16IKNK4a and Ki-67 antigens in cervical
cytology preparations. The interest of these antigens in cervical cancer diagnosis
research has already been discussed in depth in Biomarkers section 1.6 (chapter 1).
The CINTec® PLUS kit works on the principle that the simultaneous expression of
p16IKNK4a and Ki-67 can be used as an indicator of transformed cell status as virtually all
high grade CINs have been shown to over-express p16IKNK4a and a high proportion of
epithelial cells in CIN lesions show proliferative activity.
The kit includes a primary antibody cocktail comprising a mouse anti-human p16IKNK4a
antibody and a rabbit anti-human Ki-67 antibody, which are then revealed by a
horseradish peroxidase (HRP) polymer conjugated goat anti-mouse and an alkaline
phosphatase (AP) polymer conjugated goat anti-rabbit secondary antibodies
respectively. Figure 3.3 shows the mechanism of detection utilized in the CINTec®
PLUS kit. A positive reaction will result in simultaneous brown cytoplasmic and red
nuclear staining.
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Figure 3.3 CINTec® PLUS detection mechanism. The individual antigens are first detected by the primary
antibodies which are then bound by the secondary antibodies. Secondary antibodies are HRP and AP polymer
conjugated which allows them to be revealed by reaction with hydrogen peroxidase & DAB and naphthol
phosphate & fast red, respectively. The HRP reaction results in a brown precipitate which allows the detection
of p16 in the cell cytoplasm whilst the AP reaction results in a red precipitate which allows the detection of
Ki67 in the nucleus.

Before staining all samples were hydrated for an hour in dH 2 O, after which ICC was
performed as per the manufacturer’s guidelines. High temperature antigen retrieval (pH
9.0) was performed in a water bath at 95oC for 10 minutes followed by a 20 minute cool
down period. The kit peroxidase blocking reagent was applied to block the endogenous
peroxidase, and the solution containing both primary antibodies incubated for 35
minutes, both at room temperature (RT). The HRP visualization reagent was then
incubated for 35 min followed by AP visualization reagent for 35 minutes. Finally the
3,3'-diaminobenzidine (DAB) working solution was applied, followed by the fast red
working solution both for 15 minutes at RT. Four drops of the CINTec® aqueous
mounting medium were applied to each sample and allowed to dry overnight before the
slides were mounted using DPX as a mounting medium. Protocol was optimised from
manufacture’s

guidelines

available

in

https://pim-

eservices.roche.com/eLD_SF/gb/en/Documents/GetDocument?documentId=af58dbf338f5-e311-98a1-00215a9b0ba8&referrer=Dialog.
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3.5

Pap stain

The Pap stain is the “gold standard” stain for gynaecological cytology. All the samples
not subjected to ICC were Pap stained according to in-house optimised protocol. All
reagents were purchased from Sigma-Aldrich, UK. Firstly the samples were hydrated
for an hour in dH 2 O before staining. After this they were rinsed in tap water and
submerged in Harris' haematoxylin for 3 minutes. The samples were then rinsed in tap
water and in 95% ethanol for 2 minutes. OG-6 stain was applied for 1.5 minutes,
following which the samples were again rinsed in 95% ethanol for 2 minutes before
being stained with EA-50 for 2.5 minutes. The samples were then rinsed twice in 95%
ethanol for 2 minutes before being placed in 2 changes of 100% ethanol for 3 minutes
each and cleared in 2 changes of xylene of 5 minutes each. Finally the samples were
mounted using DPX as the mounting medium. Figure 3.4 shows a cervical cytology
sample after Pap stain.

X100

Figure 3.4 Pap stained negative Thinprep slide showing parabasal (black arrowheads), intermediate (solid
arrows) and superficial (dashed arrows) cells and white blood cells (red arrowheads).
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3.6 Light Microscopy
For the microscopic evaluation of both ICC and Pap stain samples an upright an
Olympus BX60 microscope was used. Images were captured using a digital camera and
software program Capture Pro v8.0 (MediaCybernetics, UK), where they were saved
without further manipulation.
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CHAPTER 4

EVALUATION OF SUBSTRATE CORRECTION

METHODS FOR RAMAN SPECTRA RECORDED FROM
THINPREP® CERVICAL CYTOLOGY SAMPLES
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This study is part of on-going technology development research that aims to use Raman
spectroscopy in the clinic to screen and diagnose cervical pre-cancer. For this reason,
the substrate chosen and used for our samples had to be the commonly used ThinPrep®
glass slide. Although routinely used in the clinic and significantly cheaper than other
substrates used for spectroscopy (eg. calcium fluoride), ThinPrep® glass slides pose a
greater challenge to the data analysis due to the strong glass contribution to the cellular
spectra. Moreover, although the spectrum obtained from the glass substrate is similar
across all sample groups (Figure 4.1), the glass contribution to the cellular spectra is
not. Due to their bigger and flatter nuclear morphology, the average spectra of CIN 1
samples (magenta) for example have more pronounced glass features indicated by the
arrows in Figure 4.2 than the spectra of normal cells (green) which present with small,
round, pyknotic nuclei.

99

Figure 4.1 Mean Raman spectra of the ThinPrep® glass substrate recorded from all sampling groups. ;
negative (green,) CIN 1 (magenta,) CIN 2 (red) and CIN 3 (black.)

Figure 4.2 Mean Raman spectrum and SD (shadowing) obtained for each sampling group. Negative samples
are represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. Arrows
indicate the areas where the glass substrate contribution is visible. Highest contribution of glass spectral
features can be seen in the average spectra of CIN 1 samples.
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4.1

Uncorrected spectra for glass substrate

The raw Raman spectra were smoothed by the application of a Savitsky-Golay filter (5th
order, 13 points), baseline corrected and vector normalized to facilitate comparison. The
mean Raman spectrum and standard deviation (SD) obtained for each sampling group
recorded are shown in Figure 4.2. Strong contribution from the glass substrate can be
observed, especially around 550 cm-1 and 1095 cm-1 as indicated by the arrows.
It can be inferred that glass contribution is not of the same magnitude (1) across all
sampling groups (intergroup), as it seems to be more prominent in the spectra of CIN 1
samples in magenta; or (2) between samples from the same group (intragroup), as
highlighted by the greater variability shown in the SD in the spectral regions indicated
by the arrows, especially in CIN 3 samples in black.
Principal component analysis (PCA) was employed to further highlight the variability of
the data set recorded. The PCA scatterplot for all sampling groups is presented in Figure
4.3 A. The percentage of variance explained by PC1, PC2 and PC3 is 76.1%, 9.49% and
3.97% respectively.
Negative samples separate from the other sampling groups according to PC1. From the
analysis of PC loadings presented in Figure 4.3 B, it can be observed that PC1 is
positively dominated by glass features at below 600 cm-1 and ~1100 cm-1 which are
therefore more prominent in the spectra of CIN samples and account for the highest
variability (76%) within the dataset. Although PC2 and 3 do not seem to contain a
strong glass contribution, they do not provide clear separation between the sampling
groups; and no clear separation was provided using any other PC combination (data not
shown). Furthermore, pairwise combination of all individual sample groups is shown in
Figure 4.4. Despite, clear separation between all sample groups being observed, when
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looking at corresponding PC loadings, these separations are mostly dominated by glass
features. Indeed, PC1 is completely dominated by spectral glass features which are
therefore more prominent in the spectra of CIN samples compared to negative samples.
It is therefore very important to somehow correct the contribution of the glass to the
sample spectra in order to be able to compare and understand the biochemical
differences between the cells of the different sampling groups. Similarly, the glass
contribution needs to be addressed before true sample profiles and classification models
are created. However, the PC 2 and 3 loadings which also account for the separation
between some of the sample groups do not seem to present as many glass features,
therefore indicating underlying spectral differences, other than substrate contribution,
may be present and allow sample separation if glass is corrected from the sample
spectra.

102

A

B

Figure 4.3 (A) PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC
loadings for PC1, 2 and 3 which explain respectively 76.1%, 9.49% and 3.97% of the variance within the dataset.
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Figure 4.4 PCA scatter plot for pairwise comparison of all sampling groups (right) and relevant PC loadings (left); Negative samples are represented in green, CIN 1 samples in
magenta, CIN2 samples in red and CIN3 samples in black.
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Nevertheless, PCA-LDA was used to evaluate if an accurate disease classification
model could be generated from the raw sample spectra. LOPOCV was used and the
sensitivity and specificity results obtained are presented in Table 4.1.
Table 4.1 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was
obtained based on the Raman spectra for the full spectral range without glass correction.

Sampling
Group

Sensitivity
(%)

Specificity
(%)

Negative

100

98.72

CIN 1

100

99.24

CIN 2

100

100

CIN 3

95.45

100

Accuracy of the LOPOCV (LOPOCVacc) =0.9940; SD of the LOPOCV accuracy
(SD_LOPOCVacc) =0.0776

Results show the performance of this PCA-LDA model to be very encouraging with
sensitivity varying from 95.45 to 100% and, specificity from 98.72 to 100%. However,
the fact that the main PCs are dominated by glass features indicates these are also
responsible for the PCA-LDA classification. Further investigation into a glass
correction method is therefore needed to guarantee that the glass features have minimal
influence on the disease classifiers.

107

4.2

[1200-1800 cm-1] Spectral Range

The first approach to minimise the glass features in the samples spectra was to cut the
recorded spectral range so that only the “glass-free” range of 1200 to 1800 cm-1 was
analysed.
The mean Raman spectrum and SD for each sampling group in this new spectral range
are shown in Figure 4.5.

Figure 4.5 Mean Raman spectrum and SD (shadowing) obtained for each sampling group on the 1200 to
1800cm-1 spectral range. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples
in red and CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to
be the main difference between the mean spectra.

The main difference in the mean spectra is observed in the ratio between the peaks at
1318:1339 cm-1, indicated by the circles on Figure 4.5. The ratio seems to increase from
negative to progressively severe grades of CIN; indeed the average ratio is 0.91 for
negative samples (green), 0.94 for CIN 1 samples (magenta), 0.97 for CIN 2 samples
(red) and finally 1.01 for CIN 3 samples (black) as shown in Figure 4.6. This seems to
suggest that a decrease of CH 2 /CH 3 wagging & twisting mode in collagen, nucleic acid
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& tryptophan (assigned to 1339 cm-1) and/or an increase of guanine, -C-H deformation
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Figure 4.6 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CINI 3 (black)
cervical cytology samples. SD is also indicated for each sampling group. Mann Whitney test showed CIN 1, 2
and 3 ratios to be significantly different from that of negative samples with **p=0.0031 and ****p<<0.0001.
Ratio differences between CIN samples were also significant with ****p<0.0001, ***p=0.0008 and *p= 0.0420.

PCA was once again employed to further highlight the variability of the data set and
evaluate the glass contribution. A 2-D PCA scatterplot for all sampling groups is
presented in Figure 4.7 A. The percentage of variance explained by PC1 and PC2 is
65.7% and 17.16% respectively.
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A

B

Figure 4.7 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN 1
samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC loadings for PC1 and 2 which
explain respectively 65.7% and 17.16% of the variance within the dataset.
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PC scatterplots presented in Figure 4.7(B) do not seem to be overshadowed by glass
spectral features.
Negative samples seem to separate from the CIN samples according to PC1. PC1 is
positively dominated by Amide III assignments at 1245 and 1375 cm-1, Amide I at 1669
cm-1 and by several CH 2 and C-H vibrations of lipids and proteins (1304 and 1552 cm1

), indicating these are more predominant in negative samples.

PC2 seems to suggest a separation between CIN 1 and negative samples on the negative
side and CIN 2 & 3 samples on the positive side. Despite this separation not being as
clear and there are some overlapping of CIN 1 samples with CIN 2 and 3, it is positively
dominated by Amide I at 1600-800 cm-1 and by -C=C- carotenoid and amide carboxyl
vibrations around 1520-680 cm-1 thus more intense in CIN 2 and 3 cells' spectra; and
negatively dominated by Amide III and ring breathing modes of nucleic acids at 1250
and 1373 cm-1, respectively.
The peak at 1339 cm-1 also contributes to the separation of negative samples (positively
on PC1) from CIN samples and of negative and CIN 1 (negatively on PC2) from the
CIN 2 and 3. This is in line with what can be observed on the mean spectra (Figure 4.5)
further supporting a decrease of these features when disease progresses gradually from
negative to CIN 1, 2 and 3.
Pairwise PCA analysis in Figure 4.7 provided additional separation between CIN
samples based on other PC combinations. Negative samples seem to separate from all
other sample groups through a similar combination of PC1 and PC2 with both loadings
being very similar regardless of CIN sample group involved in the pairwise
combination (1, 2 or 3). The spectra of negative samples are negatively dominated by
assignment of the PC1 loading which are equivalent of those described for PC1 loading
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of Figure 4.5 (B). Similarly, PC2 seems to also contribute to the separation of CIN 3
and negative samples and its assignments are also as described before.
The PC loadings responsible for the pairwise separation between CIN groups are
slightly noisier. The separation between CIN 1 samples and CIN 2 and 3 is negatively
dominated by PC1 which in the pairwise combinations in Figure 4.8 display the
cytosine assignment at 1290 cm-1 and the C-H and C=C bending modes of proteins at
1420-70 cm-1 and 1600-800 cm-1, respectively, as the main features. These are therefore
more prominent in the spectra of CIN 2 and 3 samples. And finally, the CIN 2 and 3
samples are separated according to PC3 which is dominated by negative features
assigned to C=C (Amide I) at 1650 cm-1, overlapping asymmetric CH 3 bending & CH 2
scissoring (associated with elastin, collagen and phospholipids) at 1454 cm-1 and the
band at 1302 cm-1 attributed to Amide III and the CH 3 /CH 2 twisting or bending mode
of lipids, collagen and proteins; all more prominent in the spectra of CIN 2 samples.
PCA-LDA was employed to generate a classification model based on the Raman spectra
of the samples which was further tested by LOPOCV. The sensitivity and specificity
results obtained are shown in Table 4.2.
Table 4.2 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was
obtained based on the Raman spectra for the 1200-1800cm-1 range only.

Sampling
Group

Sensitivity
(%)

Specificity
(%)

Negative

92.05

92.21

CIN 1

91.43

92.31

CIN 2

95.24

97.06

CIN 3

86.36

94.33

LOPOCVacc = 0.9157; SD_LOPOCVacc =0.2787
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This model has good specificity across all sample groups, ranging from approximately
92% to 97% with similar sensitivity values being obtained for all sample groups part
from CIN 3, which had the lowest value at 86.36%. These results seem to suggest that
the analysis of 1200-1800cm-1 spectral range is enough to achieve a good spectral
classifier however other routes ought to be explored in order to minimize the glass
contribution to the cellular spectra whilst retaining most of the spectral data recorded.
By not analysing the full fingerprint spectral region, a great deal of spectral
information/data is being overlooked. For example, most literature reports the majority
of the DNA and nucleic acids assignments to fall outside the 1200-1800cm-1 range,
~800 cm-1 which might prove an important classification feature as the cell nuclei are
being targeted in this study.
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Figure 4.8 PCA scatter plot for pairwise combination of all sampling groups (right) and relevant PC loadings (left) in the 12001800 cm-1 spectral range. Negative samples are
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black.
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4.3 Glass subtraction (iterative glass correction)
Another glass subtraction method was tested; in summary it subtracted a reference glass
spectrum from the dataset in order to eliminate/minimise the glass contribution. The
method was developed in-house at DIT (Bonnier et al. 2014) is described in more detail
in section 3.3.2.2 of chapter 3.
The mean spectra for each sampling group before and after iterative glass correction are
displayed in Figure 4.9. Although the strong glass features around 550 cm-1 and 1095
cm-1 are reduced in the corrected spectra, the overall SD is increased after iterative
correction as indicated by the shadowing in the middle plots of Figure 4.9. This is
particularly noticeable in CIN 1 and CIN 3 samples, the sample groups displaying large
SD in the spectral regions attributed to the glass features before glass correction shown
in the upper plots.
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Figure 4.9 Mean spectra for each sampling group before (continuous line) and after iterative correction (IT) (dotted line). SD is represented by shadowing. Negative samples are indicated in
green, CIN 1 samples in magenta, CIN 2 in red and CIN 3 in black.
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The increase in SD can also be observed when the mean Raman spectra of each sample
group after iterative correction are plotted together in Figure 4.10.

Figure 4.10 Mean Raman spectrum and SD (shadowing) obtained for each sampling group after FC
correction. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and
CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main
difference between the mean spectra. Other visible differences between the spectra are indicated by the black
arrows and the blue arrow heads.

The ratio between 1339 and 1318 cm-1 still appears as the main visible difference
between the spectral profiles of the sample groups recorded. Figure 4.11 shows this
ratio and SD for all sample groups. Similar to what was observed before, the ratio
between these two peaks is increased in CIN samples when compared to negative
samples (0.78). CIN 1 samples present the highest value of 1.06 as well as the highest
standard deviation; CIN 2 and CIN 3 samples present a similar ratio value of 0.87 with a
higher SD being observed for CIN 3 samples. The fact that the 1339:1318 cm-1 ratio no
longer increases gradually from negative to CIN 1, 2 and 3, might be related to the fact
that this glass correction method seems to introduce more intra-sample variability,
especially in CIN 1 and 3 samples which seem to be more affected by the glass
substrate.
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Another visible difference between the sample spectra is the peak at 1370 cm-1 indicated
by the blue arrow heads (Figure 4.11) which is assigned to saccharides. This is only
visible in the spectra of negative and CIN 1 samples, seeming lost in CIN 2 and 3
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Figure 4.11 1318/1339 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CINI 3 (black)
cervical cytology samples. SD is also indicated for each sampling group. Mann Whitney test showed CIN 1, 2
and 3 ratios to be significantly different from that of negative samples with ****p<<0.0001, p=0.0069 and
p=0.0020 respectively. Ratio differences between CIN samples were not statistically significant.

PCA was further employed to highlight the variability within the dataset and evaluate
the correction of glass features from the spectra. The PCA scatterplot obtained is shown
in Figure 4.12 A.
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A

B

Figure 4.12 (A) 2-D PCA scatter plot for all sampling groups; Negative samples are represented in green, CIN
1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC loadings for PC1 and 3 which
explain respectively 92.01% and 0.30% of the variance within the dataset.

The combination of PC1 and PC3 accounting respectively for 92.01% and 0.30% of the
variance within the dataset, seems to allow the separation of negative and the CIN
sample groups. The PC1 loading in Figure 4.12 B, is suggested to relate to the overall
spectral intensity as it looks like the average Raman spectrum of a cervical cytology
sample; therefore suggesting the overall spectral intensity of the samples on the positive
side of the 2-D PCA plot, namely the negative and some CIN 3 is higher than that of
CIN 2 and CIN 1 samples on the other side of the PCA scatterplot.
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PC2 (not shown), which explains 7.43% of the variation within the dataset, does not
provide any separation between the sample groups. PC3 suggests a separation between
negative samples, on the negative side of the 2-D PCA plot, from CIN samples on the
positive side. However, the PC3 loading is positively dominated by what seem to be
glass spectral features at around 600cm-1 and 1100cm-1 which are therefore more
prominent in the spectra of CIN samples.
Other PC combinations did not provide further separation between the sample groups,
especially between CIN sample groups (data not shown). PCA pairwise combinations of
all sampling groups were also plotted and are shown in Figure 4.13. All sample groups
are shown to separate from one another through a combination of PC1 and PC3 with the
loadings shown to the left of Figure 4.13. Similar to what was observed before, the PC1
loading of pairwise PCA combinations resembles the sample average spectra.
Furthermore, some glass features can still be observed in the loadings for PC3, further
suggesting incomplete glass correction from the sample spectra. The visual separation
between CIN 3 and negative samples and also between CIN 3 and CIN 2 samples is
however not marked with much overlap observed between both sample groups.
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Figure 4.13 PCA scatter plot for pairwise combination of all sampling groups (right) and relevant PC loadings (left) after iterative glass correction. Negative samples are represented in
green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black.
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Nevertheless, PCA-LDA was employed to generate a classification model based on the
Raman spectra of the samples which was further tested by LOPOCV. The sensitivity
and specificity results obtained are shown in Table 4.3.
Table 4.3 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was
obtained based on the Raman spectra after iterative glass correction.

Sampling
Group

Sensitivity
(%)

Specificity
(%)

Negative

100

97.44

CIN 1

100

98.47

CIN 2

100

100

CIN 3

90.91

100

LOPOCVacc = 0.9880; SD_LOPOCVacc = 0.1094
The sensitivity and specificity values obtained after the iterative glass correction are an
improvement on what was previously reported for the analysis of only the 1200-1800
cm-1 spectral range. Despite good specificity and sensitivity values, above 90%, across
all the samples, this glass correction method seems to only provide partial glass
correction of the samples spectral profiles. Glass features are still observed and seem to
account for the third (PC3) highest source of variability within the dataset, which
provides the separation between negative and CIN samples. Furthermore, iterative glass
correction seems to increase the overall intra-group spectral variability as shown by an
increase in the SD of the mean spectra after correction; and, the fact that this increase,
especially higher in CIN 1 samples (the most affected by glass contribution) seems to
impact on further analysis like the peak ratio analysis. These results suggest further
research is needed to achieve a more effective glass correction method.
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4.4 Non-negative least squares (NNLS)
The non-negative least squares (NNLS) glass correction model, described in section
3.3.2.3 of chapter 3, was initially developed in-house at DIT by Ibrahim et al (2016) to
correct wax contribution to the Raman spectra of FFPP oral tissues.
Unlike the iterative glass correction that uses one single glass spectrum, NNLS uses a
glass matrix composed of the glass spectra recorded from each analysed sample in this
study. This matrix together with a matrix of cellular components such as DNA and
RNA, aims to better fit the glass contribution to the spectra, therefore allowing a more
precise glass subtraction from each sample.
The mean spectra of each sampling group after NNLS correction does not seem to be as
variable as observed for the iterative glass correction (Figure 4.9 and Figure 4.10) which
can be observed through the SD indicated by the shadowing in all plots. The mean
Raman spectra after NNLS correction for each sampling group are plotted together as in
Figure 4.14.

Figure 4.14 Mean Raman spectrum and SD(shadowing) obtained for each sampling group after NNLS
correction. Negative samples are represented in green, CIN 1 samples in magenta, CIN2 samples in red and
CIN3 samples in black. The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main
difference between the mean spectra. Another visible difference between the spectra is the peak ~1093cm-1
indicated by the black arrows.
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Furthermore, when plotting the mean spectra for each sampling group before and after
correction, Figure 4.15, it is possible to observe that the most prominent glass features
around 550 cm-1 and 1095 cm-1 are reduced in the corrected spectra and, unlike the
iterative glass correction, the overall SD does not seem to be increased after NNLS
correction.
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Figure 4.15 Mean spectra for each sampling group before (continuous line) and after correction (dotted line). SD is represented by shadowing. Negative samples are indicated in green, CIN 1
samples in magenta, CIN 2 in red and CIN 3 in black.
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Similar to what has been observed before, the ratio between 1339 and 1318 cm-1
appears to be the main visible difference between the spectral profiles of the sample
groups.
Figure 4.16 shows this ratio and its SD for all sample groups. The ratio between 1339
and 1318 cm-1 is increased in CIN samples when compared to negative samples (0.89).
CIN 3 samples present the highest overall value of 0.99, with CIN 1 and CIN 2 samples
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Figure 4.16 1339:1318 cm-1 peak ratios for negative (green), CIN 1 (magenta), CIN 2 (red) and CIN 3 (black)
cervical cytology samples. SD is indicated for each sampling group. Mann Whitney test showed CIN 1, 2 and 3
ratios to be significantly different from that of negative samples with **p=0.0042 and ****p<<0.0001. Ratio
differences between CIN 1 and 2 samples were not statistically significant whilst CIN 3 ratios displayed a
****p<0.0001 and p=0.0011 against CIN 1 and 2 respectively.

Furthermore, the peak at 1093 cm-1 assigned to the PO 2 - stretching vibration of the
DNA backbone and indicated in Figure 4.14 by the black arrows, seems to be more
prominent in the spectral profile of negative and CIN 3 samples, with the peak being
more broad in CIN1 and 2 samples. The average Raman intensity at this peak is
represented in Figure 4.17. Negative samples show the highest intensity at this peak
when compared to CIN samples. Amongst the CIN samples, the peak intensity seems to
increase with the severity of disease from 0.02 in CIN 1, to 0.03 in CIN 2 and finally
0.03 in CIN 3.
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Figure 4.17 Mean Raman intensity at the 1093 cm-1 peak for negative (green), CIN 1 (magenta), CIN 2 (red)
and CINI 3 (black) cervical cytology samples. SD is indicated for each sampling group. Mann Whitney test
showed all intensity differences to be statistically significant with ****p< 0.0001 and **P=0.0094.

PCA was also used to highlight the variability within the dataset and results are
presented in Figure 4.18. The 2-D PCA scatterplot between PC1 and PC2 (Figure 4.18
A) which account respectively for 76.81% and 7.548% of the variance explained in the
dataset, shows separation between all sample groups with the distinction between CIN 2
(red) and CIN 3 (black) samples being not so obvious. Both PC loadings are also shown
in Figure 4.18 B and they seem free of the major glass spectral features observed thus
far.
The negative samples (green) seem to separate from the CIN 1 samples (magenta)
according to PC1, with negative samples having more DNA (~814 cm-1), protein and
lipids (1307, 1446, 1453 cm-1), and Amide III (1242 cm-1) and I (1690 cm-1) also
featuring prominently. Furthermore, the negative samples separate to a large extent
from both CIN 2 and 3 samples according to PC2. Negative samples therefore show
stronger Amide III (1243, 1375 cm-1) and protein/lipid (1339 cm-1) features, whereas
CIN 2 and 3 samples display stronger Amide I (1606 cm-1) and Amide II (1544 cm-1). In
addition, the PC2 loading also highlights differences in nucleic acids, the features at
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1458 and 1485/7 cm-1 being more prominent in the spectra of negative samples. DNA
features at 481 and 786 cm-1 are also more prominent in negative samples, whereas the
feature at 893 cm-1 is more prominent in CIN 2 and 3 samples. Similarly, phosphate and
phosphodiester bonds at 812 cm-1 are more prominent in the spectra of CIN 2 and 3
samples, whereas those at 1087-9 cm-1 are more prominent in negative samples. The
separation between CIN 1 and CIN 2 and 3 samples results from a combination of PC1
and PC2. Taking the PC1 and PC2 assignments for the negative samples as a reference,
the CIN 1 samples have a similar PC2 profile to the negative samples whereas the CIN
2 and 3 samples have a similar PC1 profile to the negative samples.
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Figure 4.18 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. Negative samples are
represented in green, CIN 1 samples in magenta, CIN2 samples in red and CIN3 samples in black. (B) PC
loadings for PC1 and 2 which explain respectively 99.54% and 0.15% of the variance within the dataset.
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PCA of pairwise combinations between CIN sample groups (Figure 4.19) were further
explored to investigate the differences between these sample groups. The PCA
comparison of CIN 2 and 3 samples is particularly important as the separation between
these sample groups was not clear in the overall PCA shown in Figure 4.18.
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Figure 4.19 PCA scatter plot for pairwise combination of all CIN sample groups (right) and relevant PC loadings (left) after NNLS glass correction. CIN 1 samples in magenta, CIN2
samples in red and CIN3 samples in black.
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Despite some overlap, CIN 1 and CIN 2 samples seem to separate along PC1 which is
positively dominated by Amide I (1663 cm-1) and other protein features (~1309, 1449
cm-1), as shown on the left side of Figure 4.19, indicating that these are more prominent
in CIN2 samples. Similarly, CIN 1 and CIN 3 show separation along PC1 which in this
case, is also positively dominated by Amide I (1669 cm-1) and other protein features
(~1308, 1453 cm-1), therefore more prominent in CIN 3 samples compared to CIN 1
samples. Finally, CIN 2 and CIN 3 samples show reasonably good separation along
PC3. From its loading, it can be observed that PC3 is positively dominated by nucleic
acid features at 722, 786, 810 and 850 cm-1 and Amide III at 1242 cm-1, which are
therefore more intense in the spectra of CIN 3 samples, whereas Amide I features at
1651 cm-1 and C-H vibration of proteins and lipids at 1449 cm-1 are more prominent in
the Raman spectra of CIN 2 samples.

PCA-LDA was employed to generate a classification model based on the Raman spectra
of the samples which was further tested by LOPOCV. The sensitivity and specificity
results obtained are shown in Table 4.4.
Table 4.4 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV. The model was
obtained based on the Raman spectra after NNLS glass correction.

Sampling
Group

Sensitivity
(%)

Specificity
(%)

Negative

100

100

CIN 1

100

99.24

CIN 2

100

99.31

CIN 3

95.45

100

LOPOCVacc = 0.9940; SD_LOPOCVacc = 0.0776
With all sensitivity and specificity values above 95% this glass correction method
provides the best PCA-LDA classifier so far. Furthermore, the fact that no glass features
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are observed in PCA loadings, suggests this classifier to be independent from glass
contribution and NNLS to be an efficient glass correction method whilst retaining
valuable spectral information to allow discrimination between the samples.
Based on the results presented in this chapter, NNLS can be inferred to be the best glass
correction method and will therefore be applied to all further analysis.

4.5

Discussion

Healthcare systems worldwide are under increasing financial stress to provide a variety
of services ranging from disease prevention to diagnosis and treatment. Screening
programmes such as for cervical cancer have led to a decrease in both disease incidence
and mortality, showing early diagnosis and monitoring of pre-cancer conditions has a
positive impact on the overall disease burden (Kitchener et al. 2011).
The Pap smear test has evolved since it was first introduced for cervical cancer
screening (Safaeian et al. 2007). Indeed, the introduction of LBC and standardised
reporting systems allowed sensitivity and specificity rates to improve significantly.
However, the subjectivity of the grading characteristics and the constant intra and interlaboratory cross-validation needed to achieve the highest rates reported in literature
(Kitchener et al. 2011) lead to research into improved, less subjective screening
methods like HPV-testing (Poljak et al. 2016) and optical methods such as Raman
spectroscopy (Ramos et al. 2015).
This project is part of a technology development programme aiming to incorporate
Raman spectroscopy into the current cytology screening programmes for cervical
cancer, providing a non-subjective, automated diagnosis outcome for each case.
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In this chapter it was demonstrated that Raman spectroscopy can successfully be
applied to the study and diagnosis of cervical ThinPrep® cytology samples. Although
spectroscopy substrates like calcium fluoride slides would prove easier to obtain a good
“clean” spectrum, they are too expensive to be cost effective for healthcare systems.
Recording spectra from the routinely used ThinPrep® glass slides is imperative if the
technology is ever to make headway into the clinical setting. However, using glass
slides as a substrate for Raman spectroscopy results in a glass contribution to the overall
spectral profile which our group and others have been trying to overcome.
Despite many wavelengths being reported in the literature for the study of biological
samples, and indeed 785 and 830 nm being the most widely reported for biological
samples (Butler et al. 2016), in this project 532nm was used as previous studies by our
group found this wavelength to provide reduced glass fluorescence in the spectra of
ThinPrep® cervical samples and therefore was found to be the most suitable wavelength
for this application (Ostrowska 2011; Bonnier et al. 2014). More recently, this
wavelength was also reported on a study of urine cytology samples also on glass
substrate (Kerr et al. 2016), following a study on the optimal substrate and laser
wavelength for Raman spectroscopy analysis of biological samples (Kerr et al. 2015).
PCA and PCA-LDA results for the analysis of Raman spectroscopy data collected for
the full fingerprint range are reported. Despite showing good separation across all
sample groups, this was dominated by glass features. It was observed that glass
substrate spectral features not only contributed to the spectral profile of the samples but
they further had different degrees of interference across the sampling groups. Glass
contribution seems to be directly related to the morphology of the cell and its nucleus;
the bigger and less compact the nucleus, the higher the glass contribution. For this
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reason, different glass correction methods were explored in order to minimise the glass
interference in the sample spectra and discrimination algorithms.
Results for three different models of glass correction are also presented. The first
method consisted of restricting the spectral range analysed in order to avoid the areas of
the Raman spectrum with more significant glass features. Although this method allowed
PCA discrimination between all sample groups and the PCA-LDA classification model
with LOPOCV achieved good performance with high sensitivity and specificity, this
method ignores more than half the spectral information contained in the fingerprint
region, including the region around 800 cm-1 to which many nucleic acid features are
assigned. Despite the so called spectral fingerprint region between 400 to 1800 cm1

being the most extensively studied for biological and biomedical applications, several

reports have emerged in recent years exploring the diagnosis potential of the high
wavenumber region (2400-3800 cm-1). Indeed, it is conceivable that not all
spectroscopic information is necessary in order to achieve accurate discrimination
between disease and non-disease samples. By focusing on the cell nuclei we expected to
find very subtle biochemical changes able not only to differentiate between normal and
high grade of abnormality but also between normal and early abnormal stages. The
biochemical difference between a normal cervical squamous cell and high grade
dysplastic one is, even morphologically, more pronounced than the difference between a
normal and early dysplastic cell or an HPV infected cell where morphologically the
cells are not as different. For this reason we set to investigate two further glass
correction methods to attempt to minimise the glass contribution to the full fingerprint
spectrum whilst retaining the most spectral and biochemical information possible.
Firstly the analysis of mean spectra after iterative glass correction (Bonnier et al. 2014),
which performs sequential subtractions of a reference glass spectrum from the sample
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spectra until a specific peak ratio, determined by spectral studies of cervical cytology on
calcium fluoride substrates, is achieved, showed a decrease in glass features observed in
the sample spectra. However, glass features were still visible in the loadings of the third
PC, responsible for the discrimination of the different sample groups on PCA,
indicating the glass removal from the sample spectra to be incomplete and still
influencing the highly sensitive and specific PCA-LDA classification model.
Secondly, a more sophisticated NNLS glass correction method (Ibrahim et al. 2016)
was used which estimated the contribution of the glass spectral features to the sample
spectra after modelling with a reference matrix of glass spectra and several other
biomolecules. On analysis of the mean spectra, a more marked reduction of glass
spectral features was observed after NNLS correction in comparison with the iterative
method. In addition, no obvious glass features were observed in the PC loadings
indicating these do not dominate the PCA-LDA classification model.
Although both iterative and NNLS corrected samples achieved very high performance
on PCA-LDA models with LOPOCV with sensitivity and specificity rates across all
sample groups above 90% and with no statistically significant difference in the accuracy
of the two models; NNLS provides a more complete subtraction of the glass features
from the sample spectra, minimising substrate contribution towards the discrimination
of the samples.
In the literature, very few spectroscopic studies of biological samples are reported on
glass substrates. The glass contribution to the spectra and its necessary removal or
minimisation constitutes a major challenge, as a balance between glass removal and
intrinsic sample spectra needs to be achieved.

140

In 2010, Kamemoto et al. reported that despite the investigation of several transparent
substrates, such as quartz, sapphire, plexiglass, and mica, none were found to be
suitable for Raman spectroscopy of cervical cancer tissue and “the search for an ideal
transparent substrate suitable for 785 nm Raman investigation was terminated”
(Kamemoto et al. 2010). Gardner’s group reported that relevant spectral information
was contained in “glass free” HW areas of the infrared spectrum of breast tissue
microarray samples, in an approach similar to the one described here restricting the
analysis to a defined spectral range (Bassan et al. 2014). The relevance of the HW
region of the Raman spectrum in cervical cancer has only been investigated by
Duraipandian et al. in an in vivo study (Duraipandian et al. 2012). Results showed
overall diagnostic accuracies of 80.3%, 74.2%, and 82.6%, respectively, for fingerprint
region, high-wavenumber region and integrated fingerprint and high-wavenumber
regions for in vivo diagnosis of cervical precancer. This project however, was focussed
on the fingerprint region of the Raman spectrum; This was due in part to time
constraints but mostly to the fact that this is the spectral region which is reported to
contain more significant biochemical information from nucleic acids, Amide and
protein features, most likely to have an impact on the underlying cervical cancer
progression and its consequent detection.
More recently, Kerr et al. reported the use a multiplicative signal correction (EMSC)
algorithm for the correction of glass substrate for Raman spectra of bladder cell lines
T24 (high grade urothelial carcinoma) and RT112 (low grade urothelial carcinoma)
(Kerr et al. 2016).

This least squares algorithm fits a reference Raman spectrum

obtained from the mean of a dataset recorded on a calcium fluoride substrate, the glass
signal and an N order polynomial. It computes a background signal from the N order
polynomial and a weighted glass signal. Sensitivity and specificity results for
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classification of the samples with PCA-LDA LOPOCV were similar to what are
reported here, about 90%. The project timeframe did not allow this EMSC algorithm to
be analysed as part of this study however it could constitute a further line of analysis of
cervical cytology spectral data acquired thus far and in the future. It seems to
incorporate principles of both iterative and NNLS corrections by fitting a reference
glass spectrum until a particular cell reference spectrum (recorded on CaF 2 ) is reached.
Nevertheless, our results show that using a glass matrix (for NNLS) as opposed to one
single reference glass spectrum (for the iterative correction method) allows for a more
complete glass correction. The fact that other cellular components are included in the
NNLS fitting of the glass spectra, should in principle allow for a more realistic
estimation of how much glass actually contributes to a particular spectral feature as real
cellular components can also show in similar spectral ranges.
In the next chapter, clinical features, such as age and HPV inflection, are correlated with
the samples spectral profiles in order to investigate their influence to the PCA-LDA
classifier constructed after NNLS correction.
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CHAPTER 5

THE INFLUENCE OF CLINICAL FEATURES ON
THE RAMAN SPECTROSCOPIC PROFILES
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Despite the cytological screening outcome, all samples in this study arise from a
heterogeneous group of patients comprising different biological and clinical
characteristics such as age, menstrual cycle, HPV infection or previous disease, all of
which could contribute to the biochemical composition of the sample and therefore the
Raman spectroscopy profile. In this chapter the Raman profile was analysed according
to each feature in order to not only evaluate the influence on spectral profiles but also to
establish any interference to the disease classification algorithms.

5.1

Age

All samples considered in the study were divided according to age of the patients into
four categories:
•

[20-29] years old

•

[30-39] years old

•

[40-49] years old

•

[50-60+] years old.

The number of samples in each category, according to disease classification is presented
in Figure 5.1.
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[20-29]

[30-39]

[40-49]

[50-60+]

27 28
21
12

16

15
11

9 10

7

4

2
Negative (n=88)

CIN 1 (n=35)

1 0

2 1

CIN 2 (n=21)

CIN 3 (n=22)

Figure 5.1 Sample database according to patient’s age by decades; [20-29] years are represented in green, [3039] in blue, [40-49] in red and [50-60+] in black.

The mean Raman spectra for negative and CIN samples according to age categories are
presented in Figure 5.2. Although no significant differences were found in the mean
spectra of each sample group or PCA results due to this feature, an increased variability
can be observed in the SD of CIN 3 samples namely the ones aged 20 to 29 and 40 to 49
years old. In the latter group, the increased variability could be a result of the small
sample number which compose this group (n=2); which may exacerbate a slightly
different biochemical profile perhaps as a result of age itself or other clinical feature like
menopausal status associated with this age group. For the 20 to 29 age group (n=9), the
increased sample variability is however harder to explain. Perhaps women in this age
group have severe dysplasia for a shorter period of time therefore display higher
variability in their cells. Nevertheless both sample numbers are too low to allow further
conclusions.
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Figure 5.2 Mean spectra for each sampling group according to patient’s age interval. Standard deviation is represented by shadowing. Samples where patient is between [20-29] years old are
indicated in green, [30-39 ]in magenta, [40-49] in red and [50-60+] in black.
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It should also be noted that the sample database in this study is asymmetrical not only
with regards to the abnormality grade of the samples but also with regards to patient
age. Because the samples are from a screening population, it was expected most
samples to be negative for abnormality. With increased sample numbers in this group it
is understandable that samples span all different age decades. Furthermore, screening
programmes are aimed at younger women; the Northern Ireland Cervical Screening
Programme, from which the samples in this study originated, offers cytology screening
every 3 years from women aged 25 to 49; with women aged 50 to 64 offered screening
every five years.
In this study, most negative samples arise from patients aged between 30 and 49 years
old whereas the majority of CIN samples arise from patients aged 20 to 39, with very
few cases of 50 years or above. Nevertheless, PCA was also employed to highlight any
differences related to this clinical feature; a 3-D scatterplot is presented in Figure 5.3.

Figure 5.3 3-D PCA scatterplot of all samples according to age and disease classification. Negative samples are
represented in green, CIN 1 samples in magenta, CIN 2 samples in red and CIN 3 samples in black. Each
sample is also represented according to the patient age interval with [20-29] represented by a circle, [30-39]
represented by a square, [40-49] represented by an inverted triangle and [50-60+] represented by an upright
triangle.
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All samples seem to separate according to their disease classification and no visible
separation can be attributed to the different age groups. Nevertheless, PCA-LDA with
LOPOCV was also used to evaluate the influence of age in the spectral profile of the
samples. For sample group analysis, only negative and CIN 1 samples could be
considered as they were the only groups with more than one sample across all age
subgroups allowing cross validation. Sensitivity and specificity results are presented in
Table 5.1 and Table 5.2 respectively.
Table 5.1 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the negative samples by age group.

Negative samples by age group Sensitivity (%) Specificity (%)
[20-29]

25.00

44.07

[30-39]

29.63

45.65

[40-49]

39.29

37.50

[50-60+]

33.33

42.31

LOPOCVacc=0.3295; SD_LOPOCVacc=0.4727

Table 5.2 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the CIN 1 samples by age group.

CIN 1 samples by age group Sensitivity (%) Specificity (%)
[20-29]

13.33

61.54

[30-39]

54.55

25.53

[40-49]

14.29

45.00

[50-60+]

50.00

30.00

LOPOCVacc=0.2857; SD_LOPOCVacc=0.4583
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Both Table 5.1 and Table 5.2 indicate that PCA-LDA models to predict age from
negative and CIN 1 sample groups respectively perform poorly, with limited sensitivity
and specificity. Such results are therefore suggestive that age cannot be predicted from
the Raman spectroscopy profiles of cervical cytological samples. Nevertheless, the
complete dataset was analysed, regardless of abnormality outcome, based on age.
Sensitivity and specificity results are presented in Table 5.3.
Table 5.3 Sensitivity and specificity values obtained for PCA-LDA classification model with LOPOCV for the
complete dataset by age group.

Sample by age group Sensitivity (%) Specificity (%)
[20-29]

37.04

41.67

[30-39]

34.62

45.65

[40-49]

31.58

49.48

[50-60+]

41.67

41.67

LOPOCVacc =0.3571; SD_LOPOCVacc = 0.4806
Similar to what was observed for individual age group analysis (Table 5.1 and Table
5.2), this new PCA-LDA model also showed limited sensitivity and specificity to
predict patient age. This result further suggests that this feature does not bear
significance towards the disease classification algorithm as it cannot be inferred from
the samples regardless of their cytological classification.
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5.2 Menstrual cycle
Information concerning the patients last menstruation period (LMP) was also provided
to this study as part of each patient’s clinical information for both negative and CIN
samples. The patient’s menstrual cycle day was calculating by comparing the LMP with
the smear date. Table 5.4 summarises the menstrual cycle information for each sampling
group.
Table 5.4 Sample database, information regarding menstrual cycle day.

Day of the
Number of samples
Menstrual
Negative CIN 1 CIN 2 CIN 3
Cycle
1
2
3
4
1
5
3
1
6
1
7
4
1
8
2
2
1
9
1
1
10
3
11
1
1
12
1
1
1
13
13
14
1
2
1
15
1
1
1
16
4
17
1
18
1
1
19
1
3
1
20
4
1
1
2
21
3
1
22
2
23
24
2
25
26
27
2
1
28
1
TOTAL
40
15
7
6
no
samples
150

It can be observed that the study’s sample database is also asymmetrical with regards to
menstrual cycle information. As the largest sample group, it is understandable that
negative samples also display higher numbers of samples (n=40) with available
menstrual cycle information, followed by CIN 1 with 15 samples and CIN 2 and 3 with
7 and 6 samples respectively. Menstruation cycle day was therefore only available for
less than 50% of the samples studied; this was because some patients did not know or
chose not to disclose their last menstrual period date upon smear collection meaning
that menstruation cycle date could not be inferred.
The analysis of the spectral data based on specific menstrual cycle days is therefore not
viable due to the limited sample numbers across each day of the cycle. The samples
were consequently grouped according to their menstrual cycle phases. Samples within
day 5 to 13 were considered to be in the proliferative phase of the cycle whereas
samples from day 14 to 28 were considered to be in the secretory phase as described in
chapter 1 section 1.1.2.
Proliferative

Secretory

22
18
11
4

3

Negative (n=40) CIN 1 (n=15)

4

CIN 2 (n=7)

4

2

CIN 3 (n=6)

Figure 5.4 Sample database according to menstrual cycle phases. Only samples with known menstrual date
could be included.
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To further explore the influence of menstrual cycle to the samples spectral profiles both
negative and CIN (1, 2 and 3) samples were studied with PCA and PCA-LDA.

5.2.1 Negative Samples

Results of PCA of the negative samples according to their menstrual cycle phase are
shown in Figure 5.5. Negative samples in the proliferative phase of the cycle are
represented by a light green circle whilst a dark green square represent those in the
secretory phase. Combined PC1, PC2 and PC3 represent approximately 81% of the
explained variance within the dataset but no visible separation can be observed between
negative samples in both phases of the menstrual cycle. Despite other PC combinations
being further tested (data not shown) no clear separation was observed between the two
groups.

Negative Proliferative
Negative Secretory
0.1

PC3

0.05
0
-0.05
-0.1
0.1
0.2
0
PC2

0
-0.1 -0.2

PC1

Figure 5.5 3-D PCA scatterplot of negative samples according to their menstrual cycle phase. Samples in the
proliferative phase, from day 5 to 13, are represented by a light green circle whereas samples in the secretory
phase, from day 14 to 28, are represented by a dark green square. PC1, PC2 and PC3 represent 45.56%,
21.09% and 13.66% of the explained variance within the dataset.
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Nevertheless, a PCA-LDA model was generated to classify negative samples according
to their menstrual cycle phase. LOPOCV was used and the sensitivity and specificity
results obtained are presented in Table 5.5.
Table 5.5 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the menstrual cycle phase of negative samples.

Negative samples’
Sensitivity (%) Specificity (%)
menstrual cycle phase
Proliferative

66.67

100

Secretory

50.00

100

LOPOCVacc =0.5750 SD_LOPOCVacc = 0.5006
PCA-LDA results indicate the model is 100% specific for classification of menstrual
cycle phase in the negative samples; whilst displaying moderate sensitivity of 66.67%
for proliferative and 50% for secretory phase. However the model overall accuracy of
57.5% might be compromised by the low sample numbers which undermine more
robust conclusions.

5.2.2 CIN 1, 2 and 3 Samples

Similar to what was described for negative samples, the analysis of CIN samples
according to their specific day of the cycle was likewise not viable as only one or no
sample was available for some days. However, specific days were grouped into cycle
phases (proliferative and secretory) to allow PCA to be performed and a PCA-LDA
classification model to be tested. The PCA of CIN samples according to their menstrual
cycle phase is shown in Figure 5.6. CIN 1 samples are represented in magenta, CIN 2 in
red and CIN 3 in black; samples in the proliferative phase are represented by a circle
whilst those in the secretory phase are represented by a square.
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Figure 5.6 (A) 2-D PCA scatterplot of CIN 1, 2 and 3 samples according to their menstrual cycle phase.
Samples in the proliferative phase, from day 5 to 13, are represented by a circle whereas samples in the
secretory phase, from day 14 to 28, are represented by a square. CIN 1 samples are represented in magenta,
CIN 2 in red and CIN 3 in black. PC2 and PC4 represent 0.23% and 0.07% of the explained variance within
the dataset. (B) PC2 loading.

No visible separation of the CIN samples according to their menstrual cycle phase could
be observed in the 2-D PCA scatterplot (Figure 5.6 A). PC2 and PC4 account
respectively for 0.23 and 0.07% of the variance within the dataset and despite other PC
combinations being tested (data not shown), no clear separation could be observed
between CIN samples in proliferative (circles) or secretory (squares) phase of the
menstrual cycle. The samples seem to rather separate based on their CIN classification
into CIN 1 (magenta), CIN 2 (red) and CIN 3 (black) according to PC2, in a similar
fashion to what was described in section 4.4 of chapter 4. PC2 is negatively dominated
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by assignments of phenylalanine (1005 cm-1), Amide I and fatty acids at 1657 cm-1 and
Amide I C=C stretching at 1672/3 cm-1. In addition, Amide II at 1247 and 1260 cm-1,
desoxyribose at 1457 cm-1 and guanine & CH deformation of proteins and
carbohydrates at 1342 cm-1, the latter also assigned to the peak at 1449 cm-1, further
dominate the loading negatively. In contrast, PC2 is positively dominated by nucleic
acids assignments between 700-800 cm-1 and the bands at 1540–680 cm-1 assigned to
the Amide carbonyl group vibrations and aromatic hydrogen, as well as Amide I (at
early 1600 cm-1).
Nevertheless, PCA-LDA was used to investigate if classification of CIN samples
according to their menstrual cycle phase could be achieved. The sensitivity and
specificity results for the PCA-LDA classification model of CIN 1 samples according to
their menstrual cycle phase are shown in Table 5.6.
Table 5.6 Sensitivity and specificity results for the PCA-LDA classification model with LOPOCV of CIN 1
samples according to their menstrual cycle phase.

Samples

Sensitivity (%) Specificity (%)

Proliferative

25.00

100

Secretory

63.64

100

CIN 1

LOPOCVacc =0.5333 SD_LOPOCVacc = 0.5164
The model is 100% specific for the classification of menstrual cycle phase of CIN 1
samples and, although moderately sensitive for classification of the secretory phase
(63.64%), it is only 25% sensitive for the classification of the proliferative phase.
Similar PCA-LDA models could not be constructed for CIN 2 and CIN 3 samples
individually as the total number of samples in these groups was less than 10, therefore
not allowing the 10-fold cross-validation used thus far to test the optimal number of PCs
to generate the PCA-LDA model.
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Given the somewhat encouraging results obtained for PCA-LDA models of negative
and CIN 1 samples alone, and that CIN 1 samples are the first grade of cervical
abnormality, a PCA-LDA model was generated to evaluate the distinction of the two
sample groups according to their menstrual cycle phase. The sensitivity and specificity
results obtained after LOPOCV are represented in Table 5.7.
Table 5.7 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
menstrual cycle phase for negative and CIN 1 samples.

Samples

Sensitivity (%) Specificity (%)

Proliferative

44.44

88.89

Secretory

54.55

86.96

Proliferative

50.00

60.00

Secretory

40.91

52.38

Negative

CIN 1

LOPOCVacc = 0.5818 SD_LOPOCVacc = 0.4978
For this model, the specificity values obtained for both negative and CIN 1 sample
groups were below the 100% reported for the PCA-LDA models considering each
group individually, in Table 5.5 and Table 5.6. Similarly, the sensitivity for negative
samples in the proliferative phase of the cycle and for CIN 1 samples in the secretory
phase was also decreased by approximately 22%. The opposite was however observed
for the sensitivity of negative samples in the secretory phase and CIN 1 samples in the
proliferative phase which increased by approximately 5 and 25% respectively.
Given the potential for false positive results arising mainly between negative and CIN 1
samples, an additional PCA-LDA model was also tested which would classify between
negative samples in the proliferative and secretory phase of the menstrual cycle against
CIN 1 samples. The sensitivity and specificity results after LOPOCV are presented in
Table 5.8.
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Table 5.8 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of
negative samples according to their menstrual cycle phase and CIN 1 samples.

Samples

Sensitivity (%) Specificity (%)

Proliferative

55.56

100

Secretory

54.55

100

100

55.00

Negative

CIN 1

LOPOCVacc = 0.7600 SD_LOPOCVacc = 0.4300
When CIN 1 samples are included in the PCA-LDA classifier for negative samples
according to their menstrual cycle phase, the model still shows 100% specificity for
classification of both proliferative and secretory phase in the negative samples as seen
in Table 5.5. And, despite an increase in sensitivity for negative samples in the secretory
phase, a decrease can also be observed for the negative samples in the proliferative
phase, both by approximately 5%. For the detection of CIN 1 samples, the model was
shown to be 100% sensitive and 55% specific.
Nevertheless, PCA-LDA was further used to generate a model which would not only
classify the samples between negative and CIN cytology but further subcategorise
negative samples according to their menstrual cycle phase. LOPOCV was performed
and sensitivity and specificity results are presented in Table 5.9.
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Table 5.9 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
Negative - proliferative or secretory menstrual cycle phase, and CIN 1, 2 and 3 samples.

Sampling group

Sensitivity (%) Specificity (%)

Proliferative

44.44

100

Secretory

63.64

100

CIN 1

100

78.31

CIN 2

100

81.44

CIN 3

100

81.25

Negative

LOPOCVacc = 0.8475 SD_LOPOCVacc = 0.3611
Despite being 100% specific to detect proliferative and secretory phase of negative
samples; this PCA-LDA model has moderate sensitivity of 44.44% for negative samples
in proliferative phase and 63.64% for those in the secretory phase of the menstrual
cycle. The model’s sensitivity of 100% to all CIN categories represents an increment to
CIN 3 samples compared to the classification model reported in Table 4.4 (chapter 4);
however, a decrease in specificity can be observed across all CIN groups, by
approximately 21% for CIN 1, 19% for CIN 2 and 18.75% for CIN3. It should be noted
that although the sample numbers remained unaltered for CIN groups, the negative
sample database in this model is reduced by half, from 88 (in Table 4.4, chapter 4) to 40
as this is the number of samples which had menstrual cycle data available.
Overall, PCA-LDA results for menstrual cycle phase suggest the models to be limited in
terms of sensitivity which varies from 50 and 66.67% for negative samples and from 25
to 63.64% for CIN 1 samples, despite being highly specific (100%) when both sample
groups are considered independently; not improving when the PCA-LDA models also
considered other sample groups. The small sample databases (n<10) for CIN 2 and 3
samples meant the PCA-LDA analysis of these samples was not feasible. Similarly, the
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spectral data could not be analysed with regards to the specific days of menstrual cycle
due to insufficient numbers across most days.
Another PCA-LDA model was created to evaluate the menstrual cycle phase regardless
of cytological classification. After LOPOCV, sensitivity and specificity results are
shown in Table 5.10.
Table 5.10 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the menstrual cycle phase of all samples considered in the study regardless of cytological classification.

Menstrual cycle phase Sensitivity (%) Specificity (%)
Proliferative

34.14

100

Secretory

43.59

100

LOPOCVacc = 0.3881SD_LOPOCVacc = 0.4910
This PCA-LDA model is still limited in terms of sensitivity ranging from 34.14 to
43.59%, despite showing high specificity (100%).
Nonetheless, the results presented in this section are suggestive that menstrual cycle
phase could potentially be inferred for negative samples. Normal patient variation due
to this feature was hypothesised to potentially increase false positive rates as normal
samples could be deemed abnormal in case their spectral profile variations due to
different menstrual cycle phases resembled abnormal signatures. However, the PCALDA classifier that further discriminates negative samples according to their menstrual
cycle phases (Table 5.9) did not perform as well as the model which did not use this
information (Table 4.4, chapter 4). This seems to suggest that menstrual cycle might not
act as a confounding factor to the correct classification of the samples. It would
however be important to monitor this clinical feature in future studies as the limited
database restricted the PCA-LDA analysis and undermines a definitive conclusion.
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5.3 HPV status
Cervical cytology samples included in this study were also analysed according to their
HPV status and profile. At the time of diagnosis HPV testing was performed at the
Altnagelvin Hospital using the Cobas 4800 HPV Test (Roche Molecular Systems,
Pleasanton, Calif). According to in-house procedures only samples diagnosed as CIN
were tested for HPV so no information regarding HPV was provided for the negative
samples included in this study.
As described in chapter 1 (section 1.4.2) , the Cobas HPV test is a qualitative multiplex
assay that provides specific genotyping information for HPV types 16 and 18 while
concurrently detecting the other 12 high-risk HPV types in a pooled result. Table 5.11
shows the sample database according to HPV result, as well as the number of samples
in each HPV category.
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Table 5.11 HPV test results for CIN samples.

Sample group
HPV test result

CIN
1

CIN
2

HPV negative

15

1

HPV positive for 12 other high risk HPV
types

16

10

7

HPV 16 positive

1

6

8

3

5

HPV 16 and 12 other high risk HPV types
positive
HPV 18 positive

2

HPV 16 and 18 positive

1

HPV 16, 18 and 12 other high risk HPV
types positive

CIN
3

16

2

35

32
15
8
4
1
1

1

Total no. of samples

Total no. of
samples

21

22

78

5.3.1 CIN 1 samples according to HPV test
PCA was performed to evaluate the influence of HPV on the CIN 1 sample population.
A 2-D PCA scatterplot is presented in Figure 5.7 A.

Results seem to suggest a

separation of HPV negative from HPV positive CIN 1 samples according to PC2 which
accounts for 0.21% of the variability within the dataset. A separation between HPV
positive subsets could not be inferred due to the low sample number across all
categories.
The PC2 loading presented in Figure 5.7 B indicates the separation is negatively
dominated by assignments of phenylalanine (1007cm-1), C-C stretch (1100, 1339 and
1674 cm-1), Amide III (1246 cm-1), nucleic acids (1458 cm-1) and Amide I & fatty acids
(1657 cm-1) , which are more prominent in the spectra of CIN 1 HPV negative samples.
Assignments for Amide II and I, specifically the C=C stretch at 1628 cm-1 are however
more prominent in the spectra of HPV positive samples.
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A

B

Figure 5.7 (A) 2-D PCA scatterplot of CIN 1 samples according to HPV. HPV negative samples are represented in
green, HPV positive for 12 other high-risk types in magenta, HPV 18 in blue, HPV 16 and 18 in orange and HPV
16 in red. PC1 and PC2 account for 99.53% and 0.21% of the variability within the dataset respectively. (B) PC2
loading.

As some of the HPV testing results arise from only one to two samples cross validation of
a PCA-LDA model to predict a stratified HPV result was not viable. However, a PCALDA model that would report CIN 1 samples as either HPV positive or negative was tested
with LOPOCV and the sensitivity and specificity values obtained are shown in Table 5.12.
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Table 5.12 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
HPV positive or negative CIN 1 samples.

CIN 1 HPV
sampling
group

Sensitivity
(%)

Specificity
(%)

HPV negative

73.33

100

HPV positive

75.00

100

LOPOCVacc =0.7429; SD_LOPOCVacc = 0.4434
This PCA-LDA model is 100% specific and presents a sensitivity of 73.33 and 75% to
classify CIN 1 samples into either HPV positive or negative, respectively.
PCA and PCA-LDA were also used to investigate the potential to not only classify
cytology negative samples from CIN 1 samples but to further sub-classify CIN 1
samples into HPV negative or positive. The PCA results are presented in Figure 5.8.
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Figure 5.8 (A) 3-D PCA scatterplot of Negative and CIN 1 HPV negative and positive samples. Negative
samples are represented in green, CIN 1 HPV negative samples in magenta and CIN 1 HPV positive samples
in red. PC1, PC2 and PC3 account for 99.56%, 0.18% and 0.08% of the variability within the dataset
respectively. (B) PC2 and PC3 loadings.

Negative samples (green) seem to separate from CIN 1 samples according to PC2 whilst
CIN 1 HPV negative (magenta) separate from CIN 1 HPV positive (red) according to
PC3 (Figure 5.8 A). Both loadings are presented in Figure 5.8 B and account for 0.26%
of the variance found within the dataset. PC2 is dominated by positive features assigned
to phenylalanine (1000cm-1) and Amide I C=O and C=C vibrations of proteins and
lipids (1655-6 cm-1) which are more prominent in the Raman spectral profile of negative
samples. PC3 is negatively dominated by C-C vibrations (855, 938, 1086-7 and 1339
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cm-1) and glycogen (484 cm-1), more prominent in the spectra of CIN 1 HPV negative
samples; and, on the other hand, positively dominated by Amide I around 1600 cm-1,
more prominent in the spectra of HPV positive CIN 1 samples. The sensitivity and
specificity values obtained for the PCA-LDA model after LOPOCV are reported in
Table 5.13.
Table 5.13 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
Negative and CIN 1 samples - HPV positive or negative.

Sampling Group

Sensitivity
(%)

Specificity
(%)

Negative

100

85.71

HPV negative

86.67

100

HPV positive

85.00

100

CIN 1
LOPOCVacc =0.9593; SD_LOPOCVacc = 0.1983
The sensitivity and specificity results obtained for this PCA-LDA classification model
(Table 5.13) were superior to those obtained for the CIN 1 model alone (Table 5.12).
When the negative category is included, the specificity to detect CIN 1 both HPV
positive and negative samples remains at 100% but the sensitivity is increased by
approximately 10% to 86.67% and 85% respectively. The model further displayed
100% sensitivity and 85.71% specificity to detect negative samples. Such promising
results show the potential to not only distinguish CIN 1 from negative samples based on
their Raman spectroscopy profiles, but also to sub-classifying CIN 1 samples according
to their HPV positivity or negativity.

5.3.2 CIN 2 and CIN 3 samples according to HPV test

PCA was also performed to evaluate the influence of HPV in the CIN 2 sample
population. A 3-D PCA scatterplot of PC1, 2 and 3 which together represent more than
99% of the variance found within the dataset is represented in Figure 5.9. As no clear
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separation was observed, even when other PC combinations were tested (data not
shown), results suggest it is not possible to sub-classify CIN 2 samples spectra
according to their HPV test result outcome. PCA-LDA was not performed due to the
low number of samples overall and the fact that no sample was available for some HPV
test results would undermine the cross validation of the model.

Figure 5.9 3-D PCA scatterplot of CIN 2 samples according to HPV. HPV negative samples are represented in
green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV 16 and 12 other high-risk
types in orange and HPV 16, 18 and 12 other high-risk types in blue. PC1, PC2 and PC3 account respectively
for 99.77, 0.11 and 0.03% of the variability within the dataset.

For CIN 3 samples, the 3-D PCA scatterplot of PC1, PC2 and PC3 is represented in
Figure 5.10. Together they account for more than 99% of the variance found within the
dataset. However, similar to what was observed for CIN 2 samples, no clear separation
was observed in the PCA plot or when other PC combinations were tested (data not
shown). PCA results therefore suggest it is not possible to sub-classify CIN 3 samples
according to their HPV test results. As found for CIN2 samples, a PCA-LDA model
with LOPOCV was not viable for CIN 3 according to HPV test results due to the low
sample numbers across all categories.
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Figure 5.10 3-D PCA scatterplot of CIN 3 samples according to HPV. HPV negative samples are represented
in green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV 16 and 12 other high-risk
types in orange and HPV 18 in blue. PC1, PC2 and PC3 account respectively for 99.66%, 0.17% and 0.06% of
the variability within the dataset.

In an attempt to increase the sample numbers across each category, PCA was also
performed on CIN 2 and 3 samples according to HPV test result. A 3-D scatterplot of
PC1, PC2 and PC3 is presented in Figure 5.11. No clear separation can be seen based on
the HPV profiles represented by different symbols; rather the most visible separation
was found to be between CIN 2 and 3 samples in red and black respectively.

Figure 5.11 3-D PCA scatterplot of CIN 2 and 3 samples according to HPV. CIN 2 samples are represented in
red and CIN 3 are represented in black. HPV negative samples are represented by a circle, HPV positive for
12 other high-risk types by a square, for HPV16 by an upright triangle, for HPV 16 and 12 other high-risk
types, for HPV 18 by an asterisk mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 other high-risk
types by a cross. PC1, PC2 and PC3 account respectively for 99.67%, 0.15% and 0.06% of the variability
within the dataset.
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The limited sample numbers across all HPV outcome categories is however an
important limitation and does not allow PCA-LDA models to be generated and tested.
Sub-classification of CIN 2 and 3 samples into HPV negative or positive was not
attempted as only one CIN 2 sample tested negative for HPV.
Despite this, a model was created to evaluate the classification between all CIN samples
(1, 2 and 3) with the subclassification of CIN 1 samples into HPV positive or negative,
which seemed to be achieveble as reported in the previous section (5.3.1). The
sensitivity and specificity values obtained for this PCA-LDA model are shown in Table
5.14.
Table 5.14 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of
negative, CIN 1 HPV negative or positive, CIN 2 and 3.

Sensitivity
(%)

Specificity
(%)

HPV negative

60.00

94.83

HPV positive

70.00

94.34

CIN 2

90.48

78.95

CIN 3

95.65

77.78

Sampling Group

CIN 1

LOPOCVacc = 0.8101; SD_LOPOCVacc = 0.3947
Despite showing encouraging results ranging from 60 to 95.65% for both sensitivity and
specificity, the model did not perform as well as those reported in Table 5.12 and Table
5.13. The specificity to detect HPV positive and negative CIN 1 samples dropped from
100% to approximately 94% whereas the sensitivity now varies from 60 to 70%
respectively. In addition, the sensitivity and specificity to detect CIN 2 and 3 samples is
also reduced when compared to those obtained for the PCA-LDA CIN classification
model in Table 4.4 of chapter 4 (section 4.4).
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5.3.3 All CIN samples according to HPV test result
PCA and PCA-LDA were further used to analyse all CIN samples according to their
HPV test result. A 2-D PCA scatterplot of PC2 and PC3 accounting for 0.36% of the
dataset variance is presented in Figure 5.12.

0.08

CIN 1 HPV negative
CIN 2 HPV negative
CIN 1 HPV positive for 12 other high risk types
CIN 2 HPV positive for 12 other high risk types
CIN 3 HPV positive for 12 other high risk types
CIN 1 HPV 16 positive
CIN 2 HPV 16 positive
CIN 3 HPV 16 positive
CIN 2 HPV 16 and 12 other high risk types positive
CIN 3 HPV 16 and 12 other high risk types positive
CIN 1 HPV18 positive
CIN 3 HPV 18 positive
CIN 1 HPV 16 and 18 positive
CIN 2 HPV 16, 18 and 12 other high risk types positive

0.06
0.04

PC3

0.02
0
-0.02
-0.04
-0.06
-0.1

-0.05

0

0.05
PC2

0.1

0.15

Figure 5.12 2-D PCA scatterplot of all sampling groups according to HPV test result. Negative samples are
represented in green, CIN 1 samples in magenta, CIN 2 samples in red and CIN 3 samples in black.
Furthermore, HPV negative samples are represented by a circle, HPV positive for 12 other high-risk types by
a square, for HPV16 by an upright triangle, for HPV 16 and 12 other high-risk types, for HPV 18 by an
asterisk mark, for HPV 16 and 18 by a star and for HPV 16, 18 and 12 other high-risk types by a cross. PC2
and PC3 account respectively for 0.27% and 0.08% of the variability within the dataset.

As reported previously, apart from the distinction between the different CIN groups
(CIN 1 in magenta, CIN2 in red and CIN 3 in black), and the slight separation between
CIN 1 HPV positive (dark magenta) and negative (light magenta), no other separations
were observed which could be attributed to the specific HPV profiles of the samples.
All CIN samples were also studied according to their HPV profile only, to evaluate if it
was possible to identify different HPV profiles regardless of the CIN classification.
PCA results are shown in Figure 5.13.
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Figure 5.13 (A) 3-D PCA scatterplot of CIN samples only according to the HPV test result. HPV negative
samples are represented in green, HPV positive for 12 other high-risk types in magenta, HPV 16 in red, HPV
16 and 12 other high-risk types in orange, HPV 18 in dark blue, HPV 16 and 18 by light blue and, HPV 16, 18
and 12 other high-risk types in black. PC1, PC2 and PC3 account respectively for 99.47%, 0.27% and 0.08%
of the variability within the dataset. (B) PC2 loading which accounts for 0.27% of the variability within the
dataset.

The only suggested separation seen on the PCA scatterplot (Figure 5.13 A) is between
HPV negative samples and all HPV positive samples regardless of HPV type. This
separation is along PC2 which accounts for 0.27% of the variability within the dataset.
The PC2 loading in Figure 5.13 B, is similar to that shown in Figure 5.7 for CIN 1
samples according to HPV with main assignments as described previously.
The limited sample numbers across each HPV category did not allow for PCA-LDA
models to be constructed which would classify (1) CIN samples further stratifying their
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HPV test result and (2) the HPV profile of the samples regardless of their CIN
classification.
Nevertheless, PCA-LDA was used to generate a classification model of all categories
further sub-classifying CIN 1 into HPV positive or negative. The sensitivity and
specificity results obtained are presented in Table 5.15. Encouraging overall sensitivity
and specificity values, above 73% and 87% respectively, suggest the stratification of
CIN 1 samples into HPV positive or negative might also be achievable when negative
and CIN 2 and 3 categories are also considered.
Table 5.15 Sensitivity and specificity values obtained for a PCA-LDA classification model with LOPOCV that
would classify negative, CIN 1 HPV negative, CIN 1 HPV positive, CIN 2 and CIN 3 samples.

Sampling Group

Sensitivity
(%)

Specificity
(%)

Negative

100

87.84

HPV negative

73.33

95.95

HPV positive

80.00

95.80

CIN 2

100

91.03

CIN 3

77.27

94.44

CIN 1

LOPOCVacc =0.9162; SD_LOPOCVacc = 0.2780
Overall, PCA results suggest HPV typing not to have significant influence on the
Raman spectra of CIN samples. In addition, the limited sample database did not allow
PCA-LDA models to be created to classify HPV result (subtype).
Nevertheless, a HPV positive or negative result seems to be relevant in the spectral
profile of CIN 1 samples. Although CIN 1 HPV negative samples may be argued as a
false positive, the HPV test used only tested for HPV16, 18 and 12 other high-risk HPV
types, therefore excluding all low-risk HPV types which may be present in this group,
causing the CIN 1 phenotype. Likewise, it may also be plausible that these samples
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arise from patients who were able to clear a recent HPV infection, and although no viral
DNA is detected upon HPV testing, spectrally the samples still exhibit CIN 1 profile.
From the PCA, it is possible to observe a subtle separation between CIN 1 HPV positive
and HPV negative samples dominated by Amide and C-C vibrational features. When
included in PCA-LDA classification models, the sub-classification of CIN 1 samples
according to HPV test result achieved the best results against negative samples only,
100% specificity and approximately a 10% increase in sensitivity when compared with
modelling with CIN 1 samples only. This may be an effect of the LOPOCV on small
sample numbers but further investigation might provide insights with regards to the best
stage at which to ask for a HPV result, for example, based on our PCA-LDA results,
once it was established a sample is neither CIN 2 or 3, it seems to be more accurately
tested on a model that classifies into negative or CIN 1 HPV positive/negative.
As the current sample database is a major limiting factor for any robust conclusions to
be drawn from this analysis, the need to extend the sample database in future research to
include a greater body of samples with representative numbers of all different HPV
types is recognized. In addition, based on the interesting CIN 1 results, it is further
suggested that a more thorough HPV testing, including low-risk HPV types and testing
for HPV mRNA as well as HPV DNA should be carried out.
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5.4 Previous disease history
As part of the sample database, information regarding previous disease history was also
collected for all samples. To facilitate comparison, the analysis is presented in section
5.4.1 for negative and CIN 1 samples and in section 5.4.2 for CIN 2 and CIN 3 samples.
First smear samples that had no available history were considered to be negative for
previous disease. When multiple disease history was recorded only the more severe was
considered so that each sample was only analysed once. The previous disease history of
each sample included in this study was then considered to be negative, low to mild
dysplasia, or moderate to severe dysplasia. Negative and CIN 1 samples also had
previous history of borderline disease which was not observed for any of the CIN 2 or 3
samples

5.4.1 Negative and CIN 1 samples

The negative and CIN 1 sample database according to their previous history is presented
in Table 5.16.
Table 5.16 Previous disease history for negative and CIN 1 samples.

Total
no. of
Negative CIN 1 samples
Sample group

Previous disease history
Negative

70

17

87

Borderline

4

6

10

Low to mild dysplasia

13

11

24

Moderate to severe dysplasia

1

1

2

Total no. samples

88

35

123

PCA analysis of negative samples according to their previous disease history is
presented in Figure 5.13. Although PC1, PC2 and PC3 represent more than 99% of the
variance found within the dataset, no separation was visible in the 3-D PCA scatterplot;
173

suggesting specific previous disease history might not act as a confounding factor to
disease classification.

Negative with Negative history
Negative Borderline history
Negative Low to mild dysplasia history
Negative Moderate to severe dysplasia history
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Figure 5.14 3-D PCA scatterplot of negative samples according to previous disease history. PC1 , PC2 and PC3
account respectively for 99.66%, 0.17% and 0.06% of the variability within the dataset.

Nevertheless, PCA-LDA was also applied to further establish if specific previous
disease could be inferred from the Raman spectroscopy profiles of negative samples. As
only one sample had moderate to severe previous disease history this category was not
included as LOPOCV could not be undertaken. The sensitivity and specificity values
obtained are shown in Table 5.17.
Table 5.17 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for negative
samples by previous disease history.

Negative samples previous history Sensitivity (%) Specificity (%)
Negative

61.43

72.73

Borderline

50.00

68.06

Low to mild dysplasia

46.15

81.82

LOPOCVacc = 0.5862 SD_LOPOCVacc = 0.4954
As expected from the non-existent separation on PCA scatterplot, the PCA-LDA model
showed limited power in sub-classifying negative samples according to their specific
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previous disease history with sensitivity values ranging from 46.15 to 61.43%, whilst
specificity ranged from 68.06 to 81.82%.
Nevertheless, another PCA-LDA classification model with LOPOCV was also tested,
this time to classify the negative samples into those with no previous disease history and
those with previous disease history. Sensitivity and specificity results obtained after
LOPOCV are presented in Table 5.18.
Table 5.18 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for negative
samples classified into negative or positive previous disease history.

Negative samples previous history Sensitivity (%) Specificity (%)
Negative

61.43

100

Positive

61.11

100

LOPOCVacc=0.6136; SD_LOPOCVacc= 0.4394
For this “yes or no” PCA-LDA model, results were more encouraging with 100%
specificity and approximately 61% sensitivity being obtained for both negative and
positive previous disease history. These are therefore suggestive that previous disease
status may be inferred from the spectral profile of the negative samples.
As mentioned in the menstrual cycle phase section (5.2.) of this chapter, the false
positives arise primarily from the misclassification of negative and CIN 1 samples. For
this reason, PCA-LDA was further used to evaluate the classification of negative
samples according to their previous disease history when compared with CIN 1
samples. After LOPOCV, the sensitivity and specificity results obtained are presented in
Table 5.19.
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Table 5.19 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV
considering negative samples according to their previous disease history and CIN 1 samples.

Sample group

Sensitivity (%) Specificity (%)

Negative without previous disease history

77.14

91.56

Negative with previous disease history

33.33

100

CIN 1

97.14

68.10

LOPOCVacc = 0.7642 SD_LOPOCVacc = 0.4262
When CIN 1 samples were included in the PCA-LDA classification model of negative
samples according to their previous disease history, the sensitivity of negative samples
without previous disease history is increased by approximately 15% whereas a decrease
of 27.78% is observed in the sensitivity of the samples with previous disease history.
Despite a decrease in the negative samples without previous history, the specificity for
both negative sample groups is still above 90%. The classification of CIN 1 samples has
a high sensitivity of 97.14% and moderate specificity of 68.10%.
Finally a PCA-LDA model was then generated to evaluate the ability to sub-classify
negative samples according to their previous disease history as well as further classify
samples into CIN 1, 2 and 3. LOPOCV was performed and the sensitivity and
specificity results obtained are reported in Table 5.20. Although specificity ranges from
71 to 99% across all categories, the model’s sensitivity to negative samples with
previous disease was only 33%. Much like what was reported before in this chapter, the
small sample numbers in this category might be undermining this analysis and this
should therefore be further investigated in future research.
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Table 5.20 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV
considering negative samples previous disease history.

Sample group

Sensitivity (%) Specificity (%)

Negative without previous disease history

65.71

97.62

Negative with previous disease history

33.33

99.16

CIN 1

97.14

71.76

CIN 2

100

74.31

CIN 3

95.45

74.31

LOPOCVacc=0.7711; SD_LOPOCVacc= 0.4214
Finally, the negative samples with previous disease history were omitted from the
database so only "true negatives" were included, and the PCA-LDA disease
classification algorithm was run with LOPOCV. The sensitivity and specificity results
obtained are presented in Table 5.21. With all values ranging from 95 to 100% this
model showed very good performance but it did not differ significantly from that shown
in Table 4.4 (chapter 4) which also included negative samples with previous disease
history.
Table 5.21 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering
negative samples previous disease history.

Negative samples previous history

Sensitivity (%) Specificity (%)

Negative without previous disease history

100

100

CIN 1

100

99.12

CIN 2

100

99.21

CIN 3

95.45

100

LOPOCVacc=0.9932; SD_LOPOCVacc= 0.0822
Similar results were obtained for CIN 1 samples. PCA results presented in Figure 5.15
showed no clear separation of CIN 1 samples based on their specific disease history.
Nevertheless, the sensitivity and specificity values obtained for the PCA-LDA model
for CIN 1 samples by previous disease history are shown in Table 5.22. The moderate to
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severe dysplasia previous disease category was however not considered as it contained
only one sample.

CIN 1 Negative history
CIN 1 Borderline history
CIN 1 Low to mild dysplasia history
CIN 1 Moderate to severe dysplasia history
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Figure 5.15 3-D PCA scatterplot of CIN 1 samples according to previous disease history. PC1 , PC2 and PC3
account respectively for 99.53%, 0.21% and 0.07% of the variability within the dataset.
Table 5.22 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 1
samples by previous disease history.

CIN 1 samples previous history Sensitivity (%) Specificity (%)
Negative
Borderline
Low to mild dysplasia

47.06

55.56

0

54.17

45.45

57.14

LOPOCVacc = 0.3824 SD_LOPOCVacc = 0.4933
Results showed poor performance of the PCA-LDA model which showed zero
sensitivity for detecting a borderline previous disease history in CIN 1 samples. These
samples are, like for negative samples, one of the most underrepresented groups with
only 6 samples.
A "yes or no" PCA-LDA classification model with LOPOCV was then tested to classify
CIN 1 samples into those with previous disease history and those without previous
disease history. The sensitivity and specificity results obtained are presented inTable
5.23.
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Table 5.23 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 1
samples by previous disease history.

CIN 1 samples previous history Sensitivity (%) Specificity (%)
Negative

70.59

100

Positive

61.11

100

LOPOCVacc=0.6571; SD_LOPOCVacc= 0.4816
The results of this PCA-LDA model are comparable to those obtained for an analogous
model for the negative samples Table 5.18. The “yes or no” PCA-LDA model resulted
in 100% specificity and approximately 61% and 70% sensitivity being obtained for both
negative and positive previous disease history, further suggesting it might be possible to
accurately infer previous disease information based on the spectral profile of the
samples.
An additional PCA-LDA classification model was created to evaluate the stratification
of CIN 1 samples according to their previous disease history against all possible
diagnosis categories (negative and CIN 2 and 3). LOPOCV was performed and the
sensitivity and specificity results obtained are presented in Table 5.24.
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Table 5.24 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering CIN
1 samples previous disease history.

Sample classification

Sensitivity (%) Specificity (%)

Negative

100

76.62

CIN 1 without previous disease history

52.94

99.28

CIN 1 with previous disease history

44.44

99.29

CIN 2

100

86.90

CIN 3

95.45

87.50

LOPOCVacc =0.8855 SD_LOPOCVacc =0.3193
This model shows limited performance for the detection of CIN 1 samples according to
their previous disease history. Although a slight decrease of less 1% in specificity was
observed for these samples, a more significant decrease in sensitivity of 17.65% for
samples without previous disease and of 16.67% for samples with previous disease was
observed. The sensitivity and specificity values for the classification of the other sample
groups was also inferior to what was observed before in this chapter and chapter 4.

5.4.2 CIN 2 and CIN 3 Samples

The previous disease information obtained for the CIN 2 and 3 samples considered in
this study is presented Table 5.25.
Table 5.25 Previous disease history for CIN 2 and 3 samples.

Total
no. of
CIN 2 CIN 3 samples
Sample group

Previous disease history
Negative

11

14

25

Low to mild dysplasia

7

3

10

Severe to moderate dysplasia

3

5

8

Total no. of samples

21

22

43
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PCA analysis of CIN 2 samples according to their previous disease history is presented
in Figure 5.17. No clear separation can be observed and PCA-LDA results in Table 5.26
show sensitivity and specificity values to be very low for a previous disease history
classification model.

CIN 2 Negative history
CIN 2 Low to mild dysplasia history
CIN 2 Moderate to severe dysplasia history
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Figure 5.16 3-D PCA scatterplot of CIN 2 samples according to previous disease history. PC1 , PC2 and PC3
account respectively for 99.66%, 0.21% and 0.05% of the variability within the dataset.

Table 5.26 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2
samples by previous disease history.

CIN 2 samples previous history Sensitivity (%) Specificity (%)
Negative

18.18

50.00

Low to mild dysplasia

42.86

22.22

0

45.45

Moderate to severe dysplasia
LOPOCVacc =0.2381 SD_LOPOCVacc = 0.4364

Indeed, with sensitivity values as low as 0% for CIN 2 samples with previous history of
moderate to severe dysplasia, and specificity values ranging from 22.22% and 50%, a
“yes or no” PCA-LDA model was generated to evaluate CIN 2 samples by their
previous disease history. The sensitivity and specificity results obtained after LOPOCV
are presented in Table 5.27.
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Table 5.27 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2
samples positive or negative previous disease history.

CIN 2 samples previous history Sensitivity (%) Specificity (%)
Negative

54.55

100

Positive

60.00

100

LOPOCVacc = 0.5714 SD_LOPOCVacc = 0.5071
In addition to being 100% specific, the sensitivity values for this PCA-LDA model were
54.55% and 60.00% for CIN 2 samples with and without previous history, respectively.
The detection of CIN 2 samples according to their previous disease history was further
tested on a PCA-LDA classification algorithm which also considered negative, CIN 1
and CIN 3 sample groups. The sensitivity and the specificity results obtained are shown
in Table 5.28.
Table 5.28 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 2
samples by previous disease history versus Negative, CIN 1 and CIN 3.

Sample group

Sensitivity (%) Specificity (%)

Negative

100

85.90

CIN 1

100

91.60

CIN 2 without previous history

45.45

100

CIN 2 with previous history

50.00

100

100

92.36

CIN 3

LOPOCVacc =0.9337 SD_LOPOCVacc = 0.2495
This model showed 100% specificity to detect CIN 2 samples with and without previous
disease. The specificity values for CIN 1 and 3 samples were found to be above 90%
whereas the specificity to detect negative samples was of 85.90%. In addition, the
model was most sensitive to negative, CIN 1 and 3 samples (100%), with the values
obtained for CIN 2 samples with and without disease only 45.45 and 50% respectively.
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For CIN 3 samples, the PCA analysis according to their previous disease history is
represented in Figure 5.17. Despite no clear separation being observed, a PCA-LDA
classification model was created and sensitivity and specificity values are shown in
Table 5.29.

CIN 3 Negative history
CIN 3 Low to mild dysplasia history
CIN 3 Moderate to severe dysplasia history
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Figure 5.17 3-D PCA scatterplot of CIN 2 samples according to previous disease history. PC1 , PC2 and PC3
account respectively for 99.23%, 0.49% and 0.12% of the variability within the dataset.

Table 5.29 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3
samples by previous disease history.

CIN 3 samples previous history Sensitivity (%) Specificity (%)
Negative

40.00

66.67

Low to mild dysplasia

20.00

46.67

Moderate to severe dysplasia

33.33

53.85

LOPOCVacc = 0.3478 SD_LOPOCVacc =0.4870
Much like what was observed for CIN1 and 2 samples (Table 5.22 and Table 5.26
respectively) the PCA-LDA showed limited performance to stratify CIN 3 samples
according to their previous history background, with the highest sensitivity (40.00%)
and specificity (66.67%) being obtained for CIN 3 samples without previous disease
history. Similarly, a PCA-LDA model which would classify CIN 3 samples into those
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with previous disease history and those without was also evaluated with LOPOCV. The
sensitivity and specificity results obtained are shown in Table 5.30.
Table 5.30 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3
samples positive or negative previous disease history.

CIN 3 samples previous history Sensitivity (%) Specificity (%)
Negative

66.67

100

Positive

50.00

100

LOPOCVacc = 0.6087 SD_LOPOCVacc =0.4990
Results are similar to those obtained for a comparable model of CIN 2 samples (Table
5.27). The PCA-LDA model is shown to be 100% specific to detect the presence or
absence of previous disease; whilst sensitivity values range from 50 % for CIN 3
samples with previous disease history, to 66.67% for those without.
The ability of detect CIN 3 samples previous disease history was further tested on a
PCA-LDA model which would also classify negative, CIN 1 and 2 samples. LOPOCV
was used and the sensitivity and specificity results obtained are shown in Table 5.31.
Table 5.31 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV for CIN 3
samples positive or negative previous disease history versus Negative, CIN 1 and CIN 2.

Sample group

Sensitivity (%) Specificity (%)

Negative

100

94.87

CIN 1

100

96.21

CIN 2

100

96.58

CIN 3 without previous history

86.67

99.33

CIN 3 with previous history

62.50

100

LOPOCVacc = 0.8802 SD_LOPOCVacc = 0.3257
Results show the model to be 100% sensitive to the detection of negative, CIN 1 and 2
samples; whilst displaying more than 94% specificity for the same sample groups. The
sensitivity for CIN 3 samples with and without previous disease history was better than
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what was reported for the CIN 2 model (Table 5.28), 62.50 and 86.67% respectively. In
addition, the model was 100 and 99.33% specific for CIN 3 samples with and without
previous disease.
Overall, PCA and PCA-LDA results revealed poor performance in predicting stratified
disease history but encouraging results in “yes or no” models across all samples. Such
results are suggestive that previous disease history might bear significance to the Raman
spectroscopic profiles of the samples. This is particularly important in the case of
negative samples as previous disease might induce abnormal spectroscopic profiles
leading to false positives. Although results show limited sensitivity (33.33%) for the
detection of negative samples with previous disease when the PCA-LDA disease
classification models included all other sample groups (Table 5.19) and only CIN 1
samples (Table 5.18); these might be obscured by the fact that only a small proportion
of negative samples were previously diseased (20%), compared to CIN 1, 2 and 3
samples with approximately 51%, 47.6% and 36% respectively. Furthermore, only one
negative sample had a previous history of moderate to severe dysplasia.
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5.5 Discussion
In this chapter the influence of several biological factors such as age and menstrual
cycle as well as clinical factors like HPV infection and previous disease history on the
spectral profile of the analysed samples was investigated.
However it is important to acknowledge that with the exception of age, none of these
factors are linear and it was not possible to control or manipulate these variables
experimentally as patient samples were used. Furthermore, the quality and amount of
information available from the clinical collaborators was limited.

5.5.1

Age

The poor performance of the PCA-LDA models for the correct classification of patient
age on negative and CIN 1 samples seems to suggest that age does not have a
significant influence on the Raman spectral profile of cervical cytology samples. The
results should however be re-evaluated on a more comprehensive sample database in
which all sample groups, namely higher grade intraepithelial lesions CIN 2 and CIN 3,
have statistically relevant sample numbers across all age groups.
The investigation of age-related spectral changes in biological samples can be found in
the literature. Conflicting reports can be found for breast cancer detection by Raman
spectroscopy. On one hand, the analysis of ex vivo biopsy tissue is reported to be “free”
of age-related trends towards the fat and collagen content used in the disease
classification algorithm (Haka et al. 2005). On the other hand, in vivo work on a mouse
model suggests it is possible to detect age-related spectral changes but these do not
affect the disease classifier (Bhattacharjee et al. 2013).
Similarly, a recent in vivo study using Raman spectroscopy for oral cancer detection
reported that although it seemed feasible to distinguish between early and late age
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groups, great overlap was seen among mid-age groups and the age related spectral
features did not have any influence on the disease classifier (Sahu et al. 2012).
In cervical cancer, only one study reported data analysed according to patient age. The
study used ATR-FTIR spectroscopy to analyse exfoliated cervical cells and investigate
spectral features in relation to HPV infection. Focusing on age, and using low grade
intraepithelial lesion samples or CIN 1 only (due to higher sample numbers in this
category), it was possible to separate between patients in their third and fourth decade of
life and that this separation enhances further PCA-LDA classification of the number (0,
1 or 2) of different HPV types infecting the samples. The study claims that there is a
fundamental biological difference between third and fourth decade women with LSIL
(Kelly et al. 2010). Sahu et al. also argue that although age-induced biochemical
changes might begin earlier they become more marked after 50 years. They also state
that chronological age and biological age of organs and tissue might vary as the second
is closely linked to internal and external stimuli which vary from individual to
individual (Sahu et al. 2012).
In the cervix any age-related biochemical differences are most likely to be related with
menstrual cycle and/or menopausal status which is widely known to induce marked
changes in the cervix and has its onset about 40-45 years of age. Nevertheless, all the
spectral data collected from biological samples should be thoroughly analysed in
relation to patient age in order to establish any possible links which could help to
enhance the performance of disease classifiers either alone or in conjunction with other
clinical data like HPV infection.
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5.5.2

Menstrual Cycle

This evidence makes the case to evaluate probable menstrual cycle-related changes in
Raman spectra of cervical cytology samples. In this study it was not possible to analyse
day-related changes due to the low number of samples available for each menstrual
cycle day. Similarly, the menstrual cycle data for CIN 2 and 3 samples was limited to
less than 10 cases each which meant that PCA-LDA analysis was not viable for these
sample groups. However, PCA-LDA results revealed sensitivity of 50-66.67% and
100% specificity to classify negative samples in the proliferative or secretory phase of
the menstrual cycle. The same 100% specificity was obtained for the analysis of CIN 1
samples according to menstrual cycle phase; with sensitivity ranging from 25-63.64%
for this sample group.

The PCA-LDA models were also used to evaluate the

performance of classifiers which differentiated negative samples according to their
menstrual cycle phase, in addition to all other CIN groups and CIN 1 samples in
particular. In this case the models did not perform well, with sensitivity and specificity
results worse than what was observed when the menstrual cycle data was not
considered. This might suggest that although menstrual cycle phase might be inferred
from the negative samples spectral profiles this feature might not act as a confounding
factor to the CIN PCA-LDA classification model obtained in chapter 4 (section 4.4).
It should however be noted that menopausal status was not considered for this study as
although it could be possible to model with speculation based on patient age, this would
prove inaccurate as menopausal age varies considerably from woman to woman.
Furthermore, without clinical information regarding current or previous menopausal
treatments like hormonal therapy substitution which reverse the atrophy of the
epithelium, any results would be easily undermined.
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The influence of normal hormonal patient variability has previously been reported by
the Mahadevan-Jansen group. Kanter et al. reported that by characterising normal
hormonal changes, particularly menstrual cycle and menopausal state, and introducing
them into the in vivo diagnosis algorithm, this improved the accuracy of Raman
spectroscopy to 94% (Kanter et al. 2009a) overall reaching

97 % for low-grade

dysplasia detection (Kanter et al. 2009b). In addition, the main differences observed in
the average Raman spectra of normal and low-grade dysplasia were reported in the
1230-1300 cm-1 range and, the analysis of postmenopausal, perimenopausal and
premenopausal normal cervix before and after ovulation showed subtle but consistent
differences at 1250 cm-1 and 1300-1320 cm-1, assigned to collagen and other cellular
features like lipids, Amide III and nucleotides (Kanter et al. 2009b).
An FTIR study by Romeo et al. further showed the main differences arising from
menstrual cycle variations to the cervical epithelial cells were observed in the
carbohydrate region of 1200–1000 cm−1. These were mainly due to an increase in
glycogen bands (1025 cm-1) between days 8 and 12 of the cycle compared to days 19 to
26 due to the glycogen accumulation in the intermediate and superficial cells as a result
of estrogenic stimulation. Women taking monophasic oral contraception were also
investigated and it was concluded they did not exhibit the same degree of normal cyclic
variation as women who did not. Nevertheless, PCA results showed high-grade
dysplasia to separate from normal samples collected at different phases of the menstrual
cycle, indicating it might not influence disease classification (Romeo et al. 2002). More
recently, a study on the analysis of ThinPrep® samples by our group also showed
spectral changes, such as lower levels of glycogen and higher levels of proteins, in the
Raman spectra depending on the day of the cycle, and on the use of contraceptives.
Nevertheless, it was concluded that such variations did not act as confounding factors
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with abnormal cells discriminating well from normal cells regardless of the day on
which the sample was taken or the use of oral contraceptive (Traynor et al. 2016).
These results seem to suggest the differences reported by Kanter et al. (Kanter,
Majumder, Kanter, et al. 2009) for in vivo Raman measurements might not apply for
cytology samples when the cells are recorded ex vivo without the underlying connective
tissue support.
Finally, other hormone-related factors such as menarche age, parity, oral contraceptive
use and induced abortions have all been linked with increased risk of developing
cervical cancer and pre-cancer, by a wide range of molecular and epidemiological
studies (Roura et al. 2016). Nevertheless, with many confounding and inconclusive
reports published it would be of great interest if this information could also be collected
and made available to future Raman spectroscopy studies, for the analysis of their
influence on the sample spectral profiles.

5.5.3

HPV status

Several Raman spectroscopy studies have shown potential in identifying HPV infection
and discriminating different HPV copy numbers and types. Jess et al. was the first to
use Raman microspectroscopy to discriminate PHK (primary human keratinocytes),
PHK E7 and CaSki cells, where PHK E7 cells express the E7 gene of HPV16 and CaSki
expresses HPV16. The mean Raman spectra showed variations in DNA and protein
levels, consistent with HPV gene expression and malignancy in both live and fixed
cells. PCA results further proved Raman spectroscopy to be a valuable tool in
identifying and characterising the different stages of HPV-associated malignancies (Jess
et al. 2007).
Ostrowska et al. studied cervical cancer cell lines with both FTIR and Raman
spectroscopy and reported a discrimination of cell lines suggestive of HPV integration
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dependence (Ostroswka et al. 2010). Their results suggested HPV negative (C33a) and
low HPV copy number (SiHa with 1-2 copies) cell lines to be biochemically very
similar whilst significantly different from mid (HeLa) and high (CaSki) HPV copy
number cell lines. Protein, nucleic acid and lipid levels were the main variations
encountered in both mean spectra and PCA analysis (Ostroswka et al. 2010).
Studying cervical cytology sample pellets in addition to cell lines, Vargis et al. also
reported Raman micro-spectroscopy to successfully detect HPV and differentiate
between specific virus strains. In this study, normal HPV negative cell line NHEK was
used alongside three cervical carcinoma cell lines: HPV positive HeLa and SiHa, and
HPV negative C33a. The specificity values of 89-97% reported for cell lines and 98.5%
for cytology samples were extremely encouraging and highlighted the potential of
Raman spectroscopy to provide an accurate differential diagnosis (Vargis et al. 2012).
Therefore, HPV infection status was also investigated in this study. Information
regarding patient HPV infection status was shared by our collaborators at Altnagelvin
Hospital for CIN samples only, as negative cytology samples are not routinely tested for
HPV. HPV infection was tested via the Cobas® HPV Test which amplifies target viral
DNA by Polymerase Chain Reaction (PCR) and nucleic acid hybridization for the
detection of 14 high-risk HPV types in a single analysis.
Cobas® specifically identifies HPV 16 and HPV 18 while concurrently detecting for 12
other high risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), allowing a total
of eight different outcomes:
i.

HPV negative;

ii.

HPV16 positive;

iii.

HPV18 positive;
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iv.

HPV16 and 18 positive;

v.

12 other high-risk types positive;

vi.

HPV16 and 12 other high-risk types positive;

vii.

HPV 18 and 12 other high-risk types positive;

viii.

HPV16, 18 and 12 other high-risk types positive.

Due to the small numbers of available samples for each outcome in the study database,
HPV positivity or negativity was only considered for PCA and PCA-LDA analysis. For
CIN 1 samples, the results suggest the possibility to distinguish between HPV negative
and positive samples with relatively good sensitivity of more than 70% and 100%
specificity. Furthermore, PCA-LDA performance increased when classification models
included differential diagnosis between negative and CIN 2 and 3 categories. By
including the CIN 1 HPV result in a final PCA-LDA diagnosis model, sensitivity rates
ranged from 73 to 100%. Sensitivity was found to be 87.84% for negative samples and
above 90% for all CIN categories. These results are thus in line with those discussed
previously and supportive of the potential of Raman spectroscopy to infer HPV
infection from cytology samples as well as cytology diagnosis.
These results are based on a fairly small sample population and are limited to (a) CIN 1
samples due to the lack of HPV negative samples in the CIN 2 and 3 categories as most
samples in these groups are high-risk HPV positive and (b) HPV positivity or negativity
due to insufficient sample numbers across all HPV test outcomes. Further limitations
include the fact that cytologically negative samples were not tested for HPV and the
actual HPV testing method itself which is based on assessing the presence of viral DNA
which as mentioned in the section 1.4.2 of this thesis, only informs if the virus is
present, not if it is integrated into the host cell. It is therefore important that future
studies include not only a wider sample database but also more comprehensive HPV
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testing, maybe partnering with virology groups which could screen the HPV status of all
the samples (negatives included) using different methodologies for both viral DNA and
mRNA. Testing for low risk HPV types is equally important as HPV incidence is
thought to change due to the HPV vaccination programmes already underway in many
developed countries (Cameron et al. 2016; Palmer et al. 2016). Different progression
rates have also been attributed to lesions with single and multiple HPV infections with
high risk and/or low risk types (Spinillo et al. 2014; Seraceni et al. 2014) so evaluating
their influence on Raman spectral profiles and progression rates would add immensely
to the potential of the technology as a diagnosis tool.

5.5.4

Previous disease history

Previous disease history is seen as an increased risk for cervical cancer. Its effect on the
Raman spectral profiles of in vivo and ex vivo cervical tissue have also been investigated
by Mahadevan-Jansen’s group. In a first study they compared in vivo Raman spectra
from histologically normal cervical tissue of both healthy and previously diseased
patients. Results showed that apart from several small variations, the main spectral
difference was observed at 1250 cm−1, a peak typically assigned to collagen, where
spectra from previously diseased patients were less intense than that of “true normal”
patients (Keller et al. 2008). Following from this study, another study by the same
group further examined in vivo spectra from 172 patients which were classified into (a)
“true normal” with no history of disease, (b) previously diseased with current normal
diagnosis but with history of disease, (c) adjacent normal, with spectra acquired from a
visually normal area from a cervix with disease, (d) low grade, and (e) high grade
disease. Classification algorithms showed a 99% accuracy to distinguish between “true
normal” and previously diseased patients, and 97% to distinguish between “true
normal”, adjacent normal, low and high grade disease (Vargis et al. 2011a). These
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results argue that variations in normal spectra due to previous disease are statistically
significant and should therefore be accounted for when creating disease classifiers.
Additionally, a histology study by our group further demonstrated using Raman
microspectroscopy that the clear arrangement of the cervical epithelial layers as seen in
cervical tissue from non-diseased patients is lost in normal appearing areas of diseased
cervix. This supports the fact that the underlying tissue abnormality might be broader
than what can be observed by conventional histopathology (Rashid et al. 2014). Such
results add to the finding of Cohenford et al. who reported the neoplastic process may
be more extensive than what is recognized by morphological criteria alone; and that
normal appearing cells from abnormal cases differ biochemically from those of normal
cases, and that such differences result in different FTIR spectral profiles.
In this study it was therefore hypothesised that if previous disease history might be
responsible for variations in the spectral profiles of the samples, this would be more
noticeable in the Raman spectra of negative samples and samples with lower grades of
abnormality. In negative samples in particularly, such information could be important to
reduce false positive rates as previous disease signatures could act as confounding
factors for the disease classifiers, especially at diagnosis of negative and CIN 1 samples
where misclassification is more problematic.
Our results showed moderate performance of PCA-LDA models to separate negative
and CIN 1 samples according to their positive or negative previous disease history, with
100% specificity and approximately 61% and 61-70% sensitivity to predict negative and
CIN 1 samples previous disease history, respectively.
Nevertheless, sub-classifying negative samples on a PCA-LDA disease classification
algorithm showed limited performance for predicting previously diseased negative
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samples with only 33% sensitivity, and decreased overall sensitivity and specificity
rates across all other sampling groups. Similar results were obtained when only CIN 1
samples where considered in the classifier. PCA-LDA models further showed limited
sensitivity and specificity rates to stratify the background of previous disease due to the
small sample numbers across each category.
On one hand PCA-LDA results suggest it may be feasible to determine previous disease
history of negative and CIN 1 samples on a “yes or no” model. On the other hand,
previous disease history does not seem to improve the overall disease classification
models. The limited numbers of previous disease samples, especially in the negative
sample group (20%) might be responsible for the poor cross validation performance of
the final disease algorithms and therefore, previous disease history information should
continue to be analysed in further research considering a more comprehensive sample
database. Furthermore, only one negative sample had a previous disease history of
moderate to severe pathology which could impact in the performance of these
classifiers; as higher abnormality grades might induce more marked underlying changes
in the cervix which could then be retained after the disease has cleared. Similarly, it
would also be interesting to study the time of previous disease in relation to the current
cervical cytology sample used for Raman spectroscopy as it could be that previous
disease history only has a significant impact on Raman spectral profile of the samples
during a specific timeframe.
Furthermore, the performance of this PCA-LDA disease classification model with only
negative samples with no previous disease history considered did not improve or
worsen significantly so although this seems to support that previous disease history does
not confound the PCA-LDA disease classification algorithm, the relatively small sample
numbers being omitted from the negative sample group might not be able to
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significantly change the PCA-LDA model performance and therefore, this clinical
feature should continue to be explored further.
The next chapter explores the performance of Raman spectroscopy PCA-LDA
classifiers using both CIN and SIL reporting systems, with relevant clinical features also
being tested.
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CHAPTER 6

EVALUATION OF SIL VS CIN

CLASSIFICATION MODELS
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This chapter is adapted from the peer-reviewed original research article by Ines Ramos,
Aidan D Meade, Ola Ibrahim, Hugh Byrne, Mary McMenamin, Michael McKenna,
Alison Malkin and Fiona Lyng entitled “Raman spectroscopy for cytopathology of
exfoliated cervical cells”; Faraday Discussions 2016, 187, 187-198,
DOI: 10.1039/C5FD00197H .

198

Thus far, the spectral data has been analysed using PCA-LDA models for the CIN
reporting system; negative, CIN1, CIN2 and CIN3. As outlined in chapter 1, section
1.3.3, the SIL reporting system, negative, LSIL and HSIL, is currently recommended
for cytology screening programmes (Solomon 2002). To further explore the potential of
Raman spectroscopy in the context of cervical cancer screening, the performance of a
PCA-LDA classification model based on the SIL reporting system has been investigated
in this chapter. The influence of menstrual cycle, HPV and previous disease history has
also been investigated; similar to what was reported in chapter 5 for the PCA-LDA
models based on the CIN reporting system.

6.1

The performance of SIL classification

Mean Raman spectra of cervical cytology samples in the fingerprint region of 400-1800
cm-1 are presented according to the SIL classification in Figure 6.1. This system
considers negative, LSIL (CIN 1) and HSIL (CIN 2 and 3) samples.

Figure 6.1 Mean Raman spectrum and SD (shadowing) obtained for each sampling group after NNLS
correction. Negative samples are represented in green, SIL samples in magenta, and HSIL samples in black.
The ratio of 1318:1339cm-1 indicated by the circles on the spectra seems to be the main difference between the
mean spectra. Other visible differences are indicated by the arrow heads.
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Overall the mean spectra of negative, LSIL and HSIL samples show similar features,
much like what was observed for CIN classification, with the main differences being
observed around the 1318/1339 cm-1 region, in which the ratio of the intensities of these
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two peaks increases from negative to LSIL and HSIL samples as shown in Figure 6.2.

S a m p le g r o u p s

Figure 6.2 1339:1318 cm-1 peak ratios for negative (green), SIL (magenta) and HSIL (black) cervical cytology
samples. SD is indicated for each sampling group. Mann Whitney test showed LSIL and HSIL ratios to be
statistically significant from negative with **p=0.0042 and ****p<0.0001; and between them with
***p=0.0006.

To further highlight any differences between the spectral profiles of the samples, PCA
was employed. Figure 6.3 shows the PCA scatterplot for all SIL classified samples.
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A

B

Figure 6.3 (A) 2-D PCA scatter plot of all sampling groups showing PC1 versus PC2. Negative samples are
represented in green, LSIL samples in magenta and HSIL samples in black. (B) PC loadings for PC1 and 2
which explain respectively 76.81% and 7.55% of the variance within the dataset.

From the PCA scatterplot, it can be seen that negative (green), LSIL (magenta) and
HSIL (black) samples are separated according to PC1 and PC2 which account
respectively for 76.81 % and 7.55 % of the variance explained in the dataset. The
loadings of PC1 and PC2 are shown in Figure 6.3 B. The negative samples seem to
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separate from the LSIL samples according to PC1, negative samples having more DNA
(~814 cm-1), protein and lipids (1307, 1446, 1453 cm-1), Amide III (1242 cm-1) and I
(1690 cm-1) also featuring prominently. Furthermore, the negative samples separate to a
large extent from the HSIL samples according to PC2. Negative samples show stronger
Amide III (1243, 1375 cm-1) and protein/lipid (1339 cm-1) features, whereas HSIL
samples display stronger Amide I (1606 cm-1) and Amide II (1544 cm-1). In addition,
the PC2 loading also highlights differences in nucleic acids, the features at 1458 and
1485/7 cm-1 being more prominent in the spectra of negative samples. DNA features at
481 and 786 cm-1 are more prominent in negative samples, whereas the feature at 893
cm-1 is more prominent in HSIL samples. Similarly, phosphate and phosphodiester
bonds at 812 cm-1 are more prominent in HSIL samples, whereas those at 1087-9 cm-1
are more prominent in negative samples. The separation between LSIL and HSIL
samples results from a combination of PC1 and PC2. Taking the PC1 and PC2
assignments for the negative samples as a reference, the LSIL samples have a similar
PC2 profile to the negative samples whereas the HSIL samples have a similar PC1
profile to the negative samples.
With PCA results similar to what was observed for the CIN reporting system in chapter
4 (section 4.4), they are suggestive that significant differences can be found in the
Raman spectral profile of cell nuclei to distinguish between negative, LSIL and HSIL
samples. PCA-LDA was therefore used to generate a classification model based on the
features highlighted by PCA analysis. LOPOCV was then used to evaluate the
performance of the PCA-LDA classification model and sensitivity and specificity rates
are shown in Table 5.38.
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Table 6.1 Sensitivity and specificity values obtained for the SIL PCA-LDA classification model with LOPOCV.

Sampling Group

Sensitivity

Specificity

Negative

100

100

LSIL

100

99.24

HSIL

97.67

100

LOPOCVacc = 0.9950; SD_LOPOCVacc =0.0765
The performance of the SIL PCA-LDA model is quite encouraging, with all sensitivity
and specificity values above 97%. The model is also 100% sensitive and specific to the
detection of negative samples. These results are similar to what was observed for the
PCA-LDA model based on the CIN reporting system in Table 4.4, chapter 4.
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6.2 Influence of Clinical features on the SIL classification
In line with the analysis made for the PCA-LDA CIN classification, in chapter 4, the
influence of the most relevant clinical features was also investigated in the SIL
classification models.

6.2.1 Menstrual Cycle phase
In chapter 4, the limited menstrual cycle data available for CIN 2 (n=7) and 3 (n=6)
samples did not allow the PCA of these sample groups by menstrual cycle phase.
However, in SIL classification, CIN 2 and 3 samples are combined to form the HSIL
group; in total, the HSIL group has 13 samples with menstrual cycle data available, thus
allowing PCA-LDA models to be evaluated.
First a PCA-LDA model was used to classify HSIL samples into proliferative or
secretory phase of the menstrual cycle. The sensitivity and specificity results obtained
after LOPOCV are shown in Table 6.2.
Table 6.2 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of
HSIL samples according to their menstrual cycle phase.

Sampling group

Sensitivity (%) Specificity (%)

Proliferative

50.00

100

Secretory

50.00

100

HSIL

LOPOCVacc = 0.5000 SD_LOPOCVacc =

0.5222

Results show the PCA-LDA model to be 100% specific to the different menstrual cycle
phases of HSIL samples with only 50% sensitivity; both in line with what was obtained
for the comparable models of negative and CIN 1 samples (Table 5.5 and Table 5.6,
chapter 5).

204

Another PCA-LDA model was tested to evaluate the potential to classify HSIL from
negative and LSIL samples as well as segregate HSIL samples according to their
menstrual cycle phase. LOPOCV was used and the sensitivity and specificity results
obtained are presented in Table 6.3.
Table 6.3 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of
negative, LSIL and HSIL samples, also classifying the latter according to their menstrual cycle phase.

Sampling group

Sensitivity (%) Specificity (%)

Negative

100

82.98

LSIL

100

92.00

Proliferative

33.33

100

Secretory

33.33

100

HSIL

LOPOCVacc = 0.9407 SD_LOPOCVacc =0.2370
The model shows limited (33.33%) sensitivity for the detection of HSIL according to
their menstrual cycle phase when negative and LSIL samples are also tested, despite
good specificity being obtained across all categories. This could either be a limitation
arising from the small sample numbers in these categories or an indication that
menstrual cycle phase does not bear an impact on the spectral profile of the HSIL
samples.
In chapter 4, a PCA-LDA disease classification model that would stratify negative
samples according to their menstrual cycle phase as well as testing against all CIN
categories was also tested; as it was hypothesised the spectral variation caused by
menstrual cycle would have greater impact in negative samples. Likewise a comparable
PCA-LDA model was also tested for SIL classification and the sensitivity and
specificity results obtained after LOPOCV are presented in Table 6.4.
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Table 6.4 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
negative samples according to proliferative or secretory menstrual cycle phase and LSIL and HSIL samples.

Sampling group

Sensitivity (%) Specificity (%)

Proliferative

44.44

100

Secretory

59.09

100

LSIL

100

77.11

HSIL

100

74.67

Negative

LOPOCVacc =0.8390 SD_LOPOCVacc =0.3691
Again, the results are similar to those reported for the CIN model (Table 5.9, chapter 4).
Despite 100% specificity for negative samples, the model shows only 44.44%
sensitivity for the negative samples in the proliferative phase of the cycle and 59.09%
(4.55% decrease compared to CIN model) for those in the secretory phase. The
sensitivity for LSIL and HSIL remains at 100% as observed for CIN 1 and CIN 2 and 3
samples, with a decrease observed for the specificity of LSIL samples compared to CIN
1 (1.21% decrease) and HSIL samples compared to CIN 2 (6.77%) and CIN 3 (6.58%).

6.2.2 HPV status
Results in chapter 5 suggested HPV infection status of CIN 1 samples might be inferred
from the Raman spectral profiles of the samples and impact on the CIN PCA-LDA
classification models.
Table 6.5 shows the sensitivity and specificity values obtained for a SIL PCA-LDA
classification model that separates LSIL from HSIL and simultaneously informs on their
HPV status.
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Table 6.5 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV of
LSIL HPV negative or positive, and HSIL.

Sampling Group
HPV negative
HPV positive
HSIL
LOPOCVacc = 0.8608 SD_LOPOCVacc =
LSIL

Sensitivity
(%)
60.00
75.00
100
0.3484

Specificity
(%)
100
100
68.57

Whereas the sensitivity and specificity values obtained for LSIL HPV negative and
HPV positive samples were slightly increased and therefore an improvement to what
was obtained in Table 5.12 (chapter 5) for the parallel CIN PCA-LDA model; the
specificity of HSIL samples is however below the 78.95 and 77.78% obtained for CIN 2
and 3 samples respectively.
The samples were also evaluated on a PCA-LDA model which further included negative
samples and the sensitivity and specificity results obtained are presented in Table 6.6.
Table 6.6 Sensitivity and specificity values obtained for a PCA-LDA classification model with LOPOCV that
would classify negative, LSIL HPV negative, LSIL HPV positive, and HSL samples.

Sampling Group

Sensitivity
(%)

Specificity
(%)

Negative

100

86.67

HPV negative

66.67

97.28

HPV positive

75.00

97.18

90.91

91.87

LSIL

HSIL
LOPOCVacc = 0.9162 SD_LOPOCVacc =

0.2780

Overall the specificity values are similar to those shown in Table 5.15 (chapter 5) for
the CIN classification model. The sensitivity of negative samples remained unchanged
at 100% and the 90.91% obtained for HSIL is superior to 77.27 % achieved for CIN 3
samples, despite being less than the 100% sensitivity obtained for CIN 2. However, the
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sensitivity of HPV detection for LSIL samples in this model is approximately 5% less
than that of the corresponding CIN model.

6.2.3

Previous disease history

Previous results in chapter 5 suggested that previous disease history of negative samples
might be inferred from the Raman spectral profiles of the samples and impact on the
CIN PCA-LDA classification models.
The ability to stratify the previous disease history of HSIL samples was studied with
PCA-LDA. LOPOCV was used and the sensitivity and specificity results obtained are
shown in Table 6.7.
Table 6.7 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the HSIL sample group by previous disease history background.

HSIL Previous disease
history

Sensitivity
(%)

Specificity
(%)

Negative

46.15

69.23

Low to mild dysplasia

66.67

50.00

Moderate
dysplasia

16.67

76.92

to

severe

LOPOCVacc = 0.4773 SD_LOPOCVacc = 0.5053
Similar to what was observed for CIN 2 and 3 samples (Table 5.25 and Table 5.28,
chapter 5, respectively), results show limited performance of the PCA-LDA model to
accurately classify HSIL samples according to their previous disease history. Sensitivity
values range from 16.67 to 66.67%, whereas specificity is slightly higher with values
range from 50.00 to 76.92%.
A "yes or no" PCA-LDA was also used to classify HSIL samples into those with and
without previous disease history. The sensitivity and specificity results after LOPOCV
are shown in Table 6.8.
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Table 6.8 Sensitivity and specificity values obtained for the PCA-LDA classification model with LOPOCV for
the CIN 2 and 3 sample group by previous disease history.

HSIL samples previous
history

Sensitivity
(%)

Specificity
(%)

Negative

53.83

100

Positive

83.33

100

LOPOCVacc = 0.6591 SD_LOPOCVacc =

0.4795

Like what was observed for CIN 2 and 3 samples, this "yes or no" model is 100%
specific with moderate sensitivity. Despite the sensitivity of 83.33% for HSIL samples
with previous disease being higher than that observed for CIN 2 (Table 5.26) and CIN 3
(Table 5.29) in chapter 5; the sensitivity for HSIL samples without previous history is
only 53.83% and therefore lower than that of CIN 2 and 3 samples.
The sensitivity and specificity values obtained for the PCA-LDA SIL classification
model that further sub-classify negative samples with regards to previous disease
history are shown in Table 6.9.
Table 6.9 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering
negative samples previous disease history.

Negative samples previous history

Sensitivity
(%)

Specificity
(%)

Negative without previous disease
history

70.00

96.36

Negative with previous disease history

33.33

98.40

LSIL

97.14

72.52

HSIL

93.02

75.95

LOPOCVacc=0.7771; SD_LOPOCVacc= 0.4174
It can be observed that the values obtained are comparable to those of the CIN model in
Table 5.24 (chapter 5).The sensitivity for negative samples with previous disease
history was still limited at 33.33%, and the specificity decreased to 98.40%. For
negative samples without previous disease an increase of 4.29% was observed for the
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sensitivity, whereas specificity decreased by 1.29%. LSIL samples maintained the
specificity value of CIN 1 samples (97.14%), whilst increasing the specificity by 0.76%.
Similarly, the detection of HSIL samples is 1.64% more specific than that of CIN 2 and
3 samples, whilst the specificity is decreased to 93.02%.

However, when only negative samples without previous disease are considered, the SIL
PCA-LDA model achieves overall sensitivity and specificity of 100% as shown in
Table 6.10. This is an improvement to what was observed in Table 5.27 (chapter 5) for
the CIN classification, already a highly accurate model.
Table 6.10 Sensitivity and specificity values obtained for the PCA-LDA model with LOPOCV considering
negative samples previous disease history.

Negative samples previous history

Sensitivity
(%)

Specificity
(%)

Negative without previous disease
history

100

100

LSIL

100

100

HSIL

100

100

LOPOCVacc=1; SD_LOPOCVacc= 0
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6.3 Discussion
Overall PCA-LDA results suggest a comparable performance between CIN and SIL
reporting systems. The sensitivity and specificity of the models to detect negative and
CIN or SIL is very encouraging and higher than that reported in the literature for other
screening techniques such as Pap screening and HPV testing.
The results presented in section 6.1 of this chapter constitute an improvement over what
was reported in the Faraday Discussions publication. After publication, the data was
reanalysed and it was found that although an optimal number of PCs was established
(15 PCs) which maximised the performance of the PCA-LDA models, all PCs were
considered when building the CIN and SIL PCA-LDA classification algorithms. When
only the optimal number of PCs was used to generate both CIN (shown in chapter 4,
section 4.4) and SIL PCA-LDA classification models, the performance was better,
resulting in the increased sensitivity and specificity values.
Using the SIL reporting system, CIN 2 and 3 samples are grouped to form the HSIL
group. This allowed PCA-LDA analysis to be performed on the menstrual cycle data for
HSIL samples due to increased numbers in the group. In line with what was observed
for CIN 1 samples in chapter 5 (section 5.2.2), results showed limited performance of
the PCA-LDA models to correctly classify HSIL samples according to their menstrual
cycle phase. Moreover, when considering the menstrual cycle data of negative samples
(the sample group expected to have increased spectral variance with result to menstrual
cycle changes) against all other sample groups, both SIL and CIN models showed
moderate performance with decreases of 1.21% to 6.77% being observed in the SIL
model sensitivity and specificity values.
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The analysis of previous disease history data showed similar results with both SIL and
CIN models being limited to the ability to detect previous disease history of negative
samples in addition to the other categories.
However, when HPV detection of CIN 1/LSIL samples is considered, the specificity
achieved for the SIL model was not as good as that reported for the CIN 2 and 3 groups
in the parallel CIN model. In theory, the SIL model should be expected to improve
performance as there is one less category in which to divide the samples. However, CIN
2 samples may be a heterogeneous transition group between low and high grade lesion;
comprising samples which might be biochemically closer to CIN 1/LSIL than to CIN 3
and therefore HSIL. The fact that CIN 2 samples are also reported to have the ability to
regress (Moscicki et al. 2010a) may result in those samples displaying a CIN 1-like
profile. Follow-on studies could potentially inform if a specific regression or
progression pattern could be inferred from the Raman spectral profile of the samples.
A study by Doorbar et al. which investigated the correlation of CIN classification and
HPV infection status suggested that some reported CIN 2 cases, when analysed by an
immunohistochemistry panel of P16INK4a, MCM and HPV-encoded E4, in fact group
with CIN 1 rather than CIN 3 cases. The study showed that the combination of
identification of surrogates of high-risk HPV E6/E7 activity (P16INK4a and MCM),
together with the detection of the abundant HPV-encoded E4 protein, was able to
identify both transient and transforming lesions. This approach not only allowed to
distinguish true papillomavirus infections from similar pathologies but also to divide the
heterogeneous CIN 2 category into those that are CIN 1-like with transient HPV
infection expressing E4, and those that do not express E4 and therefore are more closely
related to CIN 3 cases with transforming HPV infection (Griffin et al. 2015). It might
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therefore be important to consider biomarker panels and thorough HPV typing in further
research of Raman spectroscopy for cervical cytology samples.
The investigation of p16 expression profiles is however the most studied putative
biomarker to aid screening and diagnosis of cervical cancer and precursor lesions
(White et al. 2016). Commercially available kits are now available for histology and
cytology specimens, showing promising results in the clinical setting. The cytology kit,
CINTec PLUSTM, allows in fact a dual staining of p16 and Ki-67 and has been shown to
be efficient in triaging women with ASC-US or LSIL cytology results by a panEuropean study (Bergeron et al. 2015). It is currently on trial in some UK screening
centres and has more recently been reported to, in addition to HPV DNA testing, lead to
a more accurate stratification of CIN in women presenting minor cytological
abnormalities (White et al. 2016). In chapter 8, p16 and Ki67 expression was
investigated in the Thinprep® cervical cytology samples (both model and test set) using
the CINTec PLUSTM kit.

CIN and SIL Raman spectroscopy PCA-LDA classifiers are further validated in the next
chapter, where an independent sample database is used as a test set instead of
LOPOCV.
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CHAPTER 7

EVALUATION OF BOTH CIN AND SIL

CLASSIFICATION MODELS ON AN INDEPENDENT TEST
SET
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As part of this study an independent set of samples was also acquired to further test the
performance of the PCA-LDA Raman models presented in Chapter 6 when faced with
new unseen ThinPrep® cytology samples. In this chapter the performance of the CIN
and SIL classification models was evaluated on this new sample database.

7.1 Mean Spectral Analysis of the Test Samples

The mean Raman spectra for the test samples according to their cytology disease
classification are presented in Figure 7.1.

Figure 7.1 Mean Raman spectra of all samples composing the test set database plotted according to their
cytology diagnosis. Negative samples are indicated in green, CIN 1 samples in magenta, CIN 2 in red and CIN
3 in black.

The average spectra of each test set group were also plotted against the average obtained
for each group in the modelling set. Figure 7.2 to Figure 7.5 allows the comparison of
the negative, CIN 1, CIN 2 and CIN 3 samples from the test set against the model set.
Although the average Raman spectra of the CIN test set groups seemed in accordance
with those of the modelling set, the same was not observed for the negative test set
samples. The mean spectra of the negative test set samples appeared to be more similar
to those of the CIN 1 modelling set. For instance, the peak intensity ratio at 1318:1339
cm-1 looks similar to that observed for CIN 1 samples.
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Figure 7.2 Mean spectra of negative samples test set (dark green) against each classification group where negative model set samples are indicated in green, CIN 1 samples in magenta, CIN 2
in red and CIN 3 in black
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Figure 7.3 Mean spectra of CIN 1 samples test set (purple) against each classification group of the model set where negative samples are indicated in green, CIN 1 samples in magenta, CIN 2
in red and CIN 3 in black.
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Figure 7.4Mean spectra of CIN 2 samples testing set (orange) against each classification group of the modeling set where negative samples are indicated in green, CIN 1 samples in magenta,
CIN 2 in red and CIN 3 in black
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Figure 7.5 Mean spectra of CIN 3 samples test set (grey) against each classification group of the model set where negative samples are indicated in green, CIN 1 samples in magenta, CIN 2 in red
and CIN 3 in black

219

To further confirm this similarity, the difference spectrum was also evaluated. Figure
7.6 shows the difference spectrum between negative samples from modelling and test
set in green and the difference spectrum between negative and CIN 1 samples from the
modelling set in magenta. Both difference spectra show a similar spectral pattern further
confirming negative test set samples resemble CIN 1 samples from the model set.
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Figure 7.6 Difference spectra plots between negative samples from model and test sets (green) and between
negative and CIN 1 samples of model set (magenta).

Nevertheless, when the difference between CIN 1 samples from model set and negative
samples from test set is plotted (Figure 7.7) variation can be observed particularly after
1200 cm-1. These results suggest that although negative test set samples resemble a CIN
1 like profile, similar to that of the CIN 1 model samples, they are not exactly the same.
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Figure 7.7 Difference spectra plots between CIN 1 samples from model set and negative samples from test set.

In addition when PCA was performed with the test set alone, the 3-D scatterplot
presented in Figure 7.8, showed no visible separation between all sample groups as
opposed to what was observed for the modelling set shown in Figure 4.21 A (chapter 4).
A resemblance between the PC loadings can however be observed between what was
observed for the model (Figure 4.21 B, chapter 4) and test set (Figure 7.8 B).
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Figure 7.8 A) 3-D PCA scatter plot of test set samples with negative samples indicated in green, CIN 1 samples
in magenta, CIN 2 in red and CIN 3 in black. B) PC loadings.

7.2 Testing the PCA-LDA disease classification models

PCA-LDA models for CIN and SIL disease classification were evaluated with the test
set samples. Confusion matrices are presented due to the small sample numbers
available in the test set for each classification category, in Table 7.1 and Table 7.2
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respectively, instead of the sensitivity and specificity results as shown in previous
chapters.
Table 7.1 Confusion matrix showing the result of the testing of the test set samples on the CIN PCA-LDA
classification algorithm.

Actual
Classes
Negative
CIN 1
CIN 2
CIN 3

Negative
0
0
0
1

Predicted Classes
CIN 1
CIN 2
27
0
9
0
3
3
0
0

CIN 3
0
0
0
4

For the CIN classification model, all CIN 1 samples were classified correctly as were
the majority of the CIN 3 samples except for one false negative. Half of the CIN 2
samples misclassified as CIN 1 and so did the entire negative test set samples. This
misclassification was expected given the similarities observed in the mean spectral
analysis. Although this model seems to be able to classify CIN 1 and CIN 3 correctly,
with several plausible explanations for the CIN 2 misclassification which will be
discussed in greater detail in the next section of this chapter; the fact that the model
displays a 100% false positive rate with this test set of samples is of greater concern.
Similar results were observed for the PCA-LDA SIL classification model presented in
Table 7.2. All negative test set samples misclassified as LSIL as did 3 HSIL samples;
one of the HSIL samples misclassified as negative whereas the rest were all considered
HSIL.

Table 7.2 Confusion matrix showing the result of the testing of the test set samples on the SIL PCA-LDA
classification algorithm.

Actual
Classes
Negative
LSIL
HSIL

Negative
0
0
1

Predicted Classes
LSIL
27
9
3

223

HSIL
0
0
7

These confusion matrices for both CIN and SIL algorithms remained unchanged when
negative samples with previous disease were omitted from the PCA-LDA model set.

The distribution of the test set samples according to age is shown in Figure 7.9. It can be
observed that the majority of the samples in each category arise from patients aged 20 to
29, which was expected given that the study was based on a screening population.
Furthermore, neither negative nor CIN 1 categories were dominated by one single age
group suggesting the misclassification of negative samples as CIN 1 might not be due to
age bias.

11

[20-29]

[30-39]

[40-49]

[50-60+]

9
5
2

Negative
(n=27)

3 3

6

5
2

1

1

CIN 1 (n=9)

0 0

CIN 2 (n=6)

0 0 0
CIN 3 (n=6)

Figure 7.9 Test sample database according to patient’s age by decades; [20-29] years are represented in green,
[30-39] in blue, [40-49] in red and [50-60+] in black.

In addition, when negative samples from the test set were tested on the PCA-LDA
algorithm which classifies negative samples according to their previous disease history,
only one sample classified as “true” negative with no previous disease history (Table
7.3). This was confirmed by the information made available by our clinical
collaborators which showed all test set negative samples to have had previous disease.
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The majority of samples had a previous history of moderate to severe dysplasia as
shown in Table 7.4.
Table 7.3 Confusion matrix of negative test set samples when tested on the PCA-LDA model to predict
negative samples according to their previous disease history.

Predicted Classes
Negative
Without previous
With previous
history
history

Actual Classes
Negative test set
samples

1

26

Table 7.4 Negative test set database according to their previous disease history.

Previous disease history

No of samples

Negative

0

Borderline

0

Low to mild dysplasia

8

Moderate to severe dysplasia

19

Total no. samples

27

However when CIN 1 samples were also tested with a PCA-LDA classifier to
distinguish between negative samples with and without previous history and CIN 1
(Table 7.5), one sample was misclassified as negative without previous disease, two
classified correctly as negative with previous disease and 25 misclassified as CIN 1.
CIN 1 samples all classified correctly.
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Table 7.5 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to
predict negative samples according to their previous disease history as well as CIN 1 disease.

Actual Classes

Predicted Classes
Negative
Without previous
With previous
history
history

CIN 1

Negative test set
samples

1

2

25

CIN 1 test set
samples

0

0

9

The menstrual cycle data of the test set samples was also analysed. The sample database
for this clinical feature was however very limited as shown in Table 7.6 where the
sample numbers available for each day of the cycle are shown for each group
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Table 7.6 Test set sample database, information regarding menstrual cycle day.

Day of the Menstrual Cycle

Number of samples Test Set
Negative CIN 1 CIN 2 CIN 3

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
TOTAL no samples

2

1

1
1

2

1

2

1

1

1

1

1
1

1

1

1
11

3

1

3

3

The samples were then grouped according to their menstrual cycle phase, proliferative
or secretory. Figure 7.10 shows the test sample database according to the menstrual
cycle phase. Again, only small sample numbers were available, especially across the
CIN sample groups which comprised fewer samples in total.
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Proliferative
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1
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(n=11)
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CIN 1
(n=3)

1

CIN 2
(n=3)

1

2

CIN 3
(n=3)

Figure 7.10 Test sample database according to menstrual cycle phases. Only samples with known menstrual
date where considered.

Negative test set samples were also tested in the PCA-LDA classification algorithm that
separates negative samples according to their menstrual cycle phase. The confusion
matrix in Table 7.7 shows that 6 of the 7 samples known to be in the secretory phase of
the cycle, were correctly classified as such whilst one sample was misclassified as being
in the proliferative phase. In addition, the 4 samples known to be in the secretory phase
of the cycle were all correctly classified. The 16 negative test set samples with unknown
menstrual cycle information were all deemed to be in the proliferative phase of the
cycle.
Table 7.7 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to
predict negative samples according to their menstrual cycle phase.

Actual Classes
Negative test set
samples

Predicted Classes
Negative
Proliferative phase
Secretory phase
21
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6

However, similar to what was observed for previous disease history, when CIN 1 test
set samples were included and tested on the PCA-LDA classification mode (Table 7.8)
all negative samples misclassified as CIN 1.
Table 7.8 Confusion matrix of negative and CIN 1 test set samples when tested on the PCA-LDA model to
predict negative samples according to their menstrual cycle phase as well as CIN 1 disease.

Actual Classes

Predicted Classes
Negative
Proliferative phase
Secretory phase

CIN 1

Negative test set
samples

0

0

27

CIN 1 test set
samples

0

0

9

Finally, negative and CIN 1 samples from the test set were tested on the PCA-LDA
algorithm to classify between negative and HPV positive or negative CIN 1 samples.
The confusion matrix in Table 7.9 revealed all CIN 1 samples classified correctly as
CIN 1, including two as CIN 1 HPV negative and, all negative samples misclassified as
CIN 1 HPV positive. Although the HPV status of the test set negative samples could not
be confirmed as cytology negative samples are not routinely tested for HPV, two of the
CIN 1 test set samples were confirmed to test negative for HPV (Appendix 4).

Table 7.9 Confusion matrix of all test set samples when tested on the PCA-LDA disease classification model
PCA-LDA which also stratifies CIN 1 samples into HPV positive or negative.

Actual Classes
Negative test set
sample
CIN 1 test set
sample

Predicted Classes
CIN 1
HPV -

Negative

HPV +

0

0

27

0

2

7
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7.3 Discussion

Thus far in this study cross validation has been used to evaluate the performance of the
PCA-LDA models generated to achieve disease classification; cross validation methods
have previously been reported to reduce the risk of overfitting when the number of
samples available is too limited to subdivide into one training, and one independent
validation set. However, much like a newly discovered biomarker, the potential to use
spectral signatures to classify patient samples needs to be tested and confirmed in an
independent, preferably large, cohort of samples to assess its true clinical viability
(Baker et al. 2016).
As part of the initial study design and, included in the ethical approval was the
collection of an independent set of samples to be used for PCA-LDA model validation.
Many of the received samples were however unsuitable for Raman spectroscopy (n=
31) due to insufficient cellularity and/or masking effects of debris as a result of the
ThinPrep® slide being prepared from residual material from the collection vial. The
overall sample number of the test set (n=48) was much smaller than that of the model
set (n=166). Nevertheless, this new database was used to test the PCA-LDA
classification models obtained thus far.
The general performance of both CIN and SIL PCA-LDA classification models for the
test set was not as good as what was achieved in previous chapters for LOPOCV.
Confusion matrices showed CIN 1 and CIN 3 detection to be satisfactory. The
misclassification of CIN 2 samples as CIN 1 could be hypothesised to be either a
misclassification in the reported cytology or perhaps due to sample regression
(Moscicki et al. 2010b) with ICC profiling of the samples needed to confirm this.
However, the fact that negative samples all misclassified as false positives posed a
greater concern. Despite being expected from the mean Raman spectral analysis, this
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misclassification could either mean (1) misclassification of the samples upon cytology
screening, which seemed very unlikely that all the negative test set samples were false
negatives; (2) complete inaccuracy of the PCA-LDA models obtained thus far; or (3)
the need to account for all possible sources of normal patient variations (i.e. menstrual
cycle, positive HPV infection) which might be deeming normal negative samples as
false positives.
The mean spectral analysis (and) showed that the negative test set samples did not have
the exact same fingerprint as the CIN 1 samples from the model set (Figure 8.7), despite
showing a CIN 1 like profile (Figure 8.6). This suggests that these samples are not true
CIN 1 samples but rather a result of confounding factors, most probably due to normal
patient variability.
To further test this, PCA-LDA models from chapter 5 were used to evaluate how the
negative samples of the test set would classify as regards previous disease history and
menstrual cycle. Analysing negative samples alone, the PCA-LDA models were able to
identify 99% of the negative test set samples as previously diseased, showing a similar
high accuracy to classify with regard to menstrual cycle. However, when compared with
CIN 1 samples, confusion matrices showed most negative samples were still
misclassified as CIN 1 regardless of menstrual cycle or previous disease. For menstrual
cycle, the limited sample numbers available may have prevented a more accurate
classification and for previous disease history it should be noted that no “true negative”
was included in the test set database. Furthermore, for the PCA-LDA classification
model for negative samples in chapter 5 (Tables 5.18 – 5.20), only one sample had
previous moderate to severe disease history. This could have undermined the model as
more severe disease status might induce more marked spectral changes accounting for
the observed misclassification.
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PCA-LDA classification that would consider samples as negative, CIN 1 HPV positive
or HPV negative was also analysed and results showed 100% of negative test set
samples to classify as CIN 1 HPV positive. Unlike disease history and menstrual cycle
phase, patient information was not available for the test set negative samples as regards
HPV as negative cytology samples are not routinely tested.
Nevertheless, our results seem to highlight the need to fully characterise the “normal”
spectrum before disease classifiers can be applied. Even though possible variability was
explored as discussed in Chapter 5, much of the information needed was not available in
significant numbers to allow conclusive models. For example, data on normal
menstruation cycle variation was limited and most importantly HPV testing of negative
samples is not carried out routinely so this information was not available at all. When
negative and CIN 1 test set samples were tested for negative versus CIN 1 HPV positive
or negative classification, all negative samples were classified as CIN 1 HPV positive.
The fact that two of the CIN 1 cases were classified as CIN 1 HPV negative, in
agreement with their HPV test result, seems to suggest that the HPV status of the
negative samples could be playing a key role in this misclassification. Unfortunately,
however, this could not be confirmed with a HPV test result.
As discussed previously, a thorough investigation into the effects of different HPV
infections, both high and low risk, on the Raman spectra needs to be undertaken across
all sampling groups. Similarly, ICC panels such as p16/Ki-67 or others could aid in
better understanding of the misclassifications occurring between sample groups
(Ikenberg et al. 2013; Griffin et al. 2015). Similarly, biomarkers could help to better
understand the importance of previous disease history as HPV infection could still be
present and/or other biochemical changes which could confound disease classification
algorithms. Indeed, HPV infection can persist after treatment for CIN with HPV and
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cytology co-testing being currently recommended as follow-up test of cure for the
CervicalCheck screening programme (CervicalCheck 2012; CervicalCheck 2015b).
Our data also seems to suggest that despite being correctly inferred, menstrual cycle
information from the patient samples does not improve the classification accuracy
despite being reported to do so in in vivo studies (Kanter et al. 2009b). Similarly,
menopausal status has also been reported to influence disease classification algorithms
based on the sample Raman spectra (Kanter et al. 2009b). Our sample database did not
comprise data with regard to this or hormonal therapy which therefore could not be
investigated. However, a recent study by our group showed spectral variability could be
observed based on hormonal variations but did not confound PCA separation between
negative and abnormal samples (Traynor et al. 2016). Finally, increasing both
modelling and test set numbers across all known clinical variables is the only way to
improve classification algorithms and interpret/ understand misclassification.
Lastly, the investigation of the samples p16 and Ki67 immunocytochemistry profiles
and their correlation with the Raman spectral profiles is considered in the next chapter.
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CHAPTER 8

INVESTIGATION OF P16 AND KI-67 STAINING

PROFILES IN THINPREP® CERVICAL CYTOLOGY
SAMPLES FOLLOWING RAMAN SPECTROSCOPIC
ANALYSIS
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In this chapter it is proposed to correlate the Raman spectroscopy profiles of the
analysed samples with two of the molecular biomarkers described in chapter 1 (Section
1.2): p16 and Ki-67. The simultaneous expression of both biomarkers is reported in the
literature to relate to the underlying mechanism of cervical cancer progression and its
most common detection method is the CINtec® PLUS kit (Roche). This
immunocytochemistry polymer assay, already used in some clinics, is designed to
provide a double stain of cytoplasmic p16 and nuclear Ki-67 proteins and is described
in detail in section 3.4.1, chapter 4. The samples’ ICC profile is deemed positive if stain
is observed for both p16 and Ki-67, or negative if only one or none of the biomarkers is
observed. Additionally, all samples not stained with CINTec® PLUS kit will be stained
with Pap stain. The complete sample set will then be subjected to confirmatory
cytological screening at Altnagelvin Hospital.
Possible correlation patterns between spectral data and ICC positivity/negativity are to
be studied using PCA with PLS-LDA used to evaluate the ability to infer ICC profiles
from Raman spectroscopy data. The ICC profiles of CIN 2 samples will be of particular
interest as they might prove useful to distinguish between samples more like CIN 1
(negative ICC) and samples more like CIN 3 (positive ICC).

Moreover, the re-

screening of all samples will be used to correct for any false positives or negatives in
the sample database, and minimise bias for the PCA-LDA classifiers built in previous
chapters.

8.1 ICC Optimization
Although the CINtec® PLUS kit (Ventana for Roche, Ireland) has been designed
specifically for cervical cytology specimens and extensively described in the literature
(Possati-Resende et al. 2015; Bergeron et al. 2015; White et al. 2016), it has never been
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reported in cervical cytology samples subjected to Raman spectroscopy. Thus, it was
necessary to establish if the H 2 O 2 treatment and/or Raman recording had any influence
on the quality of the staining obtained. For this purpose, ThinPrep® samples were used
to assess the influence of H 2 O 2 treatment and Raman recording on the
immunocytochemistry result.
ThinPrep® slides were prepared from one spare ThinPrep® vial of a known CIN3 case,
obtained from The Coombe Women and Infants University Hospital, on the
ThinPrep®2000 at the DIT School of Biological Sciences lab and subjected to both
H 2 O 2 treatment and Raman spectroscopy, firstly individually and then together.
Negative controls in which H 2 O 2 treatment and Raman spectroscopy were omitted were
also included.
ICC was performed as the manufacturer’s guidelines as described in section 3.4.1 of
chapter 4.
None of the procedures showed any influence on the quality of the immunostaining as
shown in Figure 8.1.
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A-I

A-II

B

Figure 8.1 CINtec® PLUS immunostain of CIN III ThinPrep® samples after H 2 O 2 treatment and Raman
spectroscopy. In A-I) Red Ki-67 nuclear staining (arrows) and brown p16IKNK4a cytoplasmic staining
(arrowheads) can be observed at x200 magnification under light microscopy, whereas no stain can be observed
in the negative control slide A-II). B) is a positive control image of positive CINtec® PLUS immunostain from
(Ventana® 2013).
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8.2 CINtec PLUSTM ICC staining of the samples included in this study
ICC with CINtec PLUSTM was performed after all Raman spectroscopy recordings had
been completed on all samples considered in the study, including the independent test
set samples. ICC was however confined to a limited number of cases as each CINtec
PLUSTM kit only provides enough reagents to immunostain approximately 50 samples
and the limited consumable budget available for this project made it impossible to
purchase more than one kit.
Samples were randomly selected for ICC from across all sample groups, and one
negative control in which the primary antibody was omitted was included in every
staining batch, of 10 samples each. ICC was performed as per the manufacturer’s
guidelines and optimisation protocol described in section 3.4.1 of chapter 3.
All ICC stained samples were blindly evaluated by the author (Biomedical Scientist
certified to practise by the Portuguese Health Service Administration) and Ms Alison
Malkin (Fellow of the Academy of Clinical Science & Laboratory Medicine, Ireland
and Fellow of the Institute of Biomedical Sciences, UK). Overall, the quality of the
immunostain was found to be poor, with a brownish background colour throughout all
samples (Figure 8.2, Figure 8.3 and Figure 8.4). Poorly preserved/defined nuclear
structure (Figure 8.2C) of the cells made a definitive classification difficult, especially
when trying to differentiate abnormality from metaplasia and inflammatory status; and
to determine abnormality grade. In addition, differential diagnosis of cell aggregates
was not possible in most samples as preservation of cell morphology was also found to
be inadequate (Figure 8.4B). Dual staining of p16 and Ki-67 was only observed with
confidence in one sample (Figure 8.5) classified as CIN 3 and in accordance with the
sample’s cytological report. Furthermore, the specificity of p16 stain to the cytoplasm
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(Figure 8.2) and of Ki-67 to the nucleus (Figure 8.3) was in many circumstances
dubious due to the poor detail evident upon microscopic evaluation.
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x10

x200

C

x400
TM

Figure 8.2 ThinPrep® cervical cytology samples stained with CINTecPLUS . Although brown stain, attributed to p16, can be observed (arrow heads) the morphological
and nuclear detail is lost and the specificity of the stain to cytoplasm cannot be assessed. (A), (B) and (C) show the same sample at x100, x200 and x400 magnifications with
arrow heads indicating the possible positive brown stain for p16.

A

B

x100

x200

Figure 8.3 ThinPrep® cervical cytology sample stained with CINTecPLUSTM. (A)
Shows the erratic single red stain, attributed to Ki-67, which can be observed in most
samples. However, as no cytoplasm is present it is not possible to establish which type
of cell it is or if the stain is specific. (B) is a x200 magnification of (A).
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B

x10

x400

B

Figure 8.4 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. (A) is a x100 magnification image showing inconsistent red stain indicated by the black
arrows and attributed to Ki-67, on cells without cytoplasm. Red stain, indicated by red arrow heads, can also be observed in some cells of cellular aggregate at x100
magnification; however the morphological detail is lost and the specificity of the stain to the nucleus of the cells cannot be assessed. (B) Another sample with an
aggregate of cells, at x400 magnification, where a brownish stain can be observed; in addition, red stain is also observed as indicated by the two black arrows. The
morphological detail however does not allow establishing if both stains are specific for cytoplasm and nucleus respectively.
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A

B

x400

x200

Figure 8.5 ThinPrep® cervical cytology samples stained with CINTecPLUSTM. Positive dual stain can be
observed at x200 (A) and x400 magnification (B). The cell nucleus is stained red for Ki-67 whilst the cytoplasm
stained brown for p16.

The poor staining quality led both screeners to be unsure about the definitive ICC result
of most samples and about the overall diagnosis classification; with some samples
unsuitable for screening altogether. For this reason ICC staining patterns could not be
correlated with the Raman spectroscopy profiles and the influence on the sample
classification remains to be assessed.
These results are thought to be a direct result from the long air-drying period to which
the samples were subjected. Literature suggests that air-dried smears, even if previously
alcohol-fixed before drying (like our ThinPrep® samples) could probably suffer from
antigen deterioration and even when hydration is attempted results may not be reliable
(Noorden 2015). Furthermore the ThinPrep® user’s manual does not recommend slides
to be air-dried at any time prior to staining (Hologic 2014).
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8.3 Pap staining of the samples included in this study
All outstanding samples not randomly selected for p16 and Ki-67 ICC with the CINtec
PLUS® kit were subjected to Pap stain (Sigma-Aldrich, UK) according to the method
described in section 3.5, chapter 4.
A dirty background was also observed throughout all Pap stained samples and, much
like ICC, the quality of the stain seemed to have been compromised by the long air
drying periods to which the samples were subjected. The ability to clearly see the detail
of nuclear and cell clusters was lost as can be observed in Figure 8.6, leading once again
to uncertainty with regards to final diagnosis of the samples as the degree of nuclear
abnormality or chromatin pattern was deemed not assessable. The differentiation of
metaplasia cell clusters from CIN aggregates was also often found difficult. The
majority of the cells observed originated from the squamous cervical epithelia with
superficial and intermediate cells being the most abundant types observed.

A

B

x400

x200

Figure 8.6 Pap stained ThinPrep® cervical cytology sample showing a cellular aggregate with poor cellular
morphology andAnuclear detail to allow definitive classification of the sample. (A) and (B) show the cellular
aggregate at x200 and x400 magnification respectively. Superficial cells can be observed in orange
whileintermediate cells present a blue cytoplasm.
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8.4

Discussion

The ICC results are in clear contrast to those obtained upon optimisation of the
technique therefore suggesting that the long periods of air drying to which the study
samples had been subjected to before ICC had a significant negative impact on the
quality of the ICC. Although the samples used to optimise the ICC were subjected to
air-drying and the exact same Raman spectroscopic procedure as the study samples,
they were prepared fresh from ThinPrep® vials whereas the samples included in this
study were received as a ThinPrep® slide already air-dried for an unknown period of
time. Furthermore, samples were received in several batches and ICC was only
performed after all Raman spectroscopy was concluded in order to have an unbiased
mix of all sample groups (from all received batches) being stained at the same time.
This led to long periods of air drying, estimated to range from 1 to 3 years after the
ThinPrep® slide was prepared.
The ethical approval for this study only allowed the collection of one slide per case and
therefore the biomarker part of the study was limited to a maximum of one ICC or
conventional Pap stain. CINtec® PLUS was chosen because it was already fully
optimised for cervical cytology samples and several reports have shown its clinical
value for the diagnosis of CIN 2+ samples in triage of ASCUS and LSIL cytology
(Bergeron et al. 2015; White et al. 2016).
The kit allows the dual staining of p16 and Ki-67 proteins. The first is a cyclin
dependent kinase inhibitor which is thought to slow down cell cycle by facilitating the
re-binding of retinoblastoma protein (Rb) and E2F transcription factor. However, when
present, the HPV E7 protein, a product of HPV E7 oncogene, interrupts the linkage of
Rb and E2F, disrupting this pathway and leading to the accumulation of p16 in the
cell’s cytoplasm. Overexpression of p16 protein is therefore perceived as a product of
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HPV induced transformation (Tsoumpou et al. 2009; Roelens et al. 2012). However,
positive p16 stain has also been reported in non-dysplasic cells (Trunk et al. 2004). Ki67, on the other hand, is a nuclear protein expressed in all phases of the cell cycle
except G0 and, under normal physiological conditions, limited to the basal layers of the
cervical epithelium (Scholzen et al. 2000). A positive result is indicated by the coexpression of both p16 and a Ki-67 protein in the same cell, a hallmark of the cell cycle
deregulation.
Approximately 90% of new HPV infections resolve within two years (Franco et al.
1999; Ho et al. 1998). Furthermore 58% of CIN1 lesions are thought to regress without
intervention (Ho et al. 1998; Holowaty et al. 1999) within 24 months; and although
CIN2 and 3 lesions are thought to be much more likely to persist than to regress, studies
have also reported spontaneous regression (Moscicki et al. 2010a; Trimble et al. 2005).
ICC panels are therefore used instead of or in conjunction with HPV testing, to achieve
a better differential diagnosis and estimate the risk of progression. Several studies have
further proposed this p16/Ki-67 dual staining to be used as a triage tool for equivocal or
low-grade cervical cytology samples, reporting the ICC specificity to be higher than that
of HPV testing for detection of CIN2+ in both ASCUS and LSIL populations (Bergeron
et al. 2015; White et al. 2016). Nevertheless a systematic review have found the bias
risk to the design of some preliminary studies to be high (Kisser et al. 2015).
It was originally proposed to correlate the staining profiles with the Raman
spectroscopy profile of the samples and evaluate if (1) it was possible to infer the
staining pattern from the Raman signature and (2) if this information allowed
refinement of the diagnosis algorithm for better differential diagnosis and reduction in
the false positive rates, especially amongst CIN samples. In this study ICC and Pap
stain were done manually so, in order to guarantee the processing of unbiased sample
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groups (negative, CIN 1, 2 and 3), randomly selected samples from all groups were
included in each staining batch. With samples being received at different time points,
this delayed the staining procedures until after all samples were received and analysed
by Raman spectroscopy which meant samples were air-dried for long and varied periods
of time. Despite being unable to fulfil this aim it is recommended that such a study be
carried out in the future. Furthermore, changing the sample type acquired from the
hospital from pre-prepared ThinPrep® slides to ThinPrep® vials would allow full
control over the sample air-drying time and, at the same time, would allow multiple
slides to be prepared from one single sample vial which could in turn be used to
perform additional ICC panels like those proposed by several groups (Griffin et al.
2015; Yemelyanova et al. 2013). These groups argue that the assessment of the HPV
lifecycle deregulation in cervical tissue may hold the key to improve disease
stratification. Doorbar’s group propose complementary immunohistochemistry panels
using HPV E4 protein reporting its ability to identify low-grade viral disease which due
to abundant E4 expression can be distinguished from non-viral pathologies like
metaplasia. Also reported was the combination of E4 and p16 proteins to sort CIN 2
samples into subgroups of “CIN1-like productive infection” or “CIN3-like transforming
infection” based on the extent of HPV deregulation and lifecycle completion present in
the samples (Griffin et al. 2015). In a different study, Yemelyanova et al. reported L1
and L2 (HPV capsid proteins) to be only expressed in LSIL/CIN1 lesions and rarely in
HSIL/CIN2+ thus suggesting further examination of their ability to predict persistent
infection and/or disease progression (Yemelyanova et al. 2013).
Finally, both ICC and Pap stained samples were intended to be subjected to a re-screen
in order to identify any discrepancies between the overall case classification obtained
upon sample collection and the final classification obtainable from the actual sample
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used for Raman spectroscopy. This was unfortunately not possible as although the
recording coordinates allowed cell re-visiting, the vast majority of the cells displayed
poor staining quality of both ICC and Pap stains after the Raman spectroscopy
component of the project was completed. The re-screen of all recorded cells was
intended to confirm if the cells recorded were indeed negative, CIN 1, 2 or 3, ensuring
any discrepancies between Raman spectroscopy and cytology report did not arise from
erroneous cell recording, particularly in CIN samples when multiple grades can be
present in the same sample. In addition, it would also validate if Raman spectroscopy
allowed overall sample classification regardless if all Raman-screened cells were of the
highest abnormality grade or not. Despite the re-screening of the overall samples and
the individual Raman recorded cells not being possible, the fact that the PCA-LDA
model results seem in accordance with the classification reported in the sample
cytological reports, supports our hypothesis that Raman spectroscopy is able to allow a
correct sample classification even if it cannot be guaranteed all recorded cells belong to
that specific classification category. Nevertheless it is recommended that future studies
perform any ICC or structural stains such as Pap as soon as possible after Raman
spectroscopy acquisition to avoid subjecting the samples to long air-drying periods
which was found to compromise the quality of the staining which in turn prevents the
visualization of the cellular and nuclear morphology needed to make an accurate
diagnosis classification. Additionally, having access to ThinPrep® vials would on one
hand, ensure a complete control over the sample preparation and air-drying times and,
on the other hand allow further ICC markers to be evaluated as multiple slides could
then be prepared.
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CHAPTER 9

CONCLUSIONS AND FUTURE WORK
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9.1 Conclusion
In this study the aim was to evaluate the potential of Raman spectroscopy as a
biomedical tool for the screening of routine cervical cytology samples from a screening
population.
Cervical cancer remains one of the most common cancers affecting women worldwide
(IARC 2012b) and despite the success of the current screening programmes which are
based on the cytological evaluation of cervical cells under light microscopy, new
technologies are needed. The subjectivity of the grading characteristics and the constant
intra and inter-laboratory validation necessary to achieve and maintain the highest
reported sensitivity and specificity rates has led to the investigation of better diagnosis
tools.
The performance of automated screening systems is much debated and all current
systems still require a highly trained pathologist or cytoscreener to sign-off the final
diagnosis (Kitchener et al. 2011). After HPV was accepted as the underlying condition
for cervical cancer, HPV testing has emerged, in recent years, as the ultimate diagnosis
tool with several countries trialling it as a primary, and/or co-testing screening tool. In
Ireland, HPV testing is currently used for triage of abnormal cytology samples
(CervicalCheck 2015a) and has recently been recommended as a primary test tool for
the UK (NHS Cervical Screening Programme 2016). However, HPV testing only
provides information regarding the HPV infection status which in turn depends on the
actual test used and its detection modality (for viral DNA or RNA); information
regarding cellular abnormalities remain unknown. Although a HPV negative result is a
good predictor of low risk of cervical cancer, a HPV positive result is unclear as most
infections can resolve in a few months to a year.

Similarly, HPV testing is not

recommended as a primary or co-testing tool in young women (up to 30 years of age) as
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HPV infections are most common in these women (American Cancer Society 2016).
Furthermore, the trial introduction of HPV testing as a screening tool has resulted in an
increase in colposcopy referral rates by as much as 200% and these remain increased
despite improved guidelines (Haldorsen et al. 2015).
Raman spectroscopy of cervical cytology samples would, in theory, be able to provide a
better alternative allowing a non-subjective result based on the underlying biochemical
changes that lead to cervical cancer. Previous studies have shown it is possible to
differentiate normal and abnormal samples based on Raman spectral signatures.
Although ex vivo studies have clear potential for aiding histological diagnosic, they are
not suitable for screening purposes due to the need for tissue excision/biopsy. In vivo
Raman measurements are proposed as an alternative with protocols resembling a
colposcopy-like procedure in the clinic. Nevertheless, these measurements might be
more prone to confounding factors such as blood and debris, infections and alterations
in general tissue density due to menstrual cycle or aging for example. Cytology has
been widely used for cervical cancer screening, however only two previous studies have
reported in the literature to investigate the potential of Raman spectroscopy using this
platform. Rubina et al. considered cellular pellets (Rubina et al. 2013a) rather than a cell
monolayer as studied by Bonnier et al. (Bonnier et al. 2014). Both studies identified the
need to eliminate the contribution of blood and debris to the sample spectra and
proposed suitable sample preparation methods to do so. Rubina et al. further reported
PCA-LDA classifiers to achieve a classification efficiency of approximately 80% but
both studies were limited in terms of sample numbers and did not study the influence of
any clinical factors to the Raman spectra. In this study cervical cytology samples from
a screening population were investigated by Raman spectroscopy and multivariate
analysis, namely PCA and PCA-LDA, to test the ability for disease diagnosis.
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In order to be cost-effective Raman spectroscopy and indeed all cytology and
histopathology analysis platforms, have to be performed using common glass slides as
used routinely in cervical cytology, as opposed to Raman substrates like calcium
fluoride slides which are too expensive to be cost-effective.
The use of glass as a substrate limited our recording to the nucleus of the cells as
previous studies showed the glass contribution to the cytoplasm to be too high to allow
useful spectra to be obtained (Ostrowska 2011). Nevertheless, the use of glass substrates
remain a challenge to the study as although similar glass spectra were obtained across
all slides, the glass contribution to the sample spectra differed between sample groups.
This seemed to be related to nuclear and cellular morphology, with a higher
contribution in CIN 1 samples where cells displayed bigger and flatter nuclei. Initial
PCA analysis showed it was possible to separate between negative and CIN samples
based on their Raman spectral profiles but glass features dominated the main PC
loadings. It was therefore necessary to correct for the substrate contribution in order to
avoid classification bias. From all the methods tested, NNLS seemed to provide the best
results by minimizing the glass features observed whilst retaining enough spectral
information to allow separation of the samples upon PCA. A new glass correction
method based on EMSC has recently been published (Kerr et al. 2016) and although it
would be interesting to test it on this dataset, the fact that only one single reference glass
spectrum is used might not result in any improvement against the NNLS method,
presented here, which used a matrix of glass recorded from all model set samples.
PCA-LDA analysis was further employed to construct CIN classification models of the
samples based on their spectral profile. LOPOCV was used to test the model
performance and sensitivity and specificity results obtained were very encouraging, all
above 95%, therefore better than what is reported for Pap screening and HPV testing
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(Arbyn et al. 2006; Kitchener et al. 2011; Dudding et al. 2015). The SIL reporting
system was also investigated with PCA-LDA classifiers with similarly high sensitivity
and specificity results, all above 97%.
However, patient specimens are heterogeneous; with both major advantages and
disadvantages. If on one hand, they provide the ultimate sample, on the other hand, they
do not allow for any control or testing of the variables that might affect them; making
most of the work dependent on the information received from clinic, both quantitatively
and qualitatively. The greatest limitation of the study was therefore the sample database.
Although the number of samples used was higher than that used in many spectroscopy
studies reported in the literature for cervical cancer (Ramos et al.,2015); they were
unevenly distributed across all sample groups, a direct result from collecting from a
screening population where fortunately the vast majority of the cases are negative. This
however, could have a negative impact when trying to construct classification models
like PCA-LDA as class unbalance could lead to bias (Varmuza et al. 2009; Beleites et
al. 2013). A further limitation was the clinical information made available to this study.
For example, it was not possible to control the numbers of 20, 30, 40 or 50 year old
patients being screened at the time the study samples were being collected, or that a
patient would remember the date of her last menstruation period allowing us to infer the
menstrual cycle day and phase. As a result the clinical information received was
incomplete with some information available for only some samples. Nevertheless,
having demonstrated that PCA and PCA-LDA of the Raman spectroscopy profiles of
cervical cytology samples could be used to achieve accurate sample classification, the
influence of several clinical factors on the sample spectra and the PCA-LDA algorithms
was investigated.
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The results suggested it is not feasible to infer patient age from the Raman spectral
profile of the samples and it was postulated to have no impact on the disease
classification models which is in agreement with other spectroscopy studies (Sahu et al.
2012; Bhattacharjee et al. 2013) that reported age not to influence disease classification
algorithms despite being inferred from the spectra. Nevertheless, the further evaluation
of age would still be advised in future studies. The limited sample database did not
allow CIN samples to be analysed according to age and also prevented the PCA-LDA
classification models to be organised for age, making age-related performance still
unknown.
Menstrual cycle information was more limited as it was dependent on the patient being
able to inform the clinic as to when her last menstruation period occurred. Nevertheless,
the moderate performance of the PCA-LDA results suggests it might be feasible to infer
such menstrual cycle phase from the patient Raman spectra but this information did not
improve the CIN classification algorithms.
Despite being mainly limited to CIN 1 samples, the correlation of HPV infection status
with the Raman spectral profiles seems to suggest HPV infection to have a significant
impact on the spectral profile of the sample; with PCA-LDA models showing
encouraging performance to predict CIN 1 HPV positivity or negativity in addition to
the other classification groups, particularly in the CIN PCA-LDA classifier. These
results seem in line with reports that HPV infection can be detected by Raman
spectroscopy of cervical pellets and cell lines (Jess et al. 2007; Ostroswka et al. 2010;
Vargis et al. 2012) and more recently cervical fluids (Choi et al. 2015). However it was
not possible to conclude on different HPV infection profiles (HPV typing) due to small
sample numbers across all groups on the database. Negative samples should also be
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investigated with the results obtained for the test set group (chapter 8) suggesting that it
might play an important role.
Finally, previous disease history was also considered as it has previously been reported
that underlying disease might be inferred by Raman spectroscopy for both in vivo
(Keller et al. 2008) and ex vivo studies (Rashid et al. 2014). Our results are suggestive
that previous disease information could successfully be inferred from the spectral data
of negative and CIN1 samples. However, this was only true for the presence or absence
of previous disease as specific backgrounds could not be correctly inferred due to the
small sample numbers available. Furthermore, no significant difference was found to
the model performance after LOPOCV when previously diseased negative samples were
removed from the PCA-LDA disease classification model which seems supportive that
previous disease does not bear much influence to the overall disease classification
algorithm. However, only one of the negative samples had previous history of moderate
to severe dysplasia which might result in previous disease influence being
underestimated in these models. Results for the test set sample database are supportive
of this with all negative samples presenting with previous disease history and the
majority (74.1 %) with moderate to severe dysplasia, it was reassuring the PCA-LDA
model classified 96.3% of these samples correctly as having previous disease history.
When an independent dataset to our PCA-LDA models was tested, confusion matrices
show the CIN and SIL classification models to be 100% accurate to detect CIN1/LSIL,
with one false negative case reported for CIN 3 samples (n=5), with all others correctly
classified as either CIN3 or HSIL. A mixed picture was obtained for the CIN 2 samples
with only 50% classifying correctly, perhaps a result of disease regression or further
suggesting the heterogeneity of this group with some samples being CIN1/LSIL-like
(Griffin et al. 2015). Finally, 100% the cytology screened negative samples of the test
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set were deemed as false positives by both CIN and SIL PCA-LDA models,
misclassifying as CIN 1 and LSIL, respectively. The negative samples were then
analysed according to their previous disease history with the PCA-LDA model
classifying all but one (96.3%) as having had previous disease; a result in line with the
information available for these samples all known to be positive for previous disease,
74.1% moderate or severe. These results seem to support the idea that previous disease
history might in fact act as a confounding factor in the case of negative samples. It
could be that the small sample numbers with previous disease (n=18) available in the
model set (n=88) were underfit by the rest of the “true” negative samples or, that there
is a specific timeframe since previous disease occurs in which effects can still be
translated into spectral features. HPV results for the negative samples were not available
so although dysplasia was not seen morphologically, HPV infection may still have been
present.
Both negative and CIN 1 test samples were further tested on the PCA-LDA
classification model to distinguish negative from CIN 1 HPV positive or negative
samples. In this model, all negative samples classified as CIN 1 HPV positive further
suggesting that HPV infection might indeed still be present perhaps causing the CIN 1
spectral phenotype. The fact that CIN 1 samples were all correctly classified including
the only 2 HPV negatives included as part of the test dataset, strengthens these results.
This study further attempted to analyse two of the most extensively studied biomarkers
in cervical cancer research: p16 and Ki-67 (Bergeron et al. 2015; White et al. 2016).
The dual ICC staining of both these biomarkers is accepted as a confirmation of
persistent HPV infection and an indication of CIN 2+ (Roche Diagnostics 2016). The
quality of cellular and particularly nuclear detail after ICC staining was however too
poor to allow a definitive evaluation of most of the samples considered in this study.
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Similar results were observed for the Pap stained samples and it was therefore decided
the samples did not retain the necessary morphology detail to allow grading and
differential diagnosis which could then be correlated with the Raman spectroscopy
profiles. The poor morphology and nuclear detail is thought to be direct consequence of
the long air drying periods to which the samples were subjected.
It was therefore not possible to (a) correlate the samples ICC profiles with their Raman
spectra or (b) confirm if each negative, CIN 1, 2 and 3 cell recorded was in fact of that
specific category. However, the encouraging sensitivity and specificity results obtained
for the PCA-LDA models using both CIN and SIL classifications seem supportive of
the idea that it might not be necessary that all cells recorded from a CIN 1, 2 or 3
sample need to be in fact CIN 1, 2 or 3 respectively. Although it was not possible to
confirm, for example, that only CIN 1 cells were recorded from CIN 1 samples, the
PCA-LDA classifiers showed high performance, parallel to the cytology diagnosis of
CIN 1. This notion is further supported by reports that underlying pathology can be
detected by Raman spectroscopy in normal appearing areas of a diseased sample (Keller
et al. 2008; Rashid et al. 2014) indicating that the CIN spectral signature might be
present even in normal appearing cells from a CIN sample (Schubert et al. 2010).
Nevertheless it would be important that future studies are able to do this retrospective
classification of the recorded samples as it will inform on numbers needed to achieve
good classification.
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9.2 Future directions
The results of this study show Raman spectroscopy can successfully be used for the
evaluation of cervical cytology samples collected from a screening population and
prepared through the ThinPrep® LBC platform. Compared to other techniques, and in
particular vibrational spectroscopies like scanning near-field optical microscopy in
combination with free electron-laser (SNOM-IR-EL), ATR (Halliwell et al. 2016) and
infrared micro-spectroscopy (Schubert et al. 2010) which have also been reported to be
promising diagnosis tools, the Raman methodology reported in this study has the
advantages of requiring minimal sample preparation and the ability to use a cheaper and
more common substrate, the ThinPrep® glass slide already used for cervical cancer
screening. This means Raman spectroscopy could be more easily implemented in the
current cervical cancer screening workflow process and also represents a more costeffective tool to increasingly pressured health care systems. Compared with the manual
or semi-automated screening of cytology samples, currently used for cervical cancer
screening, Raman spectroscopy would allow for a non-subjective outcome, dependent
only on the sample biochemical fingerprint rather than subjective grading characteristics
which in turn would allow for improved reproducibility and maintenance of high
sensitivity and specificity rates.
The samples in this study were however not recorded blindly or at random, as abnormal
looking cells were targeted when the samples were known to have an abnormal
cytological diagnosis. Despite saving the coordinates of the recorded cells with the
intention of revisiting and assessing them after ICC and Pap staining; the morphological
detail needed to do so was not preserved due to long air-drying periods and it was
therefore not possible to confirm the diagnosis/grade of each recorded cell.
Nevertheless, good performance was achieved for PCA-LDA classifiers based on the
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recorded Raman spectra, which had the cytology diagnosis as reference. As previously
mentioned, this suggests that it might not be necessary that in CIN/SIL samples, all cells
recorded from are in fact CIN or SIL (Schubert et al. 2010).
Future studies would however need to address some of the limitations found by this
study. Firstly, there is a need for long spanning sample collection to guarantee similar
patient numbers across all diagnosis categories and clinical features. Even though
Raman spectroscopy would still be recorded from cells prepared onto ThinPrep® slides,
future studies should however aim for the collection of the ThinPrep® vials rather than
a ready-made slide as collected for this study. The collection of vials would allow
control over all steps of the slide preparation, guaranteeing similar air-drying periods
amongst all samples, for example; whilst allowing multiple slides to be generated from
the same sample which in turn would broaden the amount of research possible. For
example, multiple biomarkers could be tested for the same sample. Future studies
should be designed so that ThinPrep® vials would be collected, slides prepared and
samples promptly subjected to Raman spectroscopy. The next step to take Raman cytospectroscopy closer to the clinic is automation of both the recording process and the
spectral analysis and classification algorithms. The ultimate system would have to be
user-friendly and independent of subjective cell selection or user knowledge of Raman
spectroscopy.
In prospective studies the samples should be recorded blind (with unknown cytology
outcome) and preferably by multiple users so that reproducibility could also be
evaluated. Similarly, users would select cells at random and evaluate multipoint (when
all cells are marked before recording starts) versus individual recording as this would
enable a more automated recording step to be tested. The results of this study are
suggestive that it might not be necessary for the correct classification of CIN and SIL
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samples that all cells recorded from those samples are of that diagnosis category,
however this still warrants further investigation.
All samples collected would obviously be anonymised and, subject to ethical approval,
all known clinical information would also be made available to the study(ies). It would
be important to gather information with regards to age, LMP, menopausal status and
any therapies undertaken, parity, previous disease history (if possible with dates), HPV
vaccination and infection status, oral contraceptive use, all previously reported
(Castellsagué et al. 2003; La Vecchia et al. 2014; Hestbech et al. 2015) to play a role in
cervical cancer pathogenesis; so that the influence of these variables on the sample
spectra and diagnosis algorithms can be thoroughly investigated. Biological samples are
dynamic, and cervical cancer research is a rapidly changing field. HPV vaccination for
example is thought to change the landscape of HPV infection and cervical
abnormalities. So it is important that these are also monitored whilst developing this
technology. Furthermore, despite much debate (Dudding et al. 2015) cervical cancer
screening guidelines are likely to change to primary HPV testing, at least in the UK
where that recommendation has been recently made (NHS Cervical Screening
Programme 2016). Although the actual screening guidelines have not yet been made
public, this will potentially mean that all cervical smears would be primary tested for
the presence of HPV and only subjected to cytology screening if HPV positive. For
development of a cytological screening tool, it would therefore be necessary to partner
with a clinical-research team of pathologist and experienced screeners in order to obtain
a cytological diagnosis of all the samples, even those which are HPV negative.
In addition, partnering with one or more screening centres would also be necessary in
order to access as many smear vials as possible, as they become ready to be discarded
after diagnosis. Samples would then be Raman screened, Pap stained and finally
259

cytologically screened by 2 or more independent screeners. Results would be compared
against HPV test results used for screening diagnosis and also against further HPV and
biomarker research which would investigate low-risk types and the pattern of HPV
infection and abnormality transformation (Yemelyanova et al. 2013; Griffin et al. 2015).
If possible, spanning sample collection over at least 2 screening calls would also allow
the investigation of regression/prognosis from the sample Raman spectra.
Finally, this study only explored PCA-LDA algorithm for the sample classification;
however more complex algorithms such as support vector machines should also be
evaluated. If significant sample numbers can also be obtained across the clinical
parameters these could also be input into the classifiers, to test if they would allow for
an improved classification.
In conclusion, this study is supportive that Raman spectroscopy could be used for the
diagnosis of cervical cytology samples. It could also potentially allow for a more
accurate diagnosis than HPV DNA testing as the underlying mechanisms of cervical
cancer progression are potentially detectable through the Raman spectra. However, the
need for automation and the necessity to investigate and fully understand how clinical
features influence the spectral profiles will be key to take the technology closer to the
clinic.
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Appendix 2 The 2001 Bethesda Classification System adapted from
(Apgar et al. 2003)

I.
SPECIMEN ADEQUACY
Satisfactory for evaluation (note presence/absence of endocervical/transformation zone component)
Unsatisfactory for evaluation . . . (specify reason)
Specimen rejected/not processed (specify reason)
Specimen processed and examined, but unsatisfactory for evaluation of epithelial abnormality
because of (specify reason)
II.
GENERAL CATEGORIZATION (Optional)
Negative for intraepithelial lesion or malignancy
Epithelial cell abnormality
Other
III.
INTERPRETATION/RESULT
Negative for Intraepithelial Lesion or Malignancy
Organisms:
Trichomonas vaginalis
Fungal oganisms morphologically consistent with Candida species
Shift in flora suggestive of bacterial vaginosis
Bacteria morphologically consistent with Actinomyces species
Cellular changes consistent with herpes simplex virus
Other non-neoplastic findings (Optional to report; list not comprehensive):
Reactive cellular changes associated with:
inflammation (includes typical repair)
radiation
intrauterine contraceptive device
Glandular cells status posthysterectomy
Atrophy
Epithelial Cell Abnormalities
Squamous cell
Atypical squamous cells (ASC):
of undetermined significance (ASC-US)
cannot exclude HSIL (ASC-H)
Low-grade squamous intraepithelial lesion (LSIL) encompassing: human papillomavirus/mild
dysplasia/cervical intraepithelial neoplasia (CIN) 1
High-grade squamous intraepithelial lesion (HSIL) encompassing: moderate and severe
dysplasia, carcinoma in situ; CIN 2 and CIN 3
Squamous cell carcinoma
Glandular cell
Atypical glandular cells (AGC) (specify endocervical, endometrial, or not otherwise specified)
Atypical glandular cells, favor neoplastic (specify endocervical or not otherwise specified)
Endocervical adenocarcinoma in situ (AIS)
Adenocarcinoma
Other (List not comprehensive)
Endometrial cells in a woman _40 years of age
IV.
AUTOMATED REVIEW AND ANCILLARY TESTING (Include as appropriate)
V.
EDUCATIONAL NOTES AND SUGGESTIONS (Optional)
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Appendix 3 Modelling set sample database with relevant patient information
Cytology sample model set database and respective clinical information. All samples received from Altnagelvin Hospital, Northern Ireland are listed with those considered unsuitable
for Raman spectroscopy highlighted.
HPV results are available for all samples with the exception of negative samples; hrHPV stands for high-risk HPV types. Regarding to clinical history, samples are classified as no
previous history, negative (NEG), borderline (BL), LSIL, HSIL or CIN 1, 2 or 3 history. Menstrual cycle day was obtained by subtracting the last menstruation period (LMP) date
from the smear date. Samples from day 4 to 13 were classified as being in the proliferative phase of the menstrual cycle whereas samples in day 14 to 28 were considered to be in the
secretory phase of the cycle.

Model
Sample
ID

Cytology
diagnosis

Smear Date

LMP

Menstrual
cyle day

Menstrual
cycle phase

HPV Result

Age

1

Negative

14-03-2012

27-02-2012

16

Secretory

n/a

37

2
3
4
5
6
7
8
9
10
11

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
14-03-2012
13-03-2012
13-03-2012
13-03-2012
14-03-2012
13-03-2012
13-03-2012
13-03-2012

n/a
n/a
n/a
n/a
03-03-2012
n/a
22-02-2012
n/a
15-02-2012
06-03-2012

n/a
n/a
n/a
n/a
10
n/a
21
n/a
27
7

n/a
n/a
n/a
n/a
Proliferative
n/a
Secretory
n/a
Secretory
Proliferative

n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

56
51
52
59
44
28
37
40
42
30
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History
Mild, BL ,
NEG, CIN1,
NEG
NEG
NEG
NEG
NEG
NEG
BL, NEG
NEG
NEG
NEG
NEG

12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

13-03-2012
14-03-2012
13-03-2012
14-03-2012
13-03-2012
15-03-2012
15-03-2012
14-03-2012
14-03-2012
14-03-2012
15-03-2012
13-03-2012
15-03-2012
14-03-2012
15-03-2012
13-03-2012
13-03-2012
13-03-2012
12-03-2012
13-03-2012
13-03-2012
13-03-2012
13-03-2012
n/a
13-03-2012

20-02-2012
n/a
25-02-2012
23-02-2012
02-03-2012
n/a
05-03-2012
n/a
28-02-2012
n/a
20-02-2012
n/a
n/a
n/a
n/a
n/a
26-02-2012
n/a
n/a
n/a
21-02-2012
08-03-2012
26-02-2012
n/a
n/a

22
n/a
17
20
11
n/a
10
n/a
15
n/a
24
n/a
n/a
n/a
n/a
n/a
16
n/a
n/a
n/a
21
5
16
n/a
n/a

Secretory
n/a
Secretory
Secretory
Proliferative
n/a
Proliferative
n/a
Secretory
n/a
Secretory
n/a
n/a
n/a
n/a
n/a
Secretory
n/a
n/a
n/a
Secretory
Proliferative
Secretory
n/a
n/a

n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

46
54
27
41
46
62
25
32
42
37
41
28
33
35
49
41
39
32
45
54
46
31
32
48
64

37

Negative

14-03-2012

09-03-2012

5

Proliferative

n/a

38
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NEG
NEG
NEG
NEG
NEG
MOD, NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG
MOD, NEG
1st Smear
BL, NEG
NEG
NEG
BL, NEG,
Mild, NEG

38
39
40
41

Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
14-03-2012
14-03-2012

n/a
n/a
06-03-2012
n/a

n/a
n/a
8
n/a

n/a
n/a
Proliferative
n/a

n/a
n/a
n/a
n/a

26
34
27
27

42

Negative

14-03-2012

24-02-2012

19

Secretory

n/a

40

43

Negative

14-03-2012

n/a

n/a

n/a

n/a

57

44

Negative

14-03-2012

01-03-2012

13

Proliferative

n/a

47

45

Negative

14-03-2012

06-03-2012

8

Proliferative

n/a

32

46
47
48
49
50
51

Negative
Negative
Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
12-03-2012
14-03-2012
13-03-2012
13-03-2012

23-02-2012
n/a
20-02-2012
n/a
n/a
n/a

20
n/a
21
n/a
n/a
n/a

Secretory
n/a
Secretory
n/a
n/a
n/a

n/a
n/a
n/a
n/a
n/a
n/a

36
45
48
30
32
42

52

Negative

13-03-2012

n/a

n/a

n/a

n/a

52

53
54
55
56
57
58
59

Negative
Negative
Negative
Negative
Negative
Negative
Negative

13-03-2012
13-03-2012
13-03-2012
13-03-2012
13-03-2012
12-03-2012
14-03-2012

n/a
n/a
18-02-2012
15-02-2012
n/a
03-03-2012
n/a

n/a
n/a
24
27
n/a
9
n/a

n/a
n/a
Secretory
Secretory
n/a
Proliferative
n/a

n/a
n/a
n/a
n/a
n/a
n/a
n/a

62
33
35
53
62
55
29
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NEG
NEG
NEG
NEG
NEG, BL,
Mild, CIN1,
NEG
Mild, NEG,
BL, NEG
NEG
NEG, BL,
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG, BL,
NEG
NEG
NEG
NEG
NEG
NEG
NEG
NEG

60

Negative

14-03-2012

n/a

n/a

n/a

n/a

53

61

Negative

13-03-2012

n/a

n/a

n/a

n/a

56

62
63
64
65
66

Negative
Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
15-03-2012
15-03-2012
15-03-2012

06-03-2012
n/a
10-03-2012
05-03-2012
24-02-2012

8
n/a
5
10
20

Proliferative
n/a
Proliferative
Proliferative
Secretory

n/a
n/a
n/a
n/a
n/a

50
27
23
38
29

67

Negative

12-03-2012

n/a

n/a

n/a

n/a

50

68
69
70
71
72
73
74

Negative
Negative
Negative
Negative
Negative
Negative
Negative

15-03-2012
15-03-2012
15-03-2012
14-03-2012
15-03-2012
15-03-2012
14-03-2012

17-02-2012
08-03-2012
01-03-2012
21-02-2012
n/a
n/a
n/a

27
7
14
22
n/a
n/a
n/a

Secretory
Proliferative
Secretory
Secretory
n/a
n/a
n/a

n/a
n/a
n/a
n/a
n/a
n/a
n/a

32
47
48
48
51
58
31

75

Negative

15-03-2012

n/a

n/a

n/a

n/a

55

76
77
78
79

Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
14-03-2012
14-03-2012

23-02-2012
07-03-2012
n/a
07-03-2012

20
7
n/a
7

Secretory
Proliferative
n/a
Proliferative

n/a
n/a
n/a
n/a

38
48
54
39

80

Negative

14-03-2012

n/a

n/a

n/a

n/a

56
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NEG
Mild, CIN3,
NEG, Mild,
NEG
NEG
1st Smear
NEG
NEG
NEG
NEG, BL,
NEG
NEG
NEG
NEG
NEG
MOD, NEG
NEG
NEG
Mild, Mild,
NEG
Mild, NEG
NEG
NEG
NEG
NEG, BL,
NEG, Mild,
NEG, BL,
NEG

81
82
83
84

Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
14-03-2012
15-03-2012

n/a
n/a
n/a
23-02-2012

n/a
n/a
n/a
21

n/a
n/a
n/a
Secretory

n/a
n/a
n/a
n/a

43
49
31
42

85

Negative

16-03-2012

n/a

n/a

n/a

n/a

47

86
87
88
89
90

Negative
Negative
Negative
Negative
Negative

n/a
14-03-2012
14-03-2012
14-03-2012
14-03-2012

n/a
01-03-2012
01-03-2012
27-02-2012
n/a

n/a
13
13
16
n/a

n/a
Proliferative
Proliferative
Secretory
n/a

n/a
n/a
n/a
n/a
n/a

38
32
41
49
63

91

Negative

14-03-2012

n/a

n/a

n/a

n/a

38

92

Negative

15-03-2012

26-02-2012

n/a

n/a

n/a

47

93

Negative

14-03-2012

02-03-2012

12

Proliferative

n/a

36

94

Negative

12-03-2012

n/a

n/a

n/a

n/a

57

95
96
97
98

Negative
Negative
Negative
Negative

14-03-2012
14-03-2012
14-03-2012
14-03-2012

n/a
n/a
n/a
05-03-2012

n/a
n/a
n/a
9

n/a
n/a
n/a
Proliferative

26
50
57
31

99

CIN 1

06-01-2014

n/a

n/a

n/a

n/a
n/a
n/a
n/a
12 other hr
HPV types +
HPV16 +
HPV18
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26

NEG
NEG
NEG
NEG
BL, Mild,
NEG
NEG
1st Smear
NEG
NEG
1st Smear
NEG, Mild,
NEG
Mild, NEG,
BL, NEG,
BL, NEG
BL, NEG
NEG, BL,
NEG
1st Smear
NEG
NEG
NEG
MILD, CIN
1, MILD,
CIN 1, BL

NEG, MID,
CIN 1

27

MILD, CIN 1

CIN 1

15-01-2014

n/a

n/a

n/a

101

CIN 1

17-01-2014

n/a

n/a

n/a

102

CIN 1

29-01-2014

n/a

n/a

n/a

103

CIN 1

07-02-2014

20-01-2014

18

Secretory

104

CIN 1

14-02-2014

n/a

n/a

n/a

105

CIN 1

20-02-2014

n/a

n/a

n/a

106

CIN 1

20-02-2014

06-02-2014

14

Secretory

12 other hr
HPV types

28

107

CIN 1

21-02-2014

n/a

n/a

n/a

12 other hr
HPV types

33

108

CIN 1

21-03-2014

07-03-2014

14

Secretory

12 other hr
HPV types

31

109

CIN 1

04-04-2014

n/a

n/a

n/a

Negative

47

110

CIN 1

07-04-2014

n/a

n/a

n/a

Negative

66

111
112
113

CIN 1
CIN 1
CIN 1

07-04-2014
09-04-2014
23-05-2014

26-03-2014
20-03-2014
15-05-2014

12
20
8

Proliferative
Secretory
Proliferative

Negative
Negative
Negative

34
32
46

114

CIN 1

10-04-2014

n/a

n/a

n/a

Negative

36
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HPV18

33

100

12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types
HPV 16 +
18
12 other hr
HPV types

23
33
25
45

NEG, MILD,
CIN 1
NEG, MILD,
CIN 1
MILD, CIN 1
CIN 1, NEG,
MILD, CIN 1
NEG, MILD,
CIN 1,
MILD, CIN 1
NEG, MILD,
CIN 1
BL, MILD,
CIN 1,
MILD, CIN 1
NEG, MILD
CIN 1, BL,
NEG, MILD
NEG, MILD
NEG, MILD
NEG, MILD
BL, NEG,
MILD

115

CIN 1

29-05-2015

n/a

n/a

n/a

Negative

46

116

CIN 1

14-04-2014

06-04-2014

8

Proliferative

Negative

45

117

CIN 1

14-04-2014

n/a

n/a

n/a

Negative

26

118

CIN 1

17-04-2014

n/a

n/a

n/a

Negative

24

119

CIN 1

23-04-2014

n/a

n/a

n/a

Negative

57

120

CIN 1

29-04-2014

01-04-2014

28

Secretory

Negative

25

121

CIN 1

06-05-2014

n/a

n/a

n/a

Negative

46

122

CIN 1

09-05-2014

12-04-2014

27

Secretory

Negative

28

123

CIN 1

12-05-2014

n/a

n/a

n/a

Negative

45

124

CIN 1

15-05-2014

26-04-2014

19

Secretory

Negative

32

125

CIN 1

16-05-2014

n/a

n/a

n/a

Negative

49

126

CIN 1

16-05-2014

n/a

n/a

n/a

Negative

27
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CIN 1, CIN 1
, MILD,
MILD, NEG,
MOD , CON
1, MOD, BL,
MILD
NEG, BL,
BL, MILD
MILD
MILD, CIN
1, MILD
NEG, BL,
MILD, CIN
1, BL, MILD
NEG, MILD
NEG, BL,
MILD
NEG, MILD,
CIN 1,
MILD, CIN
1, BL, CIN 3,
MILD
NEG, MILD
NEG, MOD,
BL, MILD
BL, NEG,
MILD
BL, NEG,
MILD

127
128

CIN 1
CIN 1

20-05-2014
n/a

01-05-2014
n/a

19
n/a

Secretory
n/a

Negative
Negative
12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types
HPV18
12 other hr
HPV types
12 other hr
HPV types

49
47

129

CIN 1

07-01-2014

n/a

n/a

n/a

130

CIN 1

08-01-2014

n/a

n/a

n/a

131

CIN 1

08-01-2014

24-12-2013

15

Secretory

132

CIN 1

21-01-2014

n/a

n/a

n/a

133

CIN 1

22-01-2014

n/a

n/a

n/a

134

CIN 1

22-01-2014

n/a

n/a

n/a

135

CIN 1

02-02-2014

14-01-2014

19

Secretory

136

CIN 1

05-02-2014

17-01-2014

19

Secretory

HPV 16

24

137

CIN 1

n/a

n/a

n/a

n/a

12 other hr
HPV types

31

138

CIN 1

07-03-2014

01-03-2014

6

Proliferative

139

CIN 1

19-03-2014

11-03-2014

8

Proliferative

140

CIN 1

27-03-2014

06-03-2014

21

Secretory
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12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types

24
44
43

NEG, MILD
NEG, MILD
MILD, NEG,
MILD
MILD, NEG,
MILD
BL, NEG,
BL, MILD

25

MILD

26

NEG, MILD

29

MILD

26

BL, MILD
BL, NEG,
MILD
NEG, MOD,
BL, NEG,
MILD, BL,
MILD

42

NEG, MILD

37

MILD

31

NEG, BL,
MILD

141

CIN 1

10-01-2014

02-01-2014

8

Proliferative

12 other hr
HPV types

26

142

CIN 2

28-07-2011

n/a

n/a

n/a

HPV16

23

12 other hr
HPV types +
HPV16 +
HPV18
12 other hr
HPV types

143

CIN 2

10-08-2011

n/a

n/a

n/a

144

CIN 2

21-09-2011

n/a

n/a

n/a

145

CIN 2

07-09-2011

n/a

n/a

n/a

146

CIN 2

06-07-2011

29-06-2011

7

Proliferative

147

CIN 2

24-08-2011

n/a

n/a

n/a

148

CIN 2

07-07-2011

10-06-2011

27

Secretory

149

CIN 2

09-08-2011

21-07-2011

19

Secretory

150

CIN 2

30-08-2011

n/a

n/a

n/a

151

CIN 2

26-08-2011

n/a

n/a

n/a

152

CIN 2

10-10-2011

n/a

n/a

n/a

HPV16

25

153

CIN 2

n/a

n/a

n/a

n/a

HPV16

32
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POS W9
12 other hr
HPV types
POS W9
12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types
12 other hr
HPV types

MILD
No previous
history
NEG

27

31
24
25
29
40
24
24
47

NEG
No previous
history
No previous
history
NEG
NEG
No previous
history
NEG
NEG
No previous
history
LSIL

154

CIN 2

17-10-2011

n/a

n/a

n/a

155

CIN 2

11-10-2011

n/a

n/a

n/a

156

CIN 2

17-08-2011

08-08-2011

9

Proliferative

157

CIN 2

03-08-2011

20-07-2011

14

Secretory

158
159

CIN 2
CIN 2

02-08-2011
19-07-2011

18-07-2011
n/a

15
n/a

Secretory
n/a

160

CIN 2

02-11-2011

21-10-2011

12

Proliferative

161

CIN 2

07-12-2011

n/a

n/a

n/a

162

CIN 2

06-12-2011

n/a

n/a

n/a

163

CIN 2

13-12-2011

23-11-2011

20

Secretory

165

CIN 3

15-07-2011

n/a

n/a

n/a

166

CIN 3

19-07-2011

n/a

n/a

n/a

167

CIN 3

26-07-2011

06-07-2011

20

Secretory

168

CIN 3

27-07-2011

22-07-2011

5

Proliferative
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12 other hr
HPV types
HPV16
12 other hr
HPV types
12 other hr
HPV types +
HPV16
Negative
HPV16
12 other hr
HPV types +
HPV16
12 other hr
HPV types +
HPV16
12 other hr
HPV types
HPV16
12 other hr
HPV types
HPV16
12 other hr
HPV types
12 other hr
HPV types

38

LSIL

29

NEG

28

HSIL

22

HSIL

35
25

LSIL
LSIL

27

LSIL

27

No previous
history

27

HSIL

24

LSIL
No previous
history
No previous
history
No previous
history

25
31
41
20

HSIL

169

CIN 3

26-07-2011

n/a

n/a

n/a

170

CIN 3

09-08-2011

29-07-2011

11

Proliferative

12 other hr
HPV types +
HPV16
HPV16

171

CIN 3

10-08-2011

n/a

n/a

n/a

HPV16

172

CIN 3

19-08-2011

15-08-2011

4

Proliferative

173

CIN 3

22-08-2011

n/a

n/a

n/a

174

CIN 3

23-08-2011

01-08-2011

20

Secretory

HPV16

29

175

CIN 3

25-08-2011

n/a

n/a

n/a

HPV 18

36

176

CIN 3

24-08-2011

04-08-2011

20

Secretory

12 other hr
HPV types

30

177

CIN 3

26-08-2011

18-08-2011

8

Proliferative

HPV16

28

178

CIN 3

05-10-2011

30-09-2011

5

Proliferative

26

179

CIN 3

n/a

n/a

n/a

n/a

180

CIN 3

12-10-2011

n/a

n/a

n/a

181

CIN 3

05-09-2011

n/a

n/a

n/a

HPV16
12 other hr
HPV types +
HPV16
12 other hr
HPV types
FAILED
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12 other hr
HPV types +
HPV16
12 other hr
HPV types

21

LSIL

34

NEG
No previous
history

31
28

No previous
history

50

HSIL
No previous
history
No previous
history
NEG
No previous
history
LSIL

29

No previous
history

31

NEG

25

LSIL

182

CIN 3

05-09-2011

n/a

n/a

n/a

12 other hr
HPV types +
HPV16

25

183

CIN 3

15-09-2011

01-09-2011

14

Secretory

HPV16

21

184

CIN 3

n/a

n/a

n/a

n/a

185

CIN 3

28-09-2011

n/a

n/a

n/a

186

CIN 3

03-10-2011

n/a

n/a

n/a

187

CIN 3

30-09-2011

n/a

n/a

n/a

188

CIN 3

04-10-2011

17-09-2011

17

Secretory

HPV 18

31

189
190
191

CIN 3
CIN 3
CIN 3

11-10-2011
11-10-2011
11-10-2011

n/a
n/a
26-09-2011

n/a
n/a
15

n/a
n/a
Secretory

32
25
39

192

CIN 3

21-10-2011

13-10-2011

8

Proliferative

193

CIN 3

25-10-2011

05-10-2011

20

Secretory

194

CIN 3

11-11-2011

20-10-2011

22

Secretory

HPV16
HPV16
HPV16
12 other hr
HPV types +
HPV16
12 other hr
HPV types
12 other hr
HPV types +
HPV16
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12 other hr
HPV types
12 other hr
HPV types +
HPV16
12 other hr
HPV types
12 other hr
HPV types

26

HSIL
No previous
history
No previous
history

54

LSIL

25

No previous
history

44

LSIL

35
38
20

No previous
history
LSIL
NEG
LSIL
No previous
history
No previous
history
NEG

195

CIN 3

11-11-2011

04-11-2011

7

Proliferative

196

CIN 3

15-11-2011

n/a

n/a

n/a

197

CIN 3

22-11-2011

n/a

n/a

n/a

198

CIN 3

09-12-2011

n/a

n/a

n/a
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12 other hr
HPV types +
HPV16
HPV16
12 other hr
HPV types
12 other hr
HPV types

NEG
32
26
39
27

HSIL
No previous
history
No previous
history

Appendix 4 Test set sample database with relevant patient information
Cytology sample test set database and respective clinical information. All samples received from Altnagelvin Hospital, Northern Ireland are listed with those considered unsuitable for
Raman spectroscopy highlighted.
HPV results are available for all samples with exception of negative samples; hrHPV stands for high-risk HPV types. Regarding to clinical history, samples are classified as no
previous history, negative (NEG), borderline (BL), LSIL, HSIL or CIN 1, 2 or 3 history. Menstrual cycle day was obtained by subtracting the last menstruation period date from the
smear date. Samples from day 4 to 13 were classified as being in the proliferative phase of the menstrual cycle whereas samples in day 14 to 28 were considered to be in the secretory
phase of the cycle.

Test
Sample
ID

Cytology
diagnosis

Smear
date

LMP date

1

CIN 1

n/a

n/a

n/a

n/a

2

CIN 1

n/a

n/a

n/a

n/a

3

CIN 1

n/a

n/a

n/a

n/a

4
5

CIN 1
CIN 1

n/a
23

n/a
Secretory

6

CIN 1

n/a

n/a

7

CIN 1

10

Proliferative

n/a
n/a
21/07/2014 28/06/2014
n/a

n/a

17/07/2014 07/07/2014

Menstruation Menstruation
HPV result
cycle day
cycle phase
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12 other hr
HPV types
+ HPV16
HPV16
12 other hr
HPV types
Negative
Negative
12 other hr
HPV types
12 other hr
HPV types
+ HPV18

Age

Previous
disease
history

27

HSIL

29

NEG

29

HSIL

36
41

NEG
NEG

21

HSIL

27

LSIL

8

CIN 1

21/07/2014 13/07/2014

9

CIN 1

n/a

10

CIN 1

11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
CIN 3

12 other hr
HPV types
12 other hr
HPV types

8

Proliferative

n/a

n/a

n/a

n/a

n/a

n/a

n/a

n/a

41

n/a
23/07/2015
22/07/2015
n/a
n/a
20/07/2015
16/07/2015
17/07/2015
n/a
n/a
n/a
n/a
20/07/2015
23/07/2015
n/a
24/07/2015
27/07/2015
n/a
17/07/2015
09/09/2014

n/a
25/06/2015
12/07/2015
n/a
n/a
06/07/2015
13/07/2015
18/06/2015
n/a
n/a
n/a
n/a
13/07/2015
11/07/2015
n/a
01/07/2015
29/06/2015
n/a
10/07/2015
18/08/2014

n/a
28
10
n/a
n/a
14
3
29
n/a
n/a
n/a
n/a
7
12
n/a
23
28
n/a
7
22

n/a
Secretory
Proliferative
n/a
n/a
Proliferative
Proliferative
Secretory
n/a
n/a
n/a
n/a
Proliferative
Proliferative
n/a
Secretory
Secretory
n/a
Proliferative
Secretory

n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
HPV16

53
30
29
53
27
33
32
31
30
35
28
46
29
35
25
37
29
49
25
40
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28

HSIL

39

LSIL
No Previous
History
LSIL
HSIL
HSIL
HSIL
HSIL
LSIL
HSIL
HSIL
HSIL
HSIL
LSIL
HSIL
HSIL
HSIL
LSIL
LSIL
HSIL
HSIL
HSIL
LSIL

31

CIN 2

29/03/2013 11/03/2013

18

Secretory

32
33

CIN 3
CIN 3

26/03/2013 02/03/2013
31/03/2013 24/03/2013

24
7

Secretory
Proliferative

34

CIN 3

n/a

n/a

n/a

n/a

35

CIN 3

n/a

n/a

n/a

n/a

36

CIN 2

n/a

n/a

n/a

n/a

37

CIN 2

n/a

n/a

n/a

n/a

38

CIN 2

19/12/2014 07/12/2014

12

Proliferative

39
40
41
42
43
44
45
46
47
48
49

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative

30/09/2015
n/a
30/09/2015
n/a
05/10/2015
n/a
02/10/2015
05/10/2015
02/10/2015
n/a
n/a

8
n/a
14
n/a
17
n/a
9
20
12
n/a
n/a

Proliferative
n/a
Proliferative
n/a
Secretory
n/a
Proliferative
Secretory
Proliferative
n/a
n/a

22/09/2015
n/a
16/09/2015
n/a
18/09/2015
n/a
23/09/2015
15/09/2015
20/09/2015
n/a
n/a
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12 other hr
HPV types
W2
HPV16
12 other hr
HPV types
+ HPV16
HPV16
12 other hr
HPV types
12 other hr
HPV types
+ HPV18
12 other hr
HPV types
+ HPV16
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a

28

NEG

32
31

NEG
LSIL

27

NEG

25

No Previous
History

25

HSIL

25

LSIL

27

No Previous
History

23
43
29
42
49
37
26
41
35
27
23

HSIL
HSIL
HSIL
LSIL
LSIL
HSIL
LSIL
HSIL
HSIL
HSIL
HSIL

50
51
52
53
54
55
56
57
58
59
60

Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
Negative
CIN 1
CIN 1

n/a
02/10/2015
n/a
n/a
25/09/2015
n/a
n/a
30/09/2015
28/09/2015
n/a
23/09/2015

n/a
01/10/2015
n/a
n/a
27/08/2015
n/a
n/a
16/09/2015
02/09/2015
n/a
28/08/2015

n/a
1
n/a
n/a
29
n/a
n/a
14
26
n/a
26

n/a
Proliferative
n/a
n/a
Secretory
n/a
n/a
Proliferative
Secretory
n/a
Secretory

61

CIN 1

n/a

n/a

n/a

n/a

62

CIN 1

n/a

n/a

n/a

n/a

63

CIN 1

n/a

n/a

n/a

n/a

64

CIN 1

n/a

n/a

n/a

n/a

65

CIN 1

21

Secretory

66

CIN 1

n/a

n/a

67

CIN 1

22

n/a

68

CIN 1

n/a

n/a

22/10/2015 01/10/2015
n/a

n/a

25/10/2015 03/10/2015
n/a

n/a
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n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
n/a
Negative
Negative
12 other hr
HPV types
12 other hr
HPV types
HPV16
12 other hr
HPV types
12 other hr
HPV types
HPV16
12 other hr
HPV types
12 other hr
HPV types
+ HPV16

35
27
34
35
27
31
52
32
26
30
27
37
51
40
33

HSIL
HSIL
LSIL
LSIL
HSIL
HSIL
HSIL
LSIL
HSIL
NEG
NEG
LSIL
LSIL
LSIL
LSIL

49

HSIL

54

NEG

42

HSIL

45

NEG

69

CIN 2

70

CIN 3

71

CIN 2

72

CIN 3

73

CIN 2

74

CIN 2

75

CIN 3

76
77

CIN 2
CIN 3

78

CIN 3

n/a

n/a

12 other hr
HPV types
+ HPV16
HPV16
12 other hr
HPV types

n/a

n/a

11

Proliferative

n/a

n/a

10/07/2015 17/06/2015

23

Secretory

04/06/2015 15/05/2015

20

Secretory

n/a

n/a

03/07/2015 19/06/2015

14

Proliferative

HPV16

47

n/a
n/a
26/06/2015 09/06/2015

n/a
17

n/a
Secretory

28
39

n/a

n/a

HPV16
HPV16
12 other hr
HPV types
+ HPV16

08/07/2015 27/06/2015
n/a

n/a

n/a

n/a

n/a

n/a
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HPV16
12 other hr
HPV types
12 other hr
HPV types
+ HPV18

28

LSIL

27

HSIL

35

NEG

26

No Previous
History

21

LSIL

34

NEG

25

No Previous
History
LSIL
NEG
No Previous
History

Appendix 5 SOP for XploRATM Raman spectrometer calibration for
cervical cytology by Fiona Lyng and Franck Bonnier, 2012

The XploRA™ Confocal Raman Microscope is a spectroscopy instrument which
collects scattered light and generates a spectrum containing a biochemical
fingerprint of cervical cells.

This SOP is an instruction guide to;
1.1:

Start up

1.2:

Calibration procedures
1.2.1 Manual calibration of the grating
1.2.2 Laser Check
1.2.3 Dark Current measurement
1.2.4 NIST 2242 Standard
1.2.5 Recording of the optics signal

Note: Please fill in the logging book when relevant. The calibrations have to be
done once a day by the first person using the Raman spectrometer during the
day.

1.3: recording of a reference spectrum
1.4: Obtaining and saving spectra from cervical cells
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PROCEDURE:
1.1 : Start up
1.1.1 Switch on laser by turning key in power box to the right,
blue light comes on
1.1.2 Leave for 20 mins
1.1.3 Enter Password
1.1.4 Double click Labspec 5
1.1.5 Wait for initialization to complete and check detector is at 70deg on bottom task bar
1.1.6 Click video on top task bar

1.2: Calibration procedures
1.2.1
•

MANUAL CALIBRATION
Place the silicon slide on the XploRA™ stage, and close
instrument doors.

•

Click on video camera icon on top task bar. Instrument will instruct
user to:
Please set illuminator to video position 2 and
focus on the sample

•

Manually turn illuminator wheel to video position 2

•

Use the joystick to move the silicon into the field of view
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•

Focus on white section of the Silicon with the 10x objective, then
moving on and focus at 50x objective and finally focus on silicon
using the 100x objective.

•

Center the grating on the silica peak. For this, enter 520 in the text
box associated to the grating. This text box can be found at the
bottom of the screen where is indicating spectrometer. The first
line correspond to the grating used. For this study the 1200T
should be in place. Below is the grating position, where 520
should be written. Press enter key to validate the value and move
the grating to this position.

•

For consistency make sure the acquisition time is set to 1s with
only 1 accumulation. The laser power should be at 50%. To start
the recording click on the Spectrum RTD icon (top of the screen).
The system will record a spectrum every second and displays it on
the screen. The recording won’t stop until the operator click on the
STOP icon (top right of the screen)

 RTD Exposure Time (s): 1
 Exposure Time (s): 20
 Accumulation: 2

•

A peak corresponding to the silica should be easily identifiable
around 520 cm-1. Using the joystick adjust the Z position to have
the maximum intensity = the max counts per second. Indicate the
max value found in the logging book.
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•

Find the peak position, either manually or using the peak search
function in the software by click of the peak search icon on the top
right of the screen. The silica peak should be at 520.7 cm-1 but
due to the spectral resolution using the 1200T grating a value
between 520.5 and 521 cm-1 will be considered acceptable. By
clicking on “approx” followed by “fit” a more exact estimation of the
peak position can be achieved.

•

In order to adjust the peak position, open the Setup window
(command list of the top right of the screen) then the instrument
calibration window. To calibrate the grating positions please
modify ONLY the zero position value. Increase the value to shift
the spectrum to left and decrease it to shift the spectrum toward
the right. Click on apply to save the new grating position, close the
instrument calibration window and the window displaying the
spectrum. Restart the recording using the spectrum RTD icon.
Check the peak position, if it is not in the range 520.5 – 521 cm-1
restart this step.

•

Re-enter 520 cm-1 in the text box corresponding to the grating
before starting

1.2.2. Laser intensity – laser check
•

When the calibration is done, check the laser intensity at the
objective using the laser check. Place the laser check under the
100x objective and record the intensity for at least 3-5 seconds.
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Read the value and restart the recording 3 times. Write done the
average value found in the logging book.

1.2.3. Dark current
•

The black current is obtained by turn off the laser and recording a
spectrum in the spectral range 400 – 1800 cm-1.

 RTD Exposure Time (s): 1
 Exposure Time (s): 20
 Accumulation: 2

•

Repeat three times using relevant parameters

•

Create a sub-folder with the date inside the folder 2012 and save
the files as follow:
o Dark current 1
o Dark current 2
o Dark current 3

1.2.4. NIST 2242 STANDARD (1/month)
•

Place NIST 2242 reference standard on the XploRA™ stage, and
close instrument doors.

•

Focus a smooth dark section of the reference standard with the 10x
objective, then moving on and focus at 50x objective and finally focus
on standard using the 100x objective.
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•

At the bottom of the screen, change the parameter settings as
follows;

 RTD Exposure Time (s): 1
 Exposure Time (s): 20
 Accumulation: 2

•

Click on “laser on” icon followed by “pink pig” acquisition icon.

•

Repeat three times and save the spectra as
o Y STD 1
o Y STD 2
o Y STD 3

1.2.5. Optics signal
•

The recording of the signal corresponding to the optics is really
important for the data correction before preprocessing and
analysis. This is included in the calibration but could be
considered as part of the data recording. This step as to be
completed for every single sample recorded. This will help to
adjust the correction of the data with the appropriate signal.

•

Position the glass slide with the sample to be analyzed on the
stage. For the data correction a spectrum from the background is
required. It corresponds to the signal of the substrate, is this case
the glass slide, and the internal signal of the optics (mirrors,
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objectives, filters). Before recording spectra from the cells move
out of the area containing the cell deposition and record a
spectrum from the blank glass. The steps are the same as used
previously for the petridish, first focus using the 10x then the 50x
and finally the 100x. The spectrum has to be recorded with the
same parameters as the cells, thus use 3 x 10s in the spectral
range 400-1800 cm-1 with a laser power at 50%. Repeat the
recording 3 times and save the spectra in a folder named
accordingly to the sample to be recorded.
•

Reminder: the signal corresponding to the optics has to be
recorded for each sample.

•

Create de folder named with the sample number and save the
spectra as follow: spectrum_glass_sample_number

1.3: Reference spectrum acquisition
•

Place the lid of a petri dish on the stage. As for the silica, first focus using
the 10x objective and then switch to the 50x and finally the 100x. This
step consists in recording a reference spectrum in the spectral range of
interest to make sure the calibrations are made identically day after day.
Click on the spectral range icon (top right of the screen) and make sure it
is set up for the spectral range 400-1800 cm-1 with relevant parameter
acquisitions.
o RTD Exposure Time (s): 1
o Exposure Time (s): 20
o Accumulation: 2
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•

Click on “laser on” icon followed by “pink pig” acquisition icon.

•

Save the spectrum with the date of day. (this is considered as the
reference spectrum day 0)

•

Compare the spectrum recoding corresponding to the plastic with the
one from the previous day (day -1). The peaks should all overlap
between the 2 spectra. If not, use the instrument calibration step to
readjust the peaks positions. This step is crucial to have a good
reproducibility in the data recorded over time but also between operators.
When the spectra collected from the plastic (at day 0 and day -1) are
found with identical peaks positions the calibration is finished and the
system is ready for recording of data from cells.

•

Save the spectrum recorded as follow: reference_spectrum_date
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